,id,ticker,title,link,topic,published_est,market,begin_price,end_price,index_begin_price,index_end_price,daily_return,index_return,daily_alpha,actual_action,predicted_action,confidence
0,2,ACIU,AC Immune Showcasing Precision Medicine Programs at AAIC 2023,https://www.globenewswire.com/news-release/2023/07/03/2698440/0/en/AC-Immune-Showcasing-Precision-Medicine-Programs-at-AAIC-2023.html,Clinical Study,7/3/2023 7:00,pre_market,2.954999924,2.940000057,443.2799988,442.9200134,-0.005076097,-0.000812095,-0.004264002,short,short,
1,3,ACIU,AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/04/05/2641522/0/en/AC-Immune-to-Host-Key-Opinion-Leader-Webinar-on-Early-Diagnosis-and-Prevention-of-Alzheimer-s-Disease.html,Calendar of Events,4/5/2023 7:00,pre_market,2.234999895,2.200000048,408.6700134,407.9100037,-0.015659888,-0.001859715,-0.013800173,short,short,
2,4,ACIU,AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic,https://www.globenewswire.com/news-release/2023/10/27/2768271/0/en/AC-Immune-Clinical-Data-Published-in-Nature-Communications-Show-Alpha-Synuclein-PET-Tracer-ACI-12589-Has-Potential-as-Neurodegenerative-Disease-Diagnostic.html,Company Announcement,10/27/2023 7:00,pre_market,2.900000095,2.690000057,412.5499878,414.1900024,-0.072413804,0.003975311,-0.076389115,short,short,
3,5,ACIU,AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline,https://www.globenewswire.com/news-release/2023/03/20/2630182/0/en/AC-Immune-at-AD-PD-2023-to-Present-New-Clinical-and-Preclinical-Data-from-its-Precision-Medicine-Pipeline.html,Calendar of Events,3/20/2023 8:00,pre_market,2.220000029,2.24000001,389.9899902,390.7999878,0.009009,0.00207697,0.00693203,long,long,
4,6,ACIU,AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43,https://www.globenewswire.com/news-release/2023/02/07/2602787/0/en/AC-Immune-Awarded-New-Grants-from-MJFF-and-Target-ALS-Supporting-Programs-Targeting-TDP-43.html,Health,2/7/2023 7:00,pre_market,2.369999886,2.400000095,409.8299866,408.8699951,0.012658317,-0.002342414,0.015000731,long,long,
5,7,ACIU,AC Immune SA Appoints New Chief Medical Officer,https://www.globenewswire.com/news-release/2023/07/26/2711171/0/en/AC-Immune-SA-Appoints-New-Chief-Medical-Officer.html,Management Changes,7/26/2023 7:00,pre_market,2.930000067,2.950000048,455.4400024,454.4700012,0.006825932,-0.002129811,0.008955743,long,long,
6,8,ACIU,AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial,https://www.globenewswire.com/news-release/2023/01/26/2595885/0/en/AC-Immune-s-ACI-24-060-Anti-Amyloid-Beta-Vaccine-for-Alzheimer-s-Shows-Positive-Initial-Interim-Safety-and-Immunogenicity-in-Phase-1b-2-ABATE-Trial.html,Clinical Study,1/26/2023 7:00,pre_market,2.339999914,2.589999914,400.3500061,403.1300049,0.106837611,0.006943921,0.09989369,long,long,
7,9,ACIU,AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update,https://www.globenewswire.com/news-release/2023/04/28/2657303/0/en/AC-Immune-Reports-First-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html,Interim information,4/28/2023 7:00,pre_market,1.879999995,1.879999995,412.4100037,411.4899902,0,-0.002230822,0.002230822,long,long,
8,10,ACIU,"AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023",https://www.globenewswire.com/news-release/2023/11/02/2772091/0/en/AC-Immune-to-Host-KOL-Webinar-on-Amyloid-Plaque-PET-Imaging-in-Alzheimer-s-Disease-as-a-Surrogate-of-Clinical-Efficacy-on-November-9-2023.html,Clinical Study,11/2/2023 7:00,pre_market,2.950000048,2.960000038,422.6600037,426.5799866,0.003389827,0.009274554,-0.005884727,short,long,
9,11,ACIU,AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update,https://www.globenewswire.com/news-release/2023/11/03/2773089/0/en/AC-Immune-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html,Earnings Releases and Operating Results,11/3/2023 7:00,pre_market,2.829999924,2.940000057,430.7600098,433.1400146,0.038869306,0.00552513,0.033344177,long,long,
10,12,ACIU,AC Immune to Present at the SVB Securities Global Biopharma Conference,https://www.globenewswire.com/news-release/2023/02/02/2600439/0/en/AC-Immune-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference.html,Calendar of Events,2/2/2023 8:15,pre_market,2.49000001,2.450000048,410.7999878,414.8599854,-0.016064242,0.009883149,-0.025947391,short,short,
11,15,ACIU,AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update,https://www.globenewswire.com/news-release/2023/08/04/2718852/0/en/AC-Immune-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html,Clinical Study,8/4/2023 7:00,pre_market,2.890000105,3.089999914,448.8399963,450.7200012,0.069204084,0.004188586,0.065015498,long,short,
12,16,ACIU,AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023,https://www.globenewswire.com/news-release/2023/10/05/2755226/0/en/AC-Immune-to-Present-at-the-Jefferies-2023-CNS-Neuro-Summit-in-October-2023.html,Calendar of Events,10/5/2023 7:00,pre_market,2.619999886,2.650000095,424.6600037,424.3599854,0.011450462,-0.000706491,0.012156953,long,long,
13,17,ACIU,AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development,https://www.globenewswire.com/news-release/2022/11/30/2564787/0/en/AC-Immune-s-Alzheimer-s-Disease-Vaccine-candidate-ACI-35-030-Selected-for-Further-Development.html,Clinical Study,11/30/2022 7:00,pre_market,2.619999886,2.859999895,395.230011,395.4899902,0.091603061,0.000657792,0.090945269,long,long,
14,18,ACIU,"AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease",https://www.globenewswire.com/news-release/2023/06/27/2695157/0/en/AC-Immune-Receives-FDA-Fast-Track-Designation-for-Anti-Amyloid-beta-Active-Immunotherapy-ACI-24-060-to-Treat-Alzheimer-s-Disease.html,Clinical Study,6/27/2023 7:00,pre_market,1.980000019,2.210000038,431.4400024,432.3500061,0.116161625,0.002109224,0.114052401,long,long,
15,29,ADAG,Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate,https://www.globenewswire.com/news-release/2023/05/04/2661611/0/en/Adagene-Achieves-3-Million-Milestone-in-Collaboration-with-Exelixis-for-Successful-Nomination-of-Second-SAFEbody-Novel-Masked-Antibody-Drug-Conjugate.html,Product / Services Announcement,5/4/2023 9:00,pre_market,1.299999952,1.299999952,408.019989,406.9299927,0,-0.002671429,0.002671429,long,long,
16,21,ACIU,"AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023",https://www.globenewswire.com/news-release/2023/03/08/2622870/0/en/AC-Immune-to-Report-Full-Year-2022-Financial-Results-and-Provide-Corporate-Update-on-March-16-2023.html,Calendar of Events,3/8/2023 7:00,pre_market,2.420000076,2.410000086,398.269989,398.3900146,-0.004132227,0.000301368,-0.004433595,short,short,
17,30,ADAG,Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023,https://www.globenewswire.com/news-release/2023/11/03/2773331/0/en/Adagene-Presents-Data-Demonstrating-the-Best-in-Class-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-SITC-2023.html,Product / Services Announcement,11/3/2023 12:00,market_open,1.330000043,1.350000024,433.1400146,434.6900024,0.015037579,0.003578491,0.011459088,long,long,
18,19,ACIU,AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/16/2628465/0/en/AC-Immune-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,3/16/2023 7:00,pre_market,2.299999952,2.299999952,389.2799988,386.8200073,0,-0.006319337,0.006319337,long,long,
19,34,ADAG,Adagene Announces Updates to its Board of Directors,https://www.globenewswire.com/news-release/2023/04/28/2657314/0/en/Adagene-Announces-Updates-to-its-Board-of-Directors.html,Directors and Officers,4/28/2023 7:00,pre_market,1.289999962,1.289999962,412.4100037,411.4899902,0,-0.002230822,0.002230822,long,long,
20,32,ADAG,天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果,https://www.globenewswire.com/news-release/2023/10/12/2759195/0/zh-hans/%E5%A4%A9%E6%BC%94%E8%8D%AF%E4%B8%9A%E5%B0%86%E5%9C%A8%E7%AC%AC38%E5%B1%8ASITC%E5%B9%B4%E4%BC%9A%E4%B8%8A%E4%BB%A5%E6%B5%B7%E6%8A%A5%E5%BD%A2%E5%BC%8F%E5%85%AC%E5%B8%83%E5%85%B6%E7%B2%BE%E5%87%86%E6%8E%A9%E8%94%BD%E5%9E%8B%E6%8A%97CTLA-4%E5%AE%89%E5%85%A8%E6%8A%97%E4%BD%93SAFEbody-ADG126%E5%89%82%E9%87%8F%E4%BC%98%E5%8C%96%E8%AF%95%E9%AA%8C%E7%BB%93%E6%9E%9C.html,Calendar of Events,10/12/2023 8:00,pre_market,1.49000001,1.539999962,436.3200073,436.9500122,0.033557015,0.001443906,0.032113109,long,long,
21,33,ADAG,Adagene to Present at Investor and Scientific Conferences in September,https://www.globenewswire.com/news-release/2023/09/07/2739093/0/en/Adagene-to-Present-at-Investor-and-Scientific-Conferences-in-September.html,Conference Calls/ Webcasts,9/7/2023 6:00,pre_market,1.355000019,1.299999952,446.2200012,443.1099854,-0.040590455,-0.006969692,-0.033620763,short,short,
22,31,ADAG,Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer,https://www.globenewswire.com/news-release/2022/12/16/2575333/0/en/Adagene-Announces-Clinical-Trial-Collaboration-to-Evaluate-Anti-CTLA-4-SAFEbody-ADG126-in-Combination-with-Roche-s-Standard-of-Care-for-First-Line-Advanced-Liver-Cancer.html,Health,12/16/2022 6:30,pre_market,1.320000053,1.399999976,389.6300049,385.1799927,0.060606,-0.011421123,0.072027123,long,long,
23,20,ACIU,AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference,https://www.globenewswire.com/news-release/2022/11/23/2561536/0/en/AC-Immune-to-Present-Progress-of-Alzheimer-s-Disease-Programs-targeting-Abeta-and-Tau-at-the-15th-CTAD-Conference.html,Clinical Study,11/23/2022 7:30,pre_market,2.700000048,2.75,399.8999939,399.5499878,0.018518501,-0.000875234,0.019393735,long,short,
24,51,ADXN,Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2737990/0/en/Addex-Announces-Participation-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,European Regulatory News,9/6/2023 1:00,no_market,,,,,,,,,long,
25,22,ACIU,AC Immune to Present at the Jefferies 2023 London Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/07/2774887/0/en/AC-Immune-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html,Calendar of Events,11/7/2023 7:00,pre_market,2.690000057,2.664999962,435.6900024,435.6900024,-0.009293716,0,-0.009293716,short,short,
26,23,ACIU,AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases,https://www.globenewswire.com/news-release/2024/01/03/2803284/0/en/AC-Immune-Progress-Update-on-Phase-2-Active-Immunotherapy-Clinical-Pipeline-for-Alzheimer-s-and-Parkinson-diseases.html,Clinical Study,1/3/2024 8:10,pre_market,4.690000057,4.650000095,472.6499939,470.4299927,-0.008528776,-0.004696924,-0.003831852,short,short,
27,24,ACIU,AC Immune to Regain Global Rights to Crenezumab and Semorinemab,https://www.globenewswire.com/news-release/2024/01/22/2812913/0/en/AC-Immune-to-Regain-Global-Rights-to-Crenezumab-and-Semorinemab.html,Licensing Agreements,1/22/2024 7:00,pre_market,4.150000095,4.150000095,482.4299927,484.0100098,0,0.003275122,-0.003275122,short,short,
28,25,ACIU,AC Immune Announces Pricing of Underwritten Offering of Common Shares,https://www.globenewswire.com/news-release/2023/12/15/2797008/0/en/AC-Immune-Announces-Pricing-of-Underwritten-Offering-of-Common-Shares.html,Financing Agreements,12/15/2023 7:56,pre_market,3.710000038,3.650000095,472.0100098,469.4899902,-0.016172491,-0.005338911,-0.01083358,short,short,
29,26,ACIU,"AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO",https://www.globenewswire.com/news-release/2023/12/01/2789221/0/en/AC-Immune-Strengthens-Management-Appoints-Madiha-Derouazi-as-CSO-and-Christopher-Roberts-as-CFO.html,Management Changes,12/1/2023 7:00,pre_market,3.309999943,3.279999971,456.3999939,455.769989,-0.009063436,-0.001380379,-0.007683057,short,short,
30,27,ACIU,AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial,https://www.globenewswire.com/news-release/2023/12/15/2796982/0/en/AC-Immune-s-Targeted-Anti-pTau-Active-Immunotherapy-for-Alzheimer-s-Disease-Advances-into-Phase-2b-Trial.html,Financing Agreements,12/15/2023 7:22,pre_market,3.710000038,3.650000095,472.0100098,469.4899902,-0.016172491,-0.005338911,-0.01083358,short,short,
31,37,ADAG,Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial,https://www.globenewswire.com/news-release/2023/01/09/2585049/0/en/Adagene-Announces-Interim-Data-Demonstrating-Safety-and-Confirmed-Clinical-Responses-of-Anti-CTLA-4-SAFEbody-ADG126-up-to-10-mg-kg-with-Repeat-Cycles-in-Combination-with-Anti-PD-1-.html,Clinical Study,1/9/2023 7:00,pre_market,1.600000024,1.639999986,388.0799866,390.3699951,0.024999976,0.005900867,0.019099108,long,long,
32,38,ADAG,Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/31/2735151/0/en/Adagene-Reports-Six-Month-Financial-Results-for-2023-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,8/31/2023 7:32,pre_market,1.179999948,1.190000057,451.0100098,451.6499939,0.00847467,0.001419002,0.007055668,long,long,
33,48,ADTX,"Aditxt, Inc. to Present at 8th Annual Dawson James Conference",https://www.globenewswire.com/news-release/2023/10/06/2756039/0/en/Aditxt-Inc-to-Present-at-8th-Annual-Dawson-James-Conference.html,Advisory,10/6/2023 8:00,pre_market,11.77999973,11.5,424.5,421.9700012,-0.023769078,-0.00595995,-0.017809128,short,short,
34,41,ADPT,Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer,https://www.globenewswire.com/news-release/2023/06/02/2681086/0/en/Adaptive-Biotechnologies-Highlights-New-Data-at-ASCO-2023-and-EHA-2023-Underscoring-the-clonoSEQ-Assay-s-Impact-as-a-Standard-for-Minimal-Residual-Disease-Assessment-in-Patients-wi.html,Clinical Study,6/2/2023 7:34,pre_market,7.050000191,7.159999847,421.8200073,424.5,0.015602788,0.006353403,0.009249384,long,long,
35,39,ADAG,Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium,https://www.globenewswire.com/news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html,Health,1/4/2024 5:00,pre_market,2.125,2.180000067,468.7900085,468.2999878,0.025882384,-0.001045288,0.026927673,long,long,
36,42,ADPT,Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology,https://www.globenewswire.com/news-release/2023/05/09/2664318/0/en/Adaptive-Biotechnologies-Announces-FDA-Acceptance-of-Genentech-s-Investigational-New-Drug-Application-for-the-First-Neoantigen-Directed-T-Cell-Therapy-Product-in-Oncology.html,Health,5/9/2023 7:30,pre_market,6.599999905,6.650000095,412.7399902,411.1300049,0.007575787,-0.003900725,0.011476512,long,long,
37,43,ADPT,Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline,https://www.globenewswire.com/news-release/2023/11/07/2774988/0/en/Adaptive-Biotechnologies-Announces-New-Translational-Collaboration-to-Measure-Minimal-Residual-Disease-with-clonoSEQ-Assay-Across-BeiGene-s-Lymphoid-Malignancy-Pipeline.html,Clinical Study,11/7/2023 7:30,pre_market,4.800000191,4.75,435.6900024,435.6900024,-0.010416706,0,-0.010416706,short,short,
38,44,ADPT,Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting,https://www.globenewswire.com/news-release/2023/12/05/2790810/0/en/Adaptive-Biotechnologies-and-Collaborators-to-Present-More-than-30-Abstracts-Demonstrating-the-Actionability-of-clonoSEQ-MRD-Testing-in-Blood-Cancer-Patient-Care-and-Drug-Developme.html,Clinical Study,12/5/2023 7:30,pre_market,4.760000229,4.739999771,456.6900024,455.2600098,-0.004201777,-0.003131211,-0.001070566,short,long,
39,45,ADPT,Adaptive Announces Launch of Epic Integration for clonoSEQ®,https://www.globenewswire.com/news-release/2023/09/13/2742380/0/en/Adaptive-Announces-Launch-of-Epic-Integration-for-clonoSEQ.html,Product / Services Announcement,9/13/2023 7:30,pre_market,6.670000076,6.690000057,445.9899902,446.2200012,0.002998498,0.000515731,0.002482767,long,long,
40,40,ADAG,"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)",https://www.globenewswire.com/news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html,Product / Services Announcement,2/9/2024 6:00,pre_market,3.5,3.450000048,498.3200073,498.8399963,-0.014285701,0.001043484,-0.015329185,short,short,
41,46,ADPT,Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/05/12/2667757/0/en/Adaptive-Biotechnologies-to-Participate-in-the-2023-RBC-Capital-Markets-Global-Healthcare-Conference.html,Calendar of Events,5/12/2023 8:00,pre_market,6.789999962,6.809999943,412.1300049,413.4200134,0.002945505,0.003130101,-0.000184596,short,short,
42,47,ADPT,Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline,https://www.globenewswire.com/news-release/2023/04/12/2645230/0/en/Adaptive-Biotechnologies-Announces-Translational-Collaboration-with-Takeda-to-Measure-Minimal-Residual-Disease-with-Its-clonoSEQ-Assay-Across-Its-Hematologic-Malignancy-Pipeline.html,Partnerships,4/12/2023 7:30,pre_market,8.170000076,8.369999886,409.7200012,411.8699951,0.024479781,0.005247471,0.019232309,long,long,
43,54,ADXN,Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration,https://www.globenewswire.com/news-release/2023/08/03/2717597/0/en/Addex-GABAB-Positive-Allosteric-Modulator-Program-to-Receive-Additional-CHF2-7-Million-from-Indivior-in-Extended-Substance-Use-Disorder-Research-Collaboration.html,European Regulatory News,8/3/2023 1:00,overnight,,,,,,,,,long,
44,74,ADXN,Addex Increases Issued Share Capital to Create Treasury Shares,https://www.globenewswire.com/news-release/2023/06/15/2688579/0/en/Addex-Increases-Issued-Share-Capital-to-Create-Treasury-Shares.html,European Regulatory News,6/15/2023 1:00,no_market,,,,,,,,,long,
45,66,ADXN,Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain,https://www.globenewswire.com/news-release/2023/09/04/2736453/0/en/Addex-s-Dipraglurant-Development-in-Post-Stroke-Recovery-Supported-by-Data-Published-in-Brain.html,European Regulatory News,9/4/2023 1:00,overnight,,,,,,,,,long,
46,73,ADXN,Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients,https://www.globenewswire.com/news-release/2023/11/14/2779698/0/en/Addex-ADX71149-Epilepsy-Phase-2-Study-Completes-Recruitment-of-Patients.html,European Regulatory News,11/14/2023 1:00,overnight,,,,,,,,,long,
47,53,ADXN,Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,https://www.globenewswire.com/news-release/2023/05/18/2671600/0/en/Addex-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html,European Regulatory News,5/18/2023 1:00,overnight,,,,,,,,,long,
48,56,ADXN,Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,https://www.globenewswire.com/news-release/2023/05/18/2671600/0/en/Addex-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html,European Regulatory News,5/18/2023 1:00,no_market,,,,,,,,,long,
49,72,ADXN,Addex Regains Nasdaq Listing Compliance,https://www.globenewswire.com/news-release/2023/11/08/2775790/0/en/Addex-Regains-Nasdaq-Listing-Compliance.html,European Regulatory News,11/8/2023 1:00,no_market,,,,,,,,,long,
50,59,ADXN,Addex Convenes Annual General Meeting 2023,https://www.globenewswire.com/news-release/2023/05/05/2662258/0/en/Addex-Convenes-Annual-General-Meeting-2023.html,European Regulatory News,5/5/2023 1:00,no_market,,,,,,,,,short,
51,62,ADXN,Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study,https://www.globenewswire.com/news-release/2023/05/10/2665174/0/en/Addex-Announces-ADX71149-Phase-2-Epilepsy-Clinical-Study-s-Independent-Interim-Review-Committee-Recommends-Continuing-Study.html,European Regulatory News,5/10/2023 1:00,no_market,,,,,,,,,long,
52,63,ADXN,Addex Reports Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/30/2637303/0/en/Addex-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,3/30/2023 1:00,no_market,,,,,,,,,long,
53,64,ADXN,Addex Completes $5.0 Million Equity Financing,https://www.globenewswire.com/news-release/2023/04/05/2641327/0/en/Addex-Completes-5-0-Million-Equity-Financing.html,European Regulatory News,4/5/2023 1:00,no_market,,,,,,,,,long,
54,67,ADXN,Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder,https://www.globenewswire.com/news-release/2023/07/24/2709220/0/en/Addex-mGlu2PAM-Demonstrates-Potential-in-Substance-Use-Disorder.html,European Regulatory News,7/24/2023 1:00,no_market,,,,,,,,,long,
55,60,ADXN,Addex Announces Participation in the Bio-Europe 2023 Conference,https://www.globenewswire.com/news-release/2023/11/02/2771873/0/en/Addex-Announces-Participation-in-the-Bio-Europe-2023-Conference.html,European Regulatory News,11/2/2023 2:00,overnight,,,,,,,,,long,
56,57,ADXN,Addex Shareholders Approve All Resolutions at Annual General Meeting,https://www.globenewswire.com/news-release/2023/06/01/2679938/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Annual-General-Meeting.html,European Regulatory News,6/1/2023 1:00,no_market,,,,,,,,,short,
57,68,ADXN,Addex Shareholders Approve All Resolutions at Annual General Meeting,https://www.globenewswire.com/news-release/2023/06/01/2679938/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Annual-General-Meeting.html,European Regulatory News,6/1/2023 1:00,overnight,,,,,,,,,short,
58,71,ADXN,Addex Reports Q3 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/29/2787467/0/en/Addex-Reports-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,11/29/2023 1:00,overnight,,,,,,,,,long,
59,70,ADXN,Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/10/2722288/0/en/Addex-Reports-2023-Half-Year-and-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,8/10/2023 1:00,overnight,,,,,,,,,long,
60,225,ANAB,AnaptysBio Announces Stock Repurchase Plan,https://www.globenewswire.com/news-release/2023/01/13/2588623/0/en/AnaptysBio-Announces-Stock-Repurchase-Plan.html,Stock Market News,1/13/2023 9:00,pre_market,23.06999969,24.01000023,396.9599915,393.6199951,0.040745581,-0.008413937,0.049159518,long,short,
61,65,ADXN,Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in  Q2 2024,https://www.globenewswire.com/news-release/2023/09/05/2736936/0/en/Addex-ADX71149-Phase-2-Epilepsy-Study-Expected-to-Readout-Data-in-Q2-2024.html,European Regulatory News,9/5/2023 1:00,no_market,,,,,,,,,long,
62,85,ADXN,Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients,https://www.globenewswire.com/news-release/2023/11/14/2779698/0/en/Addex-ADX71149-Epilepsy-Phase-2-Study-Completes-Recruitment-of-Patients.html,European Regulatory News,11/14/2023 1:00,no_market,,,,,,,,,long,
63,97,ADXN,Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.,https://www.globenewswire.com/news-release/2024/01/31/2820703/0/en/Addex-Enters-into-At-The-Market-ADS-Offering-Agreement-with-H-C-Wainwright-Co-LLC.html,European Regulatory News,1/31/2024 1:00,overnight,,,,,,,,,long,
64,100,AEON,AEON Biopharma Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html,Earnings Releases and Operating Results,11/13/2023 8:15,pre_market,4.179999828,4,440.6099854,439.230011,-0.043062162,-0.003131963,-0.039930198,short,short,
65,98,ADXN,Addex Shareholders Approve All Resolutions at Extraordinary General Meeting,https://www.globenewswire.com/news-release/2023/12/20/2799005/0/en/Addex-Shareholders-Approve-All-Resolutions-at-Extraordinary-General-Meeting.html,European Regulatory News,12/20/2023 1:00,overnight,,,,,,,,,short,
66,99,ADXN,Addex to Present at Biotech Showcase™ 2024,https://www.globenewswire.com/news-release/2024/01/05/2804455/0/en/Addex-to-Present-at-Biotech-Showcase-2024.html,European Regulatory News,1/5/2024 1:30,overnight,,,,,,,,,long,
67,86,ADXN,Addex mGlu2 NAM Cognition Program Receives €4 Million Grant,https://www.globenewswire.com/news-release/2023/09/20/2746109/0/en/Addex-mGlu2-NAM-Cognition-Program-Receives-4-Million-Grant.html,European Regulatory News,9/20/2023 1:00,overnight,,,,,,,,,long,
68,92,ADXN,Addex mGlu2 NAM Cognition Program Receives €4 Million Grant,https://www.globenewswire.com/news-release/2023/09/20/2746109/0/en/Addex-mGlu2-NAM-Cognition-Program-Receives-4-Million-Grant.html,European Regulatory News,9/20/2023 1:00,no_market,,,,,,,,,long,
69,87,ADXN,Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder,https://www.globenewswire.com/news-release/2023/07/24/2709220/0/en/Addex-mGlu2PAM-Demonstrates-Potential-in-Substance-Use-Disorder.html,European Regulatory News,7/24/2023 1:00,overnight,,,,,,,,,long,
70,93,ADXN,Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain,https://www.globenewswire.com/news-release/2023/09/04/2736453/0/en/Addex-s-Dipraglurant-Development-in-Post-Stroke-Recovery-Supported-by-Data-Published-in-Brain.html,European Regulatory News,9/4/2023 1:00,no_market,,,,,,,,,long,
71,82,ADXN,Addex Regains Nasdaq Listing Compliance,https://www.globenewswire.com/news-release/2023/11/08/2775790/0/en/Addex-Regains-Nasdaq-Listing-Compliance.html,European Regulatory News,11/8/2023 1:00,overnight,,,,,,,,,long,
72,80,ADXN,Addex Reports Q1 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/05/11/2666253/0/en/Addex-Reports-Q1-2023-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,5/11/2023 1:00,no_market,,,,,,,,,long,
73,83,ADXN,Addex Reports Q1 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/05/11/2666253/0/en/Addex-Reports-Q1-2023-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,5/11/2023 1:00,overnight,,,,,,,,,long,
74,84,ADXN,Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in  Q2 2024,https://www.globenewswire.com/news-release/2023/09/05/2736936/0/en/Addex-ADX71149-Phase-2-Epilepsy-Study-Expected-to-Readout-Data-in-Q2-2024.html,European Regulatory News,9/5/2023 1:00,overnight,,,,,,,,,long,
75,89,ADXN,Addex Reports Q3 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/29/2787467/0/en/Addex-Reports-Q3-2023-Financial-Results-and-Provides-Corporate-Update.html,European Regulatory News,11/29/2023 1:00,no_market,,,,,,,,,long,
76,90,ADXN,Addex Announces Plan to Implement ADS Ratio Change,https://www.globenewswire.com/news-release/2023/10/06/2756301/0/en/Addex-Announces-Plan-to-Implement-ADS-Ratio-Change.html,European Regulatory News,10/6/2023 16:00,after_hours,,,,,,,,,long,
77,94,ADXN,Addex Announces Participation in the Bio-Europe 2023 Conference,https://www.globenewswire.com/news-release/2023/11/02/2771873/0/en/Addex-Announces-Participation-in-the-Bio-Europe-2023-Conference.html,European Regulatory News,11/2/2023 2:00,no_market,,,,,,,,,long,
78,95,ADXN,Addex to Present at the Swiss Equities Baader Conference,https://www.globenewswire.com/news-release/2024/01/09/2805955/0/en/Addex-to-Present-at-the-Swiss-Equities-Baader-Conference.html,European Regulatory News,1/9/2024 1:00,overnight,,,,,,,,,long,
79,96,ADXN,Addex Creates Treasury Shares,https://www.globenewswire.com/news-release/2023/12/14/2795964/0/en/Addex-Creates-Treasury-Shares.html,European Regulatory News,12/14/2023 1:00,overnight,,,,,,,,,long,
80,107,AKRO,Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/13/2778893/0/en/Akero-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,11/13/2023 7:00,pre_market,14.15999985,14.14000034,440.6099854,439.230011,-0.001412394,-0.003131963,0.001719569,long,short,
81,108,AKRO,Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/01/04/2582867/0/en/Akero-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,Trade Show,1/4/2023 8:00,pre_market,49.49000168,49.59000015,380.8200073,383.1799927,0.002020579,0.006197115,-0.004176536,short,short,
82,109,AKRO,Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology,https://www.globenewswire.com/news-release/2023/10/04/2754507/0/en/Akero-Therapeutics-Announces-Publication-of-the-Harmony-Phase-2b-Trial-Results-in-The-Lancet-Gastroenterology-Hepatology.html,Clinical Study,10/4/2023 8:00,pre_market,47.45999908,47.81999969,421.5899963,422.0700073,0.007585348,0.001138573,0.006446775,long,long,
83,110,AKRO,Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023,https://www.globenewswire.com/news-release/2023/11/10/2778341/0/en/Akero-Therapeutics-to-Present-Late-Breaking-Oral-and-Poster-Presentations-on-EFX-at-AASLD-s-The-Liver-Meeting-2023.html,Clinical Study,11/10/2023 8:57,pre_market,14.07999992,14.34000015,433.8399963,435.980011,0.018465925,0.004932728,0.013533198,long,long,
84,111,AKRO,"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins",https://www.globenewswire.com/news-release/2023/10/10/2757329/0/en/Akero-Therapeutics-Reports-Encouraging-36-Week-Analysis-of-96-Week-Phase-2b-SYMMETRY-Study-with-a-Trend-on-Fibrosis-Improvement-and-Statistically-Significant-Results-for-NASH-Resol.html,Clinical Study,10/10/2023 7:00,pre_market,48.54000092,19.87000084,432.2900085,432.9400024,-0.59064688,0.001503606,-0.592150486,short,short,
85,112,AKRO,Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/03/17/2629388/0/en/Akero-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,Earnings Releases and Operating Results,3/17/2023 7:00,pre_market,39.74000168,39.97000122,396.1099854,393.2200012,0.005787608,-0.007295913,0.013083521,long,long,
86,113,AKRO,Akero Therapeutics to Present at Upcoming Healthcare Conferences in September,https://www.globenewswire.com/news-release/2023/08/31/2735089/0/en/Akero-Therapeutics-to-Present-at-Upcoming-Healthcare-Conferences-in-September.html,Calendar of Events,8/31/2023 7:00,pre_market,49.70999908,49.63000107,451.0100098,451.6499939,-0.001609294,0.001419002,-0.003028296,short,short,
87,102,AEON,AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®,https://www.globenewswire.com/news-release/2023/08/29/2733326/0/en/AEON-Biopharma-Presents-Positive-Results-from-Phase-2-Clinical-Trial-of-ABP-450-prabotulinumtoxinA-in-Cervical-Dystonia-at-the-International-Parkinson-and-Movement-Disorders-Societ.html,Research Analysis and Reports,8/29/2023 8:00,pre_market,4.110000134,4.269999981,442.7600098,442.6499939,0.038929402,-0.000248477,0.039177879,long,long,
88,114,AKRO,Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/15/2668591/0/en/Akero-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,5/15/2023 7:00,pre_market,46.33000183,45.86000061,411.5899963,412.2200012,-0.010144641,0.001530661,-0.011675302,short,short,
89,115,AKRO,"Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy",https://www.globenewswire.com/news-release/2023/01/10/2586110/0/en/Akero-Therapeutics-Appoints-Patrick-Lamy-as-Senior-Vice-President-Commercial-Strategy.html,Management Changes,1/10/2023 8:00,pre_market,44.09000015,44.25999832,387.8599854,387.25,0.003855708,-0.001572695,0.005428403,long,short,
90,104,AEON,AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine,https://www.globenewswire.com/news-release/2023/12/12/2794700/0/en/AEON-Biopharma-Completes-Enrollment-in-Phase-2-Study-of-ABP-450-prabotulinumtoxinA-for-Preventive-Treatment-of-Chronic-Migraine.html,Clinical Study,12/12/2023 8:00,pre_market,6.5,6.670000076,461.9899902,461.6300049,0.026153858,-0.000779206,0.026933064,long,long,
91,103,AEON,"Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma",https://www.globenewswire.com/news-release/2023/08/16/2726201/0/en/Strathspey-Crown-Holdings-Group-LLC-Provides-Clarifying-Statement-Regarding-Form-4-Filing-with-SEC-for-Holdings-in-AEON-Biopharma.html,Regulatory information,8/16/2023 7:00,pre_market,4.110000134,4.599999905,442.8900146,442.4599915,0.119221352,-0.000970948,0.1201923,long,long,
92,117,AKRO,Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease,https://www.globenewswire.com/news-release/2023/06/05/2681816/0/en/Akero-Therapeutics-Phase-2b-SYMMETRY-Cohort-D-Study-Met-Safety-Tolerability-Endpoints-and-Showed-Adding-EFX-to-GLP-1-Therapy-Significantly-Improved-Non-Invasive-Markers-of-NASH-Rel.html,Clinical Study,6/5/2023 7:00,pre_market,46.72999954,45.86999893,427.9200134,428.2799988,-0.018403608,0.000841245,-0.019244853,short,long,
93,116,AKRO,Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/11/2723407/0/en/Akero-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,8/11/2023 6:00,pre_market,44.61000061,46.11000061,445.9100037,443.9700012,0.033624747,-0.004350659,0.037975407,long,long,
94,125,AKYA,Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow,https://www.globenewswire.com/news-release/2023/04/12/2645262/0/en/Akoya-Biosciences-Introduces-PhenoCode-Discovery-Panels-to-Simplify-PhenoCycler-Fusion-Workflow.html,Product / Services Announcement,4/12/2023 8:00,pre_market,7.25,7.449999809,409.7200012,411.8699951,0.027586181,0.005247471,0.022338709,long,long,
95,126,AKYA,Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting,https://www.globenewswire.com/news-release/2023/02/01/2599401/0/en/Akoya-Biosciences-to-Present-First-of-its-Kind-Spatial-Multiomics-Dataset-at-2023-AGBT-General-Meeting.html,Health,2/1/2023 8:00,pre_market,11.25,11.30000019,406.480011,405.2099915,0.004444461,-0.003124433,0.007568894,long,long,
96,127,AKYA,Akoya to Participate at Three Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/11/02/2772246/0/en/Akoya-to-Participate-at-Three-Upcoming-Investor-Conferences.html,Calendar of Events,11/2/2023 8:00,pre_market,3.410000086,3.5,422.6600037,426.5799866,0.026392936,0.009274554,0.017118382,long,long,
97,129,AKYA,"Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences",https://www.globenewswire.com/news-release/2023/02/06/2602048/0/en/Akoya-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-6th-2023-and-Participate-at-Two-Upcoming-Investor-Conferences.html,Conference Calls/ Webcasts,2/6/2023 8:05,pre_market,11.98999977,11.90999985,412.3500061,409.7900085,-0.006672221,-0.006208312,-0.000463909,short,short,
98,130,AKYA,"Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023",https://www.globenewswire.com/news-release/2023/07/12/2703488/0/en/Akoya-to-Report-Second-Quarter-2023-Financial-Results-on-August-7th-2023.html,Conference Calls/ Webcasts,7/12/2023 8:05,pre_market,7.25,7.039999962,442.4599915,446.3900146,-0.028965523,0.008882211,-0.037847734,short,short,
99,131,AKYA,Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023,https://www.globenewswire.com/news-release/2023/10/31/2770244/0/en/Akoya-Biosciences-to-Showcase-New-Spatial-Biology-2-0-Solutions-and-Spatial-Phenotyping-Data-at-SITC-2023.html,Calendar of Events,10/31/2023 9:00,pre_market,3.400000095,3.390000105,415.5899963,416.1799927,-0.002941174,0.00141966,-0.004360833,short,short,
100,132,AKYA,Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data,https://www.globenewswire.com/news-release/2023/04/12/2645278/0/en/Akoya-Biosciences-and-Enable-Medicine-Introduce-Cloud-Platform-to-Power-Faster-Analysis-of-PhenoCycler-Fusion-Data.html,Partnerships,4/12/2023 8:00,pre_market,7.25,7.449999809,409.7200012,411.8699951,0.027586181,0.005247471,0.022338709,long,long,
101,133,AKYA,Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel,https://www.globenewswire.com/news-release/2023/02/28/2617008/0/en/Akoya-Biosciences-Announces-Appointment-of-Jennifer-Kamocsay-as-General-Counsel.html,Directors and Officers,2/28/2023 8:00,pre_market,12.18999958,12.18999958,397.730011,397.230011,0,-0.001257134,0.001257134,long,long,
102,134,AKYA,"Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023",https://www.globenewswire.com/news-release/2023/04/06/2642490/0/en/Akoya-to-Report-First-Quarter-2023-Financial-Results-on-May-8th-2023.html,Calendar of Events,4/6/2023 8:00,pre_market,7.449999809,7.480000019,407.6000061,406.769989,0.004026874,-0.002036352,0.006063226,long,long,
103,135,AKYA,"Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument",https://www.globenewswire.com/news-release/2023/04/27/2656258/0/en/Akoya-Biosciences-Marks-Milestone-Achievement-with-Shipment-of-1-000th-Spatial-Biology-Instrument.html,Other News,4/27/2023 8:00,pre_market,6.71999979,6.739999771,404.3599854,407,0.002976188,0.006528872,-0.003552684,short,short,
104,118,AKRO,Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022,https://www.globenewswire.com/news-release/2022/11/07/2549564/0/en/Akero-Therapeutics-to-Present-Late-Breaking-Oral-and-Poster-presentations-on-EFX-Today-at-AASLD-s-The-Liver-Meeting-2022.html,Calendar of Events,11/7/2022 7:30,pre_market,38.47999954,39.40000153,376.3500061,377.7099915,0.023908576,0.003613619,0.020294957,long,long,
105,119,AKRO,Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology,https://www.globenewswire.com/news-release/2023/06/23/2693588/0/en/Akero-Therapeutics-Presents-Analyses-of-Phase-2b-HARMONY-Study-at-the-2023-International-Liver-Congress-Reinforcing-and-Characterizing-EFX-Related-Improvements-in-Liver-Histopathol.html,Calendar of Events,6/23/2023 7:00,pre_market,52.00999832,51.59999847,436.5100098,432.9299927,-0.007883097,-0.008201455,0.000318358,long,long,
106,120,AKRO,Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH,https://www.globenewswire.com/news-release/2022/12/08/2570081/0/en/Efruxifermin-Granted-FDA-Breakthrough-Therapy-Designation-for-NASH.html,Product / Services Announcement,12/8/2022 7:00,pre_market,42.15999985,42.54999924,393.1600037,395.1400146,0.00925046,0.005036146,0.004214314,long,long,
107,121,AKRO,Akero Therapeutics to Present at Upcoming Healthcare Conferences in November,https://www.globenewswire.com/news-release/2023/11/08/2776046/0/en/Akero-Therapeutics-to-Present-at-Upcoming-Healthcare-Conferences-in-November.html,Calendar of Events,11/8/2023 7:00,pre_market,15.56999969,15.52000046,436.9299927,437.5499878,-0.003211255,0.00141898,-0.004630235,short,short,
108,122,AKRO,Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program,https://www.globenewswire.com/news-release/2023/12/18/2797681/0/en/Akero-Therapeutics-Announces-First-Patients-Dosed-in-Efruxifermin-Phase-3-SYNCHRONY-Program.html,Clinical Study,12/18/2023 7:00,pre_market,22.90999985,22.70999908,469.3299866,470.980011,-0.008729846,0.003515702,-0.012245548,short,short,
109,123,AKRO,Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803286/0/en/Akero-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,1/3/2024 8:15,pre_market,23.47999954,23.30999947,472.6499939,470.4299927,-0.007240208,-0.004696924,-0.002543284,short,short,
110,141,ALERS.PA,Eurobio Scientific : l’assemblée générale approuve l’ensemble des résolutions,https://www.globenewswire.com/news-release/2023/06/16/2689837/0/fr/Eurobio-Scientific-l-assembl%C3%A9e-g%C3%A9n%C3%A9rale-approuve-l-ensemble-des-r%C3%A9solutions.html,European Regulatory News,6/16/2023 11:45,market_open,14.68000031,14.61999989,443.019989,439.4599915,-0.004087222,-0.008035749,0.003948527,long,long,
111,142,ALERS.PA,Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO,https://www.globenewswire.com/news-release/2023/02/08/2604261/0/en/Eurobio-Scientific-formalises-the-appointment-of-Anne-Sophie-H%C3%A9relle-as-Group-CFO.html,European Regulatory News,2/8/2023 11:45,market_open,17.90999985,18.12000084,413.1300049,410.6499939,0.011725349,-0.00600298,0.017728328,long,long,
112,143,ALERS.PA,Eurobio Scientific becomes one of the first European companies to obtain IVDR1 CE marking of PCR tests,https://www.globenewswire.com/news-release/2023/05/23/2674617/0/en/Eurobio-Scientific-becomes-one-of-the-first-European-companies-to-obtain-IVDR1-CE-marking-of-PCR-tests.html,European Regulatory News,5/23/2023 11:45,market_open,16.79999924,17,417.0799866,414.0899963,0.011904808,-0.007168865,0.019073673,long,long,
113,144,ALERS.PA,EUROBIO SCIENTIFIC : RESULTATS DU 1ER SEMESTRE 2023,https://www.globenewswire.com/news-release/2023/10/11/2758684/0/fr/EUROBIO-SCIENTIFIC-RESULTATS-DU-1ER-SEMESTRE-2023.html,European Regulatory News,10/11/2023 12:52,market_open,13,13,435.6400146,436.3200073,0,0.001560905,-0.001560905,short,short,
114,145,ALERS.PA,Eurobio Scientific : Results for the First Half of 2023,https://www.globenewswire.com/news-release/2023/10/11/2758684/0/en/Eurobio-Scientific-Results-for-the-First-Half-of-2023.html,European Regulatory News,10/11/2023 12:52,market_open,13,13,435.6400146,436.3200073,0,0.001560905,-0.001560905,short,short,
115,147,ALERS.PA,Eurobio Scientific : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022,https://www.globenewswire.com/news-release/2023/04/28/2657647/0/fr/Eurobio-Scientific-MISE-%C3%80-DISPOSITION-DU-RAPPORT-FINANCIER-ANNUEL-2022.html,European Regulatory News,4/28/2023 11:45,market_open,16.37999916,16.29999924,411.4899902,415.9299927,-0.004884001,0.010790062,-0.015674062,short,long,
116,148,ALERS.PA,"Eurobio Scientific: Wietse Mulder, CEO of GenDx, holds a 2% stake",https://www.globenewswire.com/news-release/2023/02/14/2607947/0/en/Eurobio-Scientific-Wietse-Mulder-CEO-of-GenDx-holds-a-2-stake.html,European Regulatory News,2/14/2023 11:45,market_open,18.35000038,18.29999924,411.2399902,412.6400146,-0.002724858,0.003404398,-0.006129256,short,short,
117,149,ALERS.PA,EUROBIO SCIENTIFIC : RAPPORT FINANCIER ANNUEL 2022,https://www.globenewswire.com/news-release/2023/04/28/2657649/0/fr/EUROBIO-SCIENTIFIC-RAPPORT-FINANCIER-ANNUEL-2022.html,European Regulatory News,4/28/2023 11:45,market_open,16.37999916,16.29999924,411.4899902,415.9299927,-0.004884001,0.010790062,-0.015674062,short,long,
118,150,ALERS.PA,Eurobio Scientific: GenDx reduces organ matching time to 3 hours,https://www.globenewswire.com/news-release/2023/10/17/2761752/0/en/Eurobio-Scientific-GenDx-reduces-organ-matching-time-to-3-hours.html,European Regulatory News,10/17/2023 11:40,market_open,14,14.06000042,432.8099976,436.019989,0.004285744,0.00741663,-0.003130885,short,short,
119,151,ALERS.PA,Eurobio Scientific: CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER,https://www.globenewswire.com/news-release/2023/11/07/2775371/0/en/Eurobio-Scientific-CATHERINE-COURBOILLET-TO-JOIN-EUROBIO-SCIENTIFIC-BOARD-AS-AN-INDEPENDENT-MEMBER.html,European Regulatory News,11/7/2023 11:40,market_open,15.5,15.97999954,435.6900024,436.9299927,0.030967712,0.002846038,0.028121675,long,long,
120,152,ALERS.PA,Eurobio Scientific : GenDx réduit à 3h la durée des tests de compatibilité d’organes,https://www.globenewswire.com/news-release/2023/10/17/2761752/0/fr/Eurobio-Scientific-GenDx-r%C3%A9duit-%C3%A0-3h-la-dur%C3%A9e-des-tests-de-compatibilit%C3%A9-d-organes.html,European Regulatory News,10/17/2023 11:40,market_open,14,14.06000042,432.8099976,436.019989,0.004285744,0.00741663,-0.003130885,short,short,
121,153,ALERS.PA,EUROBIO : ACCÉLÉRATION DU DÉPLOIEMENT STRATÉGIQUE AU PREMIER SEMESTRE 2023,https://www.globenewswire.com/news-release/2023/07/24/2709736/0/fr/EUROBIO-ACC%C3%89L%C3%89RATION-DU-D%C3%89PLOIEMENT-STRAT%C3%89GIQUE-AU-PREMIER-SEMESTRE-2023.html,European Regulatory News,7/24/2023 11:46,market_open,15.11999989,15.03999996,453.3699951,454.2000122,-0.005291,0.001830772,-0.007121772,short,short,
122,154,ALERS.PA,Eurobio Scientific: RESULTATS ANNUELS 2022 - Très solide performance et renforcement du Cœur d’Activité,https://www.globenewswire.com/news-release/2023/04/05/2641992/0/fr/Eurobio-Scientific-RESULTATS-ANNUELS-2022-Tr%C3%A8s-solide-performance-et-renforcement-du-C%C5%93ur-d-Activit%C3%A9.html,European Regulatory News,4/5/2023 11:41,market_open,16.20000076,16.18000031,407.9100037,407.6000061,-0.001234596,-0.000759966,-0.000474631,short,short,
123,136,AKYA,Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms,https://www.globenewswire.com/news-release/2023/09/19/2745518/0/en/Akoya-Biosciences-Sets-a-New-Standard-for-Scaling-Spatial-Biology-with-the-Launch-of-2-0-Platforms.html,Product / Services Announcement,9/19/2023 8:00,pre_market,4.239999771,4.28000021,443.6300049,442.6799927,0.009434066,-0.002141452,0.011575518,long,long,
124,137,AKYA,Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases,https://www.globenewswire.com/news-release/2024/01/18/2811486/0/en/Akoya-Biosciences-Technology-Enables-Queensland-Spatial-Biology-Centre-to-Revolutionize-the-Diagnosis-and-Treatment-of-Cancer-and-Other-Diseases.html,Health,1/18/2024 8:00,pre_market,4.96999979,5.039999962,472.2900085,474.0100098,0.014084542,0.003641833,0.010442709,long,long,
125,138,AKYA,"Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board",https://www.globenewswire.com/news-release/2024/01/10/2807080/0/en/Akoya-Biosciences-Announces-that-Garry-Nolan-Ph-D-James-Allison-Ph-D-and-Padmanee-Sharma-M-D-Ph-D-Join-Newly-Created-Scientific-Advisory-Board.html,Directors and Officers,1/10/2024 8:00,pre_market,5.03000021,4.960000038,473.8800049,474.1600037,-0.013916535,0.000590864,-0.014507399,short,short,
126,139,AKYA,Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/20/2799236/0/en/Akoya-to-Participate-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/20/2023 8:05,pre_market,4.690000057,4.670000076,474.8399963,473.9599915,-0.004264388,-0.001853266,-0.002411122,short,short,
127,155,ALERS.PA,Eurobio Scientific - MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023,https://www.globenewswire.com/news-release/2023/10/30/2769525/0/en/Eurobio-Scientific-MISE-%C3%80-DISPOSITION-DU-RAPPORT-FINANCIER-SEMESTRIEL-2023.html,European Regulatory News,10/30/2023 12:45,market_open,15.5,15.68000031,413.5599976,415.5899963,0.011612923,0.004908596,0.006704327,long,long,
128,168,ALVO,Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland,https://www.globenewswire.com/news-release/2023/10/05/2755706/0/en/Alvotech-and-Islandsbanki-enter-into-Market-Making-Agreement-for-Shares-Trading-on-Nasdaq-Iceland.html,European Regulatory News,10/5/2023 13:21,market_open,9.300000191,9.100000382,424.3599854,424.5,-0.021505355,0.000329943,-0.021835299,short,long,
129,169,ALVO,"Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara",https://www.globenewswire.com/news-release/2023/11/14/2779894/0/is/Alvotech-og-JAMP-Pharma-hlj%C3%B3ta-marka%C3%B0sleyfi-%C3%AD-Kanada-fyrir-Jamteki-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara.html,European Regulatory News,11/14/2023 7:00,pre_market,9.020000458,9.050000191,440.1900024,446.3200073,0.003325913,0.013925816,-0.010599903,short,short,
130,170,ALVO,STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara,https://www.globenewswire.com/news-release/2023/11/10/2778378/0/en/STADA-and-Alvotech-receive-positive-CHMP-opinion-for-Europe-s-first-ustekinumab-biosimilar-to-Stelara.html,European Regulatory News,11/10/2023 9:30,market_open,8.699999809,9.010000229,435.980011,440.6099854,0.035632233,0.010619694,0.025012539,long,long,
131,171,ALVO,"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)",https://www.globenewswire.com/news-release/2023/11/14/2779894/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html,European Regulatory News,11/14/2023 7:00,pre_market,9.020000458,9.050000191,440.1900024,446.3200073,0.003325913,0.013925816,-0.010599903,short,short,
132,172,ALVO,Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni,https://www.globenewswire.com/news-release/2023/10/05/2755706/0/is/Alvotech-og-%C3%8Dslandsbanki-gera-samning-um-vi%C3%B0skiptavakt-me%C3%B0-hlutabr%C3%A9f-%C3%AD-Kauph%C3%B6llinni.html,European Regulatory News,10/5/2023 13:21,market_open,9.300000191,9.100000382,424.3599854,424.5,-0.021505355,0.000329943,-0.021835299,short,long,
133,167,ALVO,Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT04 í Bandaríkjunum,https://www.globenewswire.com/news-release/2023/10/12/2758971/0/is/Alvotech-birtir-n%C3%BDjar-uppl%C3%BDsingar-um-st%C3%B6%C3%B0u-ums%C3%B3knar-um-marka%C3%B0sleyfi-fyrir-AVT04-%C3%AD-Bandar%C3%ADkjunum.html,European Regulatory News,10/12/2023 4:00,pre_market,9.100000382,9.079999924,436.3200073,436.9500122,-0.002197852,0.001443906,-0.003641758,short,long,
134,156,ALERS.PA,Eurobio Scientific: all resolutions approved at the Annual General Meeting,https://www.globenewswire.com/news-release/2023/06/16/2689837/0/en/Eurobio-Scientific-all-resolutions-approved-at-the-Annual-General-Meeting.html,European Regulatory News,6/16/2023 11:45,market_open,14.68000031,14.61999989,443.019989,439.4599915,-0.004087222,-0.008035749,0.003948527,long,long,
135,157,ALERS.PA,Eurobio Scientific devient une des premières sociétés européennes à obtenir le marquage CE IVDR1 de tests PCR,https://www.globenewswire.com/news-release/2023/05/23/2674617/0/fr/Eurobio-Scientific-devient-une-des-premi%C3%A8res-soci%C3%A9t%C3%A9s-europ%C3%A9ennes-%C3%A0-obtenir-le-marquage-CE-IVDR1-de-tests-PCR.html,European Regulatory News,5/23/2023 11:45,market_open,16.79999924,17,417.0799866,414.0899963,0.011904808,-0.007168865,0.019073673,long,long,
136,158,ALERS.PA,EUROBIO : ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023,https://www.globenewswire.com/news-release/2023/07/24/2709830/0/en/EUROBIO-ACCELERATION-OF-STRATEGIC-DEPLOYMENT-IN-THE-FIRST-HALF-OF-2023.html,European Regulatory News,7/24/2023 13:45,market_open,15.11999989,15.03999996,453.3699951,454.2000122,-0.005291,0.001830772,-0.007121772,short,short,
137,159,ALERS.PA,"Eurobio Scientific : Wietse Mulder, CEO de GenDx,  détient 2% du capital",https://www.globenewswire.com/news-release/2023/02/14/2607947/0/fr/Eurobio-Scientific-Wietse-Mulder-CEO-de-GenDx-d%C3%A9tient-2-du-capital.html,European Regulatory News,2/14/2023 11:45,market_open,18.35000038,18.29999924,411.2399902,412.6400146,-0.002724858,0.003404398,-0.006129256,short,short,
138,160,ALERS.PA,Eurobio Scientific : 2022 ANNUAL RESULTS - Very strong performance and strengthening of the Core Business,https://www.globenewswire.com/news-release/2023/04/05/2641992/0/en/Eurobio-Scientific-2022-ANNUAL-RESULTS-Very-strong-performance-and-strengthening-of-the-Core-Business.html,European Regulatory News,4/5/2023 11:41,market_open,16.20000076,16.18000031,407.9100037,407.6000061,-0.001234596,-0.000759966,-0.000474631,short,short,
139,161,ALERS.PA,EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME,https://www.globenewswire.com/news-release/2024/01/17/2810996/0/fr/EUROBIO-SCIENTIFIC-CONFIRME-SON-ELIGIBILITE-AU-DISPOSITIF-PEA-PME.html,European Regulatory News,1/17/2024 11:45,market_open,16.10000038,16.18000031,471.8200073,472.2900085,0.004968939,0.000996145,0.003972794,long,long,
140,162,ALERS.PA,"Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP",https://www.globenewswire.com/news-release/2024/01/30/2820322/0/en/Eurobio-Scientific-FISCAL-YEAR-2023-STRATEGIC-TRANSFORMATION-OF-THE-GROUP.html,European Regulatory News,1/30/2024 11:45,market_open,15.60000038,15.73999977,490.5599976,490.8900146,0.00897432,0.000672735,0.008301584,long,long,
141,163,ALERS.PA,Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE,https://www.globenewswire.com/news-release/2024/01/17/2810998/0/fr/Eurobio-Scientific-BILAN-SEMESTRIEL-S2-DU-CONTRAT-DE-LIQUIDITE.html,European Regulatory News,1/17/2024 11:45,market_open,16.10000038,16.18000031,471.8200073,472.2900085,0.004968939,0.000996145,0.003972794,long,long,
142,164,ALERS.PA,Eurobio Scientific : réduction de capital par annulation d’actions auto-détenues,https://www.globenewswire.com/news-release/2024/01/10/2806894/0/fr/Eurobio-Scientific-r%C3%A9duction-de-capital-par-annulation-d-actions-auto-d%C3%A9tenues.html,European Regulatory News,1/10/2024 4:48,pre_market,16.36000061,16.23999977,473.8800049,474.1600037,-0.007335014,0.000590864,-0.007925879,short,long,
143,165,ALERS.PA,"Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE",https://www.globenewswire.com/news-release/2024/01/30/2820322/0/fr/Eurobio-Scientific-EXERCICE-2023-CONFIRMATION-DE-LA-TRANSFORMATION-STRATEGIQUE.html,European Regulatory News,1/30/2024 11:45,market_open,15.60000038,15.73999977,490.5599976,490.8900146,0.00897432,0.000672735,0.008301584,long,long,
144,181,ALVO,STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara,https://www.globenewswire.com/news-release/2023/11/10/2778383/0/en/STADA-and-Alvotech-receive-positive-CHMP-opinion-for-Europe-s-first-ustekinumab-biosimilar-to-Stelara.html,Health,11/10/2023 9:30,market_open,8.699999809,9.010000229,435.980011,440.6099854,0.035632233,0.010619694,0.025012539,long,long,
145,173,ALVO,Alvotech mun birta uppgjör fyrstu níu mánaða 2023 þann 28. nóvember og streyma uppgjörsfundi 29. nóvember kl. 13:00 að íslenskum tíma,https://www.globenewswire.com/news-release/2023/11/21/2784014/0/is/Alvotech-mun-birta-uppgj%C3%B6r-fyrstu-n%C3%ADu-m%C3%A1na%C3%B0a-2023-%C3%BEann-28-n%C3%B3vember-og-streyma-uppgj%C3%B6rsfundi-29-n%C3%B3vember-kl-13-00-a%C3%B0-%C3%ADslenskum-t%C3%ADma.html,European Regulatory News,11/21/2023 8:00,pre_market,9.140000343,8.949999809,454.2600098,453.1799927,-0.020787804,-0.002377531,-0.018410273,short,short,
146,177,ALVO,Alvotech to Present at the Jefferies 2023 London Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/07/2775024/0/en/Alvotech-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html,European Regulatory News,11/7/2023 8:00,pre_market,8.609999657,8.600000382,435.6900024,435.6900024,-0.001161356,0,-0.001161356,short,short,
147,175,ALVO,Alvotech Announces Changes to the Leadership Team,https://www.globenewswire.com/news-release/2023/09/05/2737491/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html,European Regulatory News,9/5/2023 9:30,market_open,9.909999847,9.869999886,450.730011,449.2399902,-0.004036323,-0.003305794,-0.000730529,short,short,
148,174,ALVO,"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®",https://www.globenewswire.com/news-release/2023/11/29/2787524/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT05-a-Proposed-Biosimilar-for-Simponi-and-Simponi-Aria.html,European Regulatory News,11/29/2023 4:00,pre_market,9.800000191,9.899999619,454.9299927,457.1499939,0.010204023,0.004879874,0.005324149,long,long,
149,178,ALVO,Alvotech tilkynnir um breytingar í framkvæmdastjórn,https://www.globenewswire.com/news-release/2023/09/05/2737491/0/is/Alvotech-tilkynnir-um-breytingar-%C3%AD-framkv%C3%A6mdastj%C3%B3rn.html,European Regulatory News,9/5/2023 9:30,market_open,9.909999847,9.869999886,450.730011,449.2399902,-0.004036323,-0.003305794,-0.000730529,short,short,
150,180,ALVO,Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04,https://www.globenewswire.com/news-release/2023/10/12/2758971/0/en/Alvotech-Provides-Update-on-Status-of-U-S-Biologics-License-Application-for-AVT04.html,European Regulatory News,10/12/2023 4:00,pre_market,9.100000382,9.079999924,436.3200073,436.9500122,-0.002197852,0.001443906,-0.003641758,short,long,
151,182,ALVO,Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara,https://www.globenewswire.com/news-release/2023/11/10/2778378/0/is/Alvotech-og-STADA-fyrst-til-a%C3%B0-hlj%C3%B3ta-j%C3%A1kv%C3%A6%C3%B0a-afgrei%C3%B0slu-lyfjastofnunar-Evr%C3%B3pu-%C3%A1-ums%C3%B3kn-um-marka%C3%B0sleyfi-fyrir-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara.html,European Regulatory News,11/10/2023 9:30,market_open,8.699999809,9.010000229,435.980011,440.6099854,0.035632233,0.010619694,0.025012539,long,long,
152,184,ALVO,Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London,https://www.globenewswire.com/news-release/2023/11/07/2775024/0/is/Alvotech-tekur-%C3%BE%C3%A1tt-%C3%AD-heilbrig%C3%B0isr%C3%A1%C3%B0stefnu-Jefferies-%C3%AD-London.html,European Regulatory News,11/7/2023 8:00,pre_market,8.609999657,8.600000382,435.6900024,435.6900024,-0.001161356,0,-0.001161356,short,short,
153,183,ALVO,"Alvotech kynnir jákvæðar niðurstöður úr rannsókn á lyfjahvörfum AVT05, fyrirhugaðri líftæknilyfjahliðstæðu við Simponi® og Simponi Aria®",https://www.globenewswire.com/news-release/2023/11/29/2787524/0/is/Alvotech-kynnir-j%C3%A1kv%C3%A6%C3%B0ar-ni%C3%B0urst%C3%B6%C3%B0ur-%C3%BAr-ranns%C3%B3kn-%C3%A1-lyfjahv%C3%B6rfum-AVT05-fyrirhuga%C3%B0ri-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Simponi-og-Simponi-Aria.html,European Regulatory News,11/29/2023 4:00,pre_market,9.800000191,9.899999619,454.9299927,457.1499939,0.010204023,0.004879874,0.005324149,long,long,
154,185,ALVO,Alvotech to Present at the Jefferies 2023 London Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/07/2775023/0/en/Alvotech-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html,Health,11/7/2023 8:00,pre_market,8.609999657,8.600000382,435.6900024,435.6900024,-0.001161356,0,-0.001161356,short,short,
155,186,ALVO,"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)",https://www.globenewswire.com/news-release/2023/11/14/2779896/0/en/Alvotech-and-JAMP-Pharma-Announce-Receipt-of-Marketing-Authorization-for-Jamteki-AVT04-the-First-Biosimilar-of-Stelara-ustekinumab.html,Licensing Agreements,11/14/2023 7:00,pre_market,9.020000458,9.050000191,440.1900024,446.3200073,0.003325913,0.013925816,-0.010599903,short,short,
156,187,ALVO,Alvotech Announces Changes to the Leadership Team,https://www.globenewswire.com/news-release/2023/09/05/2737492/0/en/Alvotech-Announces-Changes-to-the-Leadership-Team.html,Management Changes,9/5/2023 9:30,market_open,9.909999847,9.869999886,450.730011,449.2399902,-0.004036323,-0.003305794,-0.000730529,short,short,
157,188,ALVO,Alvotech Provides Update on Status of  Biologics License Applications for AVT02 and AVT04,https://www.globenewswire.com/news-release/2024/01/19/2812429/0/en/Alvotech-Provides-Update-on-Status-of-Biologics-License-Applications-for-AVT02-and-AVT04.html,European Regulatory News,1/19/2024 11:30,market_open,13.07999992,14.14000034,477.6499939,482.4299927,0.081039788,0.010007325,0.071032463,long,long,
158,189,ALVO,"Alvotech tilkynnir hvenær sala á AVT04, líftæknilyfjahliðstæðu við Stelara, getur hafist á alþjóðlegum mörkuðum",https://www.globenewswire.com/news-release/2024/02/15/2829780/0/is/Alvotech-tilkynnir-hven%C3%A6r-sala-%C3%A1-AVT04-l%C3%ADft%C3%A6knilyfjahli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-Stelara-getur-hafist-%C3%A1-al%C3%BEj%C3%B3%C3%B0legum-m%C3%B6rku%C3%B0um.html,European Regulatory News,2/15/2024 6:30,pre_market,15.69999981,15.75,498.5700073,499.2900085,0.003184726,0.001444133,0.001740593,long,long,
159,205,AMRN,"Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023",https://www.globenewswire.com/news-release/2023/04/19/2649963/18362/en/Amarin-to-Report-First-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-May-3-2023.html,Conference Calls/ Webcasts,4/19/2023 8:00,pre_market,1.370000005,1.360000014,414.2099915,412.2200012,-0.007299263,-0.004804303,-0.00249496,short,short,
160,199,AMRN,"Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023",https://www.globenewswire.com/news-release/2023/10/19/2763140/18362/en/Amarin-to-Report-Third-Quarter-2023-Financial-Results-and-Host-Conference-Call-on-November-1-2023.html,Conference Calls/ Webcasts,10/19/2023 8:00,pre_market,0.769999981,0.75,430.2099915,430.9500122,-0.025974002,0.001720139,-0.02769414,short,short,
161,200,AMRN,Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt,https://www.globenewswire.com/news-release/2023/07/20/2708141/18362/en/Amarin-Board-of-Directors-Announces-Executive-Compensation-Program-for-New-President-and-CEO-Patrick-Holt.html,Directors and Officers,7/20/2023 8:00,pre_market,1.080000043,1.110000014,455.2000122,454.1700134,0.02777775,-0.002262739,0.030040489,long,long,
162,201,AMRN,Amarin Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/11/01/2770981/18362/en/Amarin-Reports-Third-Quarter-2023-Financial-Results.html,Earnings Releases and Operating Results,11/1/2023 7:00,pre_market,0.699999988,0.699999988,418.2000122,419.2000122,0,0.0023912,-0.0023912,short,short,
163,202,AMRN,Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress,https://www.globenewswire.com/news-release/2023/07/26/2711275/18362/en/Latest-Research-Evaluating-Clinical-Benefits-of-VASCEPA-VAZKEPA-icosapent-ethyl-to-be-Presented-at-the-European-Society-of-Cardiology-ESC-Congress.html,Clinical Study,7/26/2023 8:00,pre_market,1.129999995,1.129999995,455.4400024,454.4700012,0,-0.002129811,0.002129811,long,long,
164,203,AMRN,Amarin Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/03/2660168/18362/en/Amarin-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,5/3/2023 7:00,pre_market,1.409999967,1.429999948,410.8399963,411.3599854,0.014184384,0.001265673,0.012918711,long,long,
165,204,AMRN,Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA),https://www.globenewswire.com/news-release/2023/06/21/2692114/18362/en/Amarin-Announces-Vascepa-Icosapent-Ethyl-Approved-to-Reduce-Cardiovascular-Risk-in-the-Kingdom-of-Saudi-Arabia-KSA.html,Product / Services Announcement,6/21/2023 9:00,pre_market,1.190000057,1.179999948,437.1799927,436.1600037,-0.008403453,-0.00233311,-0.006070343,short,short,
166,198,AMRN,Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China,https://www.globenewswire.com/news-release/2023/06/01/2680082/18362/en/Amarin-Partner-EddingPharm-Receives-Regulatory-Approval-for-Vascepa-Icosapent-Ethyl-in-Mainland-China.html,Health,6/1/2023 6:00,pre_market,1.169999957,1.210000038,417.8500061,418.0899963,0.034188105,0.000574345,0.033613759,long,long,
167,206,AMRN,Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1),https://www.globenewswire.com/news-release/2023/08/07/2719579/18362/en/Scottish-Medicines-Consortium-Accepts-VAZKEPA-icosapent-ethyl-to-Help-Reduce-Cardiovascular-Risk-for-Patients-in-Scotland-1.html,Product / Services Announcement,8/7/2023 7:00,pre_market,1.179999948,1.179999948,446.8099976,448.7099915,0,0.004252353,-0.004252353,short,short,
168,190,ALVO,"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®",https://www.globenewswire.com/news-release/2024/01/29/2818530/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html,European Regulatory News,1/29/2024 4:00,pre_market,14.64999962,15,487.4100037,487.730011,0.023890812,0.000656547,0.023234265,long,long,
169,191,ALVO,Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum,https://www.globenewswire.com/news-release/2024/01/19/2812429/0/is/Alvotech-birtir-uppl%C3%BDsingar-um-st%C3%B6%C3%B0u-ums%C3%B3kna-um-marka%C3%B0sleyfi-fyrir-AVT02-og-AVT04-%C3%AD-Bandar%C3%ADkjunum.html,European Regulatory News,1/19/2024 11:30,market_open,13.07999992,14.14000034,477.6499939,482.4299927,0.081039788,0.010007325,0.071032463,long,long,
170,192,ALVO,Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04,https://www.globenewswire.com/news-release/2024/01/19/2812432/0/en/Alvotech-Provides-Update-on-Status-of-Biologics-License-Applications-for-AVT02-and-AVT04.html,Health,1/19/2024 11:30,market_open,13.07999992,14.14000034,477.6499939,482.4299927,0.081039788,0.010007325,0.071032463,long,long,
171,194,ALVO,"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®",https://www.globenewswire.com/news-release/2024/01/29/2818535/0/en/Alvotech-Announces-Positive-Top-Line-Results-from-a-Pharmacokinetic-Study-for-AVT03-a-Proposed-Biosimilar-for-Prolia-and-Xgeva.html,Clinical Study,1/29/2024 4:00,pre_market,14.64999962,15,487.4100037,487.730011,0.023890812,0.000656547,0.023234265,long,long,
172,195,ALVO,Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab),https://www.globenewswire.com/news-release/2024/02/15/2829779/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html,Financing Agreements,2/15/2024 6:30,pre_market,15.69999981,15.75,498.5700073,499.2900085,0.003184726,0.001444133,0.001740593,long,long,
173,196,ALVO,Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab),https://www.globenewswire.com/news-release/2024/02/15/2829780/0/en/Alvotech-Announces-Expected-Global-Market-Entry-Dates-for-AVT04-Biosimilar-to-Stelara-ustekinumab.html,European Regulatory News,2/15/2024 6:30,pre_market,15.69999981,15.75,498.5700073,499.2900085,0.003184726,0.001444133,0.001740593,long,long,
174,221,ANAB,Anaptys Announces Participation in November Investor Conferences,https://www.globenewswire.com/news-release/2023/11/01/2771329/0/en/Anaptys-Announces-Participation-in-November-Investor-Conferences.html,Conference Calls/ Webcasts,11/1/2023 9:15,pre_market,16.30999947,16.13999939,418.2000122,419.2000122,-0.010423058,0.0023912,-0.012814259,short,short,
175,222,ANAB,"Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress",https://www.globenewswire.com/news-release/2023/10/11/2758455/0/en/Anaptys-to-Present-Phase-1-Data-on-ANB032-its-BTLA-Agonist-Antibody-at-the-32nd-EADV-Congress.html,Clinical Study,10/11/2023 9:15,pre_market,19.59000015,19.55999947,434.5400085,435.6400146,-0.001531429,0.002531427,-0.004062855,short,short,
176,223,ANAB,AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer,https://www.globenewswire.com/news-release/2022/12/02/2566746/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agent-JEMPERLI-dostarlimab-gxly-meets-primary-endpoint-in-Phase-3-RUBY-trial-in-primary-advanced-or-recurrent-endometrial-cancer.html,Health,12/2/2022 9:00,pre_market,27.28000069,26.98999977,407.3800049,402.25,-0.010630532,-0.012592677,0.001962145,long,long,
177,224,ANAB,AnaptysBio to Participate in Upcoming November Investor Conferences,https://www.globenewswire.com/news-release/2022/11/09/2552375/0/en/AnaptysBio-to-Participate-in-Upcoming-November-Investor-Conferences.html,Calendar of Events,11/9/2022 14:10,market_open,29.77000046,29.29000092,379.9299927,374.1300049,-0.016123599,-0.015265938,-0.000857661,short,short,
178,207,AMRN,Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events,https://www.globenewswire.com/news-release/2023/05/12/2667968/18362/en/Amarin-Highlights-New-Data-Providing-Potential-Mechanistic-Insight-into-Vascepa-Vazkepa-Icosapent-Ethyl-Reduction-of-Cardiovascular-Events.html,Health,5/12/2023 11:00,market_open,1.200000048,1.230000019,413.4200134,411.5899963,0.024999975,-0.004426532,0.029426508,long,long,
179,208,AMRN,Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel,https://www.globenewswire.com/news-release/2023/08/08/2720436/18362/en/Amarin-And-Neopharm-Announce-Exclusive-Commercialization-Agreement-for-VAZKEPA-Icosapent-Ethyl-in-Israel.html,Product / Services Announcement,8/8/2023 7:00,pre_market,1.149999976,1.139999986,450.7099915,448.0799866,-0.008695644,-0.005835249,-0.002860395,short,short,
180,209,AMRN,"Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer",https://www.globenewswire.com/news-release/2023/10/31/2770478/18362/en/Amarin-Appoints-Jonathan-Provoost-Executive-Vice-President-Chief-Legal-Compliance-Officer.html,Directors and Officers,10/31/2023 12:00,market_open,0.680000007,0.699999988,416.1799927,418.2000122,0.029411736,0.004853716,0.02455802,long,long,
181,210,AMRN,Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea,https://www.globenewswire.com/news-release/2023/07/31/2714836/18362/en/Amarin-and-Lotus-Pharmaceuticals-Announce-Exclusive-Partnership-Agreement-to-Commercialize-Vazkepa-Icosapent-Ethyl-in-Southeast-Asia-and-South-Korea.html,Partnerships,7/31/2023 8:00,pre_market,1.190000057,1.190000057,456.9200134,457.4100037,0,0.001072376,-0.001072376,short,short,
182,211,AMRN,Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health,https://www.globenewswire.com/news-release/2023/04/04/2640591/18362/en/Amarin-Announces-VAZKEPA-Icosapent-Ethyl-Approved-by-Israel-s-Ministry-of-Health.html,Product / Services Announcement,4/4/2023 8:00,pre_market,1.49000001,1.480000019,410.9500122,411.6199951,-0.006711403,0.001630327,-0.00834173,short,short,
183,212,AMRN,Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors,https://www.globenewswire.com/news-release/2023/04/17/2647757/18362/en/Amarin-Names-Aaron-Berg-Interim-President-Chief-Executive-Officer-and-Adds-Oliver-O-Connor-to-Company-s-Board-of-Directors.html,Directors and Officers,4/17/2023 7:00,pre_market,1.350000024,1.350000024,412.4599915,412.3699951,0,-0.000218194,0.000218194,long,long,
184,213,AMRN,Amarin to Present at the 2023 Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/12/2741592/18362/en/Amarin-to-Present-at-the-2023-Cantor-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,9/12/2023 8:00,pre_market,1.009999991,1,448.4500122,446.9500122,-0.009900981,-0.003344854,-0.006556126,short,short,
185,214,AMRN,Amarin Reports Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/08/02/2716719/18362/en/Amarin-Reports-Second-Quarter-2023-Financial-Results.html,Earnings Releases and Operating Results,8/2/2023 7:11,pre_market,1.190000057,1.159999967,456.480011,453.25,-0.025210159,-0.007075909,-0.01813425,short,short,
186,215,AMRN,Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024,https://www.globenewswire.com/news-release/2024/01/10/2806970/18362/en/Amarin-Provides-Preliminary-Fourth-Quarter-2023-Selected-Financials-and-Outlines-Key-Priorities-For-2024.html,Pre-Release Comments,1/10/2024 7:00,pre_market,0.970000029,1.120000005,473.8800049,474.1600037,0.154639146,0.000590864,0.154048282,long,long,
187,216,AMRN,Amarin Chairman & CEO Issue Letter to Shareholders,https://www.globenewswire.com/news-release/2024/01/22/2812941/18362/en/Amarin-Chairman-CEO-Issue-Letter-to-Shareholders.html,Major shareholder announcements,1/22/2024 7:30,pre_market,1.049999952,1.059999943,482.4299927,484.0100098,0.009523801,0.003275122,0.006248679,long,long,
188,217,AMRN,"Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024",https://www.globenewswire.com/news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html,Conference Calls/ Webcasts,2/15/2024 8:00,pre_market,1.179999948,1.179999948,498.5700073,499.2900085,0,0.001444133,-0.001444133,short,short,
189,218,AMRN,Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/11/2793825/18362/en/Amarin-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/11/2023 8:00,pre_market,0.860000014,0.839999974,460.2000122,459.6900024,-0.023255861,-0.001108235,-0.022147626,short,short,
190,241,ANNX,Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/08/07/2719531/0/en/Annexon-Highlights-Recent-Pipeline-and-Business-Progress-and-Reports-Second-Quarter-2023-Financial-Results.html,Earnings Releases and Operating Results,8/7/2023 6:30,pre_market,3.380000114,3.400000095,446.8099976,448.7099915,0.005917154,0.004252353,0.001664801,long,long,
191,232,ANNX,Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference,https://www.globenewswire.com/news-release/2023/02/27/2615857/0/en/Annexon-Biosciences-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference.html,Conference Calls/ Webcasts,2/27/2023 6:30,pre_market,5.389999867,5.440000057,396.3800049,399.8699951,0.009276474,0.008804658,0.000471816,long,long,
192,237,ANNX,Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/19/2745419/0/en/Annexon-Biosciences-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html,Calendar of Events,9/19/2023 6:30,pre_market,2.619999886,2.640000105,443.6300049,442.6799927,0.007633672,-0.002141452,0.009775124,long,long,
193,228,ANAB,Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP),https://www.globenewswire.com/news-release/2023/10/09/2756638/0/en/Anaptys-Announces-Positive-Top-Line-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html,Product / Services Announcement,10/9/2023 8:00,pre_market,19.25,20.42000008,429.5400085,427.5799866,0.060779225,-0.004563072,0.065342297,long,long,
194,231,ANNX,Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS),https://www.globenewswire.com/news-release/2023/10/10/2757271/0/en/Annexon-Announces-Clinical-and-Regulatory-Progress-for-ANX005-Pivotal-Program-in-Guillain-Barr%C3%A9-Syndrome-GBS.html,Clinical Study,10/10/2023 6:30,pre_market,1.960000038,1.99000001,432.2900085,432.9400024,0.015306108,0.001503606,0.013802501,long,long,
195,227,ANAB,AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit,https://www.globenewswire.com/news-release/2023/09/12/2741776/0/en/AnaptysBio-to-Present-at-the-Stifel-2023-Immunology-and-Inflammation-Virtual-Summit.html,Conference Calls/ Webcasts,9/12/2023 9:15,pre_market,19.69000053,19.67000008,448.4500122,446.9500122,-0.001015767,-0.003344854,0.002329087,long,long,
196,233,ANNX,Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/09/2777120/0/en/Annexon-Biosciences-to-Participate-in-2023-Jefferies-London-Healthcare-Conference.html,Conference Calls/ Webcasts,11/9/2023 6:30,pre_market,2.170000076,2.140000105,437.25,438.4299927,-0.013824871,0.002698668,-0.016523539,short,short,
197,242,ANNX,Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/27/2801303/0/en/Annexon-Biosciences-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/27/2023 6:30,pre_market,4.409999847,4.489999771,475.6499939,475.4400024,0.018140573,-0.000441483,0.018582056,long,long,
198,243,ANVS,Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report,https://www.globenewswire.com/news-release/2020/09/03/2088309/0/en/Annovis-Bio-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html,Product / Services Announcement,9/3/2020 6:45,pre_market,4.900000095,4.659999847,357.7000122,355.8699951,-0.048979642,-0.005116067,-0.043863575,short,long,
199,239,ANNX,Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2023/04/11/2644185/0/en/Annexon-Biosciences-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html,Conference Calls/ Webcasts,4/11/2023 6:30,pre_market,4.454999924,4.440000057,409.6099854,410.2600098,-0.003366974,0.001586935,-0.004953908,short,long,
200,236,ANNX,Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023,https://www.globenewswire.com/news-release/2023/07/24/2709360/0/en/Annexon-to-Report-ARCHER-Phase-2-Trial-Results-in-Geographic-Atrophy-at-ASRS-2023.html,Clinical Study,7/24/2023 6:30,pre_market,3.275000095,3.269999981,452.1799927,453.3699951,-0.001526753,0.002631701,-0.004158453,short,long,
201,238,ANNX,"Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/07/27/2711977/0/en/Annexon-Biosciences-Strengthens-Leadership-Team-with-Appointment-of-Jamie-Dananberg-M-D-as-Chief-Medical-Officer.html,Management Changes,7/27/2023 6:30,pre_market,3.369999886,3.420000076,455.5100098,459.019989,0.014836852,0.007705603,0.00713125,long,long,
202,235,ANNX,Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy,https://www.globenewswire.com/news-release/2023/10/24/2765415/0/en/Annexon-Receives-PRIME-Designation-from-the-EMA-for-ANX007-for-the-Treatment-of-Geographic-Atrophy.html,Health,10/24/2023 6:30,pre_market,1.679999948,1.74000001,420.4599915,422.6499939,0.035714324,0.005208587,0.030505737,long,long,
203,229,ANAB,AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference,https://www.globenewswire.com/news-release/2022/11/21/2560251/0/en/AnaptysBio-to-Participate-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference.html,Calendar of Events,11/21/2022 13:56,market_open,27.34000015,27.04000092,394.6400146,394.5899963,-0.010972906,-0.000126744,-0.010846161,short,short,
204,234,ANNX,Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones,https://www.globenewswire.com/news-release/2023/03/06/2620852/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Reiterates-Anticipated-Milestones.html,Earnings Releases and Operating Results,3/6/2023 6:30,pre_market,4.730000019,4.690000057,404.1900024,405.0499878,-0.008456652,0.002127676,-0.010584328,short,short,
205,230,ANAB,Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/01/31/2821240/0/en/Anaptys-to-Present-at-Guggenheim-s-6th-Annual-Biotechnology-Conference.html,Conference Calls/ Webcasts,1/31/2024 9:15,pre_market,23.93000031,23.78000069,490.8900146,488.6199951,-0.006268267,-0.004624294,-0.001643973,short,short,
206,250,ANVS,Annovis Bio CEO to Present at Meridian Clinical Trials Summit,https://www.globenewswire.com/news-release/2020/11/02/2118277/0/en/Annovis-Bio-CEO-to-Present-at-Meridian-Clinical-Trials-Summit.html,Company Announcement,11/2/2020 6:45,pre_market,4.559999943,4.199999809,326.5400085,330.2000122,-0.078947399,0.011208439,-0.090155837,short,short,
207,247,ANVS,"Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections",https://www.globenewswire.com/news-release/2023/11/27/2786071/0/en/Annovis-Bio-Announces-Full-Enrollment-of-Its-Phase-II-III-Alzheimer-s-Disease-Trial-Exceeding-Original-Projections.html,Clinical Study,11/27/2023 7:30,pre_market,6.5,6.800000191,455.2999878,454.6499939,0.046153876,-0.001427617,0.047581492,long,long,
208,246,ANVS,Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report,https://www.globenewswire.com/news-release/2020/12/17/2146815/0/en/Annovis-Bio-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html,Company Announcement,12/17/2020 6:45,pre_market,5.949999809,5.949999809,370.1700134,371.9400024,0,0.004781557,-0.004781557,short,short,
209,255,ANVS,Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference,https://www.globenewswire.com/news-release/2020/12/03/2139244/0/en/Annovis-Bio-to-Present-at-the-New-York-Academy-of-Sciences-Alzheimer-s-Disease-Therapeutics-Alternatives-to-Amyloid-2020-Virtual-Conference.html,Calendar of Events,12/3/2020 9:15,pre_market,5.400000095,5.269999981,366.7900085,366.6799927,-0.024074095,-0.000299942,-0.023774153,short,short,
210,251,ANVS,Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences,https://www.globenewswire.com/news-release/2020/12/15/2145170/0/en/Annovis-Bio-Showcases-its-Unique-Approach-to-Alzheimer-s-at-the-New-York-Academy-of-Sciences.html,Company Announcement,12/15/2020 6:45,pre_market,5.96999979,5.989999771,364.6600037,367.3999939,0.003350081,0.007513822,-0.004163741,short,short,
211,253,ANVS,Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair,https://www.globenewswire.com/news-release/2020/10/20/2110894/0/en/Annovis-Bio-CEO-Participates-in-Roundtable-Discussion-at-the-Financial-Times-Outstanding-Directors-Exchange-and-Panel-Discussion-at-the-Angel-Venture-Fair.html,Calendar of Events,10/20/2020 6:45,pre_market,4.940000057,4.989999771,342.0100098,343.4599915,0.0101214,0.004239589,0.005881811,long,long,
212,256,ANVS,Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases,https://www.globenewswire.com/news-release/2020/11/12/2125393/0/en/Annovis-Bio-Reports-Positive-Results-from-Final-Phase-of-1-9M-NIH-Funded-Chronic-Toxicology-Study-for-its-Lead-Compound-for-the-Treatment-of-Alzheimer-s-and-Parkinson-s-Diseases.html,Product / Services Announcement,11/12/2020 6:45,pre_market,4.809999943,5.099999905,356.6700134,355.5799866,0.060291053,-0.003056121,0.063347175,long,long,
213,259,ANVS,Annovis Bio to Participate in the 139th Yale CEO Summit,https://www.globenewswire.com/news-release/2023/12/11/2794161/0/en/Annovis-Bio-to-Participate-in-the-139th-Yale-CEO-Summit.html,Calendar of Events,12/11/2023 13:00,market_open,10.27999973,9.380000114,459.6900024,461.9899902,-0.087548603,0.005003345,-0.092551949,short,short,
214,252,ANVS,Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium,https://www.globenewswire.com/news-release/2020/11/16/2127426/0/en/Annovis-Bio-to-Participate-in-A-G-P-s-Virtual-Healthcare-Symposium.html,Calendar of Events,11/16/2020 9:15,pre_market,4.840000153,5,358.1000061,360.980011,0.033057819,0.00804246,0.025015359,long,short,
215,257,ANVS,Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study,https://www.globenewswire.com/news-release/2023/10/12/2759203/0/en/Annovis-Bio-Announces-Positive-Interim-Independent-Analysis-for-Statistical-Power-in-Its-Alzheimer-s-Study.html,Clinical Study,10/12/2023 8:02,pre_market,7.699999809,8,436.3200073,436.9500122,0.038961065,0.001443906,0.037517159,long,long,
216,248,ANVS,Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award,https://www.globenewswire.com/news-release/2020/10/22/2112633/0/en/Annovis-Bio-CEO-Receives-2020-Smart-Business-Dealmaker-Award.html,Calendar of Events,10/22/2020 6:45,pre_market,4.760000229,4.800000191,342.730011,342.9599915,0.008403353,0.000671025,0.007732328,long,long,
217,254,ANVS,Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights,https://www.globenewswire.com/news-release/2020/10/15/2109031/0/en/Annovis-Bio-Provides-Third-Quarter-2020-and-Year-to-Date-Business-Highlights.html,Company Announcement,10/15/2020 6:45,pre_market,4.960000038,5.179999828,347.9299927,343.7099915,0.044354796,-0.01212888,0.056483676,long,long,
218,249,ANVS,Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases,https://www.globenewswire.com/news-release/2020/08/20/2081200/0/en/Annovis-Bio-Actively-Recruiting-Patients-for-its-Phase-2a-Trials-in-Alzheimer-s-and-Parkinson-s-Diseases.html,Product / Services Announcement,8/20/2020 6:45,pre_market,5.179999828,5.690000057,337.230011,335.3599854,0.098455646,-0.005545253,0.104000899,long,long,
219,258,ANVS,"Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease",https://www.globenewswire.com/news-release/2020/09/29/2100426/0/en/Annovis-Bio-Demonstrates-Improved-Axonal-Transport-in-Nerve-Cells-and-Brain-of-Down-Syndrome-Mice-an-Animal-Model-of-Alzheimer-s-Disease.html,Research Analysis and Reports,9/29/2020 6:45,pre_market,4.489999771,4.489999771,334.1900024,333.9700012,0,-0.000658312,0.000658312,long,long,
220,260,ANVS,Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease,https://www.globenewswire.com/news-release/2023/12/05/2790799/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-III-Study-of-Buntanetap-in-Parkinson-s-Disease.html,Health,12/5/2023 7:30,pre_market,9.850000382,10,456.6900024,455.2600098,0.015228387,-0.003131211,0.018359598,long,long,
221,261,ANVS,Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease,https://www.globenewswire.com/news-release/2024/02/14/2828993/0/en/Annovis-Bio-Announces-Last-Patient-Last-Visit-in-the-Phase-II-III-Study-of-Buntanetap-in-Alzheimer-s-Disease.html,Clinical Study,2/14/2024 7:30,pre_market,10.05000019,10.35000038,494.0799866,496.7900085,0.029850765,0.005484986,0.024365778,long,long,
222,278,ARQT,Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress,https://www.globenewswire.com/news-release/2023/10/13/2759915/0/en/Arcutis-Presents-Positive-Patient-Reported-Outcome-Data-from-the-Pivotal-ARRECTOR-Phase-3-Trial-in-Scalp-and-Body-Psoriasis-at-European-Academy-of-Dermatology-and-Venereology-EADV-.html,Clinical Study,10/13/2023 8:00,pre_market,3.880000114,3.529999971,433.6600037,435.2099915,-0.09020622,0.003574201,-0.09378042,short,short,
223,279,ARQT,FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6,https://www.globenewswire.com/news-release/2023/11/29/2787702/0/en/FDA-Accepts-Arcutis-Supplemental-New-Drug-Application-for-Roflumilast-Cream-0-15-for-the-Treatment-of-Atopic-Dermatitis-in-Adults-and-Children-Down-to-Age-6.html,Clinical Study,11/29/2023 8:00,pre_market,2.039999962,2.049999952,454.9299927,457.1499939,0.004901956,0.004879874,2.20818e-05,long,long,
224,265,APTO,"Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023",https://www.globenewswire.com/news-release/2023/05/31/2679281/35575/en/Aptose-to-Hold-Interim-Clinical-Update-Webcast-on-Saturday-June-10-2023.html,Conference Calls/ Webcasts,5/31/2023 7:30,pre_market,0.419999987,0.439999998,420.1799927,418.2799988,0.047619075,-0.004521857,0.052140932,long,long,
225,266,APTO,Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical,https://www.globenewswire.com/news-release/2024/01/26/2817923/35575/en/Aptose-Announces-Pricing-of-8-4-Million-Public-Offering-and-a-Concurrent-4-Million-Private-Placement-with-Hanmi-Pharmaceutical.html,Financing Agreements,1/26/2024 8:00,pre_market,1.899999976,1.799999952,488.0299988,487.5899963,-0.052631592,-0.000901589,-0.051730003,short,short,
226,267,APTO,Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference,https://www.globenewswire.com/news-release/2023/10/16/2760527/35575/en/Aptose-Clinical-and-Preclinical-Data-to-be-Presented-at-European-School-of-Haematology-ESH-6th-International-Conference.html,Research Analysis and Reports,10/16/2023 7:30,pre_market,2.140000105,2.24000001,431.5,433.8200073,0.046728925,0.00537661,0.041352315,long,long,
227,268,APTO,Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical,https://www.globenewswire.com/news-release/2023/09/06/2738285/35575/en/Aptose-Announces-Closing-of-3-Million-Investment-by-Hanmi-Pharmaceutical.html,Financing Agreements,9/6/2023 7:45,pre_market,4.039999962,4.119999886,449.2399902,448.3999939,0.019801962,-0.001869817,0.021671778,long,long,
228,269,APTO,Aptose to Present at the Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/18/2744684/35575/en/Aptose-to-Present-at-the-Cantor-Global-Healthcare-Conference.html,Health,9/18/2023 7:45,pre_market,3.289999962,3.319999933,443.3699951,443.0499878,0.009118532,-0.000721761,0.009840294,long,long,
229,270,APTO,"Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023",https://www.globenewswire.com/news-release/2023/10/26/2767370/35575/en/Aptose-to-Report-Third-Quarter-2023-Financial-Results-and-Hold-Conference-Call-on-Thursday-November-9-2023.html,Conference Calls/ Webcasts,10/26/2023 7:11,pre_market,2.579999924,2.670000076,417.5499878,416.4500122,0.034883781,-0.002634357,0.037518138,long,long,
230,271,APTO,"Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th",https://www.globenewswire.com/news-release/2023/10/23/2764610/35575/en/Aptose-to-Hold-Clinical-Update-and-KOL-Data-Review-of-AML-Drug-Tuspetinib-on-Monday-October-30th.html,Conference Calls/ Webcasts,10/23/2023 7:30,pre_market,2.269999981,2.289999962,421.1900024,419.6099854,0.008810564,-0.003751317,0.012561881,long,long,
231,272,APTO,Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib,https://www.globenewswire.com/news-release/2023/10/30/2769327/35575/en/Aptose-Presents-Highlights-from-Clinical-Update-Webcast-Featuring-Latest-Available-Data-on-AML-Drug-Tuspetinib.html,Clinical Study,10/30/2023 9:15,pre_market,3.180000067,3.230000019,410.6799927,413.5599976,0.015723255,0.007012771,0.008710484,long,long,
232,273,APTO,Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting,https://www.globenewswire.com/news-release/2023/11/02/2772405/35575/en/Aptose-Tuspetinib-Clinical-Data-Selected-for-Oral-Presentation-at-the-2023-ASH-Annual-Meeting.html,Clinical Study,11/2/2023 9:00,pre_market,2.849999905,2.769999981,422.6600037,426.5799866,-0.02807015,0.009274554,-0.037344703,short,short,
233,274,APTO,Aptose Biosciences Provides Update on Reverse Stock Split,https://www.globenewswire.com/news-release/2023/06/05/2681857/35575/en/Aptose-Biosciences-Provides-Update-on-Reverse-Stock-Split.html,Changes in company's own shares,6/5/2023 7:30,pre_market,0.430000007,0.449999988,427.9200134,428.2799988,0.046511583,0.000841245,0.045670338,long,long,
234,262,ANVS,Annovis Bio Appoints Andrew Walsh as Vice President Finance,https://www.globenewswire.com/news-release/2023/12/01/2789245/0/en/Annovis-Bio-Appoints-Andrew-Walsh-as-Vice-President-Finance.html,Directors and Officers,12/1/2023 7:30,pre_market,8.489999771,8.699999809,456.3999939,455.769989,0.024734988,-0.001380379,0.026115366,long,long,
235,263,ANVS,Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement,https://www.globenewswire.com/news-release/2024/01/24/2815216/0/en/Annovis-Bio-Refines-Timeline-for-Parkinson-s-Phase-III-Study-Data-Announcement.html,Clinical Study,1/24/2024 8:00,pre_market,11.64000034,10.46000004,484.8599854,487.8099976,-0.101374594,0.006084256,-0.10745885,short,short,
236,295,BCAB,BioAtla Announces $65 Million Underwritten Offering of its Common Stock,https://www.globenewswire.com/news-release/2022/11/04/2548838/0/en/BioAtla-Announces-65-Million-Underwritten-Offering-of-its-Common-Stock.html,Stock Market News,11/4/2022 9:08,pre_market,6.360000134,8.069999695,371.0100098,377,0.26886785,0.016145091,0.252722759,long,long,
237,296,BCAB,BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights,https://www.globenewswire.com/news-release/2023/03/16/2628593/0/en/BioAtla-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provide-Business-Highlights.html,Conference Calls/ Webcasts,3/16/2023 8:00,pre_market,2.559999943,2.549999952,389.2799988,386.8200073,-0.003906246,-0.006319337,0.002413091,long,long,
238,281,ARQT,Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%,https://www.globenewswire.com/news-release/2023/08/29/2733332/0/en/Arcutis-Launches-First-Television-Ad-for-ZORYVE-Roflumilast-Cream-0-3.html,Product / Services Announcement,8/29/2023 8:00,pre_market,8.020000458,8.149999619,442.7600098,442.6499939,0.016209371,-0.000248477,0.016457848,long,long,
239,282,ARQT,"Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report",https://www.globenewswire.com/news-release/2023/08/31/2735212/0/en/Arcutis-Biotherapeutics-Publishes-Annual-Environmental-Social-and-Governance-ESG-Report.html,"Environmental, Social, and Governance Criteria",8/31/2023 8:00,pre_market,8.930000305,8.93999958,451.0100098,451.6499939,0.00111974,0.001419002,-0.000299262,short,long,
240,283,ARQT,FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11,https://www.globenewswire.com/news-release/2023/10/06/2756044/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-Treatment-of-Psoriasis-in-Children-Ages-6-to-11.html,Product / Services Announcement,10/6/2023 8:00,pre_market,4.429999828,4.480000019,424.5,421.9700012,0.011286725,-0.00595995,0.017246675,long,long,
241,284,ARQT,Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5,https://www.globenewswire.com/news-release/2023/09/19/2745482/0/en/Arcutis-Announces-Positive-Results-from-INTEGUMENT-PED-Pivotal-Phase-3-Trial-of-Roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html,Clinical Study,9/19/2023 7:30,pre_market,6.429999828,6.360000134,443.6300049,442.6799927,-0.010886423,-0.002141452,-0.008744971,short,short,
242,285,ARQT,Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD),https://www.globenewswire.com/news-release/2023/09/07/2739327/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-15-Showing-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Mild-to-Moderate.html,Clinical Study,9/7/2023 8:15,pre_market,7.75,8.100000382,446.2200012,443.1099854,0.04516134,-0.006969692,0.052131031,long,long,
243,287,ARQT,Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/11/03/2773109/0/en/Arcutis-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Conference Calls/ Webcasts,11/3/2023 7:30,pre_market,2.220000029,2.430000067,430.7600098,433.1400146,0.094594611,0.00552513,0.089069481,long,long,
244,288,ARQT,New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials,https://www.globenewswire.com/news-release/2023/10/20/2763969/0/en/New-Data-Shows-ZORYVE-Roflumilast-Cream-0-3-Provided-Measurable-Improvement-of-Plaque-Psoriasis-in-Nearly-All-Individuals-in-DERMIS-Trials.html,Clinical Study,10/20/2023 8:00,pre_market,3.029999971,2.410000086,426.4299927,425.980011,-0.204620426,-0.00105523,-0.203565196,short,short,
245,289,ARQT,Arcutis Appoints L. Todd Edwards as Chief Commercial Officer,https://www.globenewswire.com/news-release/2023/09/27/2750305/0/en/Arcutis-Appoints-L-Todd-Edwards-as-Chief-Commercial-Officer.html,Directors and Officers,9/27/2023 8:00,pre_market,5.829999924,5.760000229,425.8800049,427.0899963,-0.012006809,0.002841156,-0.014847965,short,short,
246,290,ARQT,"ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States",https://www.globenewswire.com/news-release/2024/01/22/2813014/0/en/ZORYVE-roflumilast-Topical-Foam-0-3-for-the-Treatment-of-Seborrheic-Dermatitis-Launches-in-the-United-States.html,Health,1/22/2024 8:00,pre_market,3.25,3.440000057,482.4299927,484.0100098,0.058461556,0.003275122,0.055186434,long,long,
247,291,ARQT,Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results,https://www.globenewswire.com/news-release/2024/02/16/2830722/0/en/Arcutis-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html,Calendar of Events,2/16/2024 8:00,pre_market,7.96999979,7.96999979,502.0100098,501.7000122,0,-0.000617513,0.000617513,long,long,
248,292,ARQT,"Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial",https://www.globenewswire.com/news-release/2024/01/29/2818829/0/en/Journal-of-the-American-Academy-of-Dermatology-Publishes-ZORYVE-roflumilast-Foam-0-3-Results-for-Seborrheic-Dermatitis-from-Pivotal-Phase-3-Trial.html,Clinical Study,1/29/2024 8:00,pre_market,5.300000191,5.480000019,487.4100037,487.730011,0.033962231,0.000656547,0.033305684,long,long,
249,293,ARQT,Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference,https://www.globenewswire.com/news-release/2024/01/31/2821035/0/en/Arcutis-to-Present-at-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html,Calendar of Events,1/31/2024 8:00,pre_market,5.869999886,5.840000153,490.8900146,488.6199951,-0.005110687,-0.004624294,-0.000486394,short,short,
250,297,BCAB,"BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma",https://www.globenewswire.com/news-release/2023/02/23/2614225/0/en/BioAtla-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-BA3182-a-CAB-EpCAMxCAB-CD3-Bispecific-T-Cell-Engager-for-the-Treatment-of-Advanced-Adenocarcinoma.html,Clinical Study,2/23/2023 8:00,pre_market,3.170000076,3.150000095,398.5400085,401.5599976,-0.006309142,0.007577631,-0.013886773,short,short,
251,298,BCAB,"BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023",https://www.globenewswire.com/news-release/2023/07/25/2710360/0/en/BioAtla-to-Announce-Second-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-August-1-2023.html,Conference Calls/ Webcasts,7/25/2023 8:00,pre_market,2.880000114,2.849999905,454.2000122,453.9200134,-0.010416739,-0.000616466,-0.009800273,short,short,
252,299,BCAB,BioAtla to Participate in the JMP Securities Hematology and Oncology Summit,https://www.globenewswire.com/news-release/2023/11/30/2788523/0/en/BioAtla-to-Participate-in-the-JMP-Securities-Hematology-and-Oncology-Summit.html,Conference Calls/ Webcasts,11/30/2023 8:00,pre_market,1.700000048,1.710000038,454.6099854,455.480011,0.005882347,0.001913785,0.003968563,long,long,
253,300,BCAB,BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index,https://www.globenewswire.com/news-release/2023/06/26/2694369/0/en/BioAtla-Added-to-Membership-of-U-S-Small-Cap-Russell-2000-Index.html,Trading information,6/26/2023 8:00,pre_market,3.5,3.450000048,433.2099915,432.6199951,-0.014285701,-0.001361918,-0.012923783,short,short,
254,301,BCAB,BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones,https://www.globenewswire.com/news-release/2023/01/10/2586086/0/en/BioAtla-Provides-Clinical-Program-Updates-and-Upcoming-2023-Milestones.html,Clinical Study,1/10/2023 8:00,pre_market,7.71999979,5,387.8599854,387.25,-0.352331589,-0.001572695,-0.350758894,short,short,
255,302,BCAB,"BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award",https://www.globenewswire.com/news-release/2023/10/12/2759131/0/en/BioAtla-s-Jay-M-Short-Ph-D-Selected-for-The-Explorers-Club-Lowell-Thomas-Award.html,Contests/Awards,10/12/2023 7:30,pre_market,1.830000043,1.840000033,436.3200073,436.9500122,0.005464476,0.001443906,0.00402057,long,long,
256,303,BCAB,"BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023",https://www.globenewswire.com/news-release/2023/05/04/2661440/0/en/BioAtla-to-Announce-First-Quarter-2023-Financial-Results-and-Provide-Business-Highlights-on-May-11-2023.html,Conference Calls/ Webcasts,5/4/2023 8:00,pre_market,3.74000001,3.759999991,408.019989,406.9299927,0.005347589,-0.002671429,0.008019017,long,short,
257,304,BCAB,BioAtla to Participate in the Jefferies London Healthcare Conference,https://www.globenewswire.com/news-release/2022/11/08/2550890/0/en/BioAtla-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html,Calendar of Events,11/8/2022 8:00,pre_market,8.069999695,8.069999695,379.9500122,381.1099854,0,0.003052963,-0.003052963,short,short,
258,305,BCAB,BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC,https://www.globenewswire.com/news-release/2023/11/28/2786858/0/en/BioAtla-to-Host-Virtual-KOL-Event-to-Review-IASLC-Data-on-BA3011-in-NSCLC.html,Conference Calls/ Webcasts,11/28/2023 8:00,pre_market,1.470000029,1.5,454.480011,454.0799866,0.020408143,-0.00088018,0.021288324,long,long,
259,306,BCAB,BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2022/12/22/2578554/0/en/BioAtla-to-Participate-in-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,Conference Calls/ Webcasts,12/22/2022 8:00,pre_market,8.260000229,8.319999695,386.230011,383.0499878,0.007263858,-0.008233496,0.015497354,long,long,
260,307,BCAB,"BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023",https://www.globenewswire.com/news-release/2023/10/10/2757357/0/en/BioAtla-Provides-Guidance-on-Near-Term-Milestones-and-Plans-to-Announce-Third-Quarter-2023-Financial-Results-and-Business-Update-on-November-7-2023.html,Conference Calls/ Webcasts,10/10/2023 7:30,pre_market,1.720000029,1.720000029,432.2900085,432.9400024,0,0.001503606,-0.001503606,short,short,
261,308,BCAB,BioAtla to Participate in the Jefferies Healthcare Conference,https://www.globenewswire.com/news-release/2023/05/31/2679301/0/en/BioAtla-to-Participate-in-the-Jefferies-Healthcare-Conference.html,Trade Show,5/31/2023 8:00,pre_market,3.029999971,3.009999991,420.1799927,418.2799988,-0.006600654,-0.004521857,-0.002078797,short,short,
262,309,BCAB,BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2738343/0/en/BioAtla-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Conference Calls/ Webcasts,9/6/2023 8:00,pre_market,2.519999981,2.539999962,449.2399902,448.3999939,0.0079365,-0.001869817,0.009806317,long,short,
263,310,BCAB,BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types,https://www.globenewswire.com/news-release/2023/12/13/2795508/0/en/BioAtla-Hosting-Virtual-R-D-Day-to-Highlight-BA3071-CAB-CTLA-4-Phase-1-Data-in-Multiple-Solid-Tumor-Types.html,Calendar of Events,12/13/2023 8:00,pre_market,1.720000029,1.789999962,464.1000061,464.4899902,0.040697635,0.000840302,0.039857333,long,long,
264,311,BCAB,BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event,https://www.globenewswire.com/news-release/2023/12/05/2790846/0/en/BioAtla-Presented-Phase-2-Clinical-Trial-Data-at-the-IASLC-2023-North-America-Conference-on-Lung-Cancer-and-Virtual-KOL-Event.html,Clinical Study,12/5/2023 8:00,pre_market,1.370000005,1.389999986,456.6900024,455.2600098,0.014598526,-0.003131211,0.017729737,long,long,
265,312,BCAB,BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/20/2799219/0/en/BioAtla-to-Participate-in-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/20/2023 8:00,pre_market,1.995000005,2.099999905,474.8399963,473.9599915,0.052631529,-0.001853266,0.054484795,long,long,
266,313,BCAB,"BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023",https://www.globenewswire.com/news-release/2023/12/06/2791717/0/en/BioAtla-to-Host-Virtual-R-D-Day-to-Review-BA3071-CAB-CTLA-4-Phase-1-Data-in-Multiple-Solid-Tumor-Types-on-Wednesday-December-13-2023.html,Clinical Study,12/6/2023 8:00,pre_market,1.399999976,1.419999957,456.6000061,458.8099976,0.014285701,0.004840104,0.009445597,long,long,
267,316,BCDA,BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs,https://www.globenewswire.com/news-release/2023/09/06/2738243/0/en/BioCardia-Announces-Clarification-and-Next-Steps-on-its-Autologous-CardiAMP-Cell-Therapy-Programs.html,Clinical Study,9/6/2023 7:15,pre_market,0.579999983,0.550000012,449.2399902,448.3999939,-0.05172409,-0.001869817,-0.049854274,short,short,
268,317,BCDA,BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan,https://www.globenewswire.com/news-release/2023/06/08/2684599/0/en/BioCardia-Announces-Helix-Biotherapeutic-Delivery-Patent-Issuance-in-Japan.html,Patents,6/8/2023 7:00,pre_market,1.99000001,2.049999952,426.5499878,426.6199951,0.030150725,0.000164125,0.0299866,long,long,
269,319,BCDA,BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected,https://www.globenewswire.com/news-release/2023/07/24/2709400/0/en/BioCardia-Announces-DSMB-Recommendation-to-Pause-New-Enrollment-in-Phase-III-Pivotal-CardiAMP-Cell-Therapy-Heart-Failure-Trial-While-Additional-Blinded-Data-is-Collected.html,Product / Services Announcement,7/24/2023 7:00,pre_market,1.980000019,1.320000053,452.1799927,453.3699951,-0.333333313,0.002631701,-0.335965014,short,short,
270,320,BCDA,BioCardia Letter to Shareholders,https://www.globenewswire.com/news-release/2022/12/22/2578489/0/en/BioCardia-Letter-to-Shareholders.html,Health,12/22/2022 7:00,pre_market,1.789999962,1.769999981,386.230011,383.0499878,-0.011173174,-0.008233496,-0.002939678,short,short,
271,321,BCDA,BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications,https://www.globenewswire.com/news-release/2023/05/09/2664254/0/en/BioCardia-Announces-US-Patent-on-Bone-Marrow-Derived-Neurokinin-1-Receptor-Positive-NK1R-Mesenchymal-Stem-Cells-for-Therapeutic-Applications.html,Patents,5/9/2023 7:00,pre_market,2.039999962,2.009999991,412.7399902,411.1300049,-0.014705869,-0.003900725,-0.010805143,short,short,
272,322,BCDA,BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies,https://www.globenewswire.com/news-release/2023/04/04/2640452/0/en/BioCardia-Announces-Issuance-of-Two-Patents-Related-to-Technology-That-Guides-Interventional-Therapies.html,Patents,4/4/2023 7:00,pre_market,2,1.960000038,410.9500122,411.6199951,-0.019999981,0.001630327,-0.021630308,short,short,
273,323,BCDA,BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure,https://www.globenewswire.com/news-release/2023/11/14/2779941/0/en/BioCardia-Announces-FDA-Approval-of-CardiAMP-Heart-Failure-II-Protocol-for-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure.html,Health,11/14/2023 7:15,pre_market,0.400000006,1.289999962,440.1900024,446.3200073,2.224999857,0.013925816,2.211074041,long,long,
274,324,BCDA,"BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023",https://www.globenewswire.com/news-release/2023/03/16/2628490/0/en/BioCardia-to-Host-2022-Financial-Results-and-Corporate-Update-Conference-Call-on-March-29-2023.html,Conference Calls/ Webcasts,3/16/2023 7:00,pre_market,1.970000029,2,389.2799988,386.8200073,0.015228412,-0.006319337,0.021547749,long,long,
275,325,BCDA,BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study,https://www.globenewswire.com/news-release/2023/05/23/2674138/0/en/BioCardia-Announces-Timing-of-the-Next-Data-Safety-Monitoring-Board-Meeting-for-the-CardiAMP-Cell-Therapy-in-Heart-Failure-Pivotal-Study.html,Calendar of Events,5/23/2023 7:00,pre_market,1.690000057,1.700000048,418.7900085,417.0799866,0.005917154,-0.004083244,0.010000398,long,long,
276,330,BCDA,BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes,https://www.globenewswire.com/news-release/2023/12/18/2797714/0/en/BioCardia-Announces-Expected-CardiAMP-Heart-Failure-Japan-Approval-Timeline-Based-on-Pharmaceutical-and-Medical-Device-Agency-Consultation-Minutes.html,Clinical Study,12/18/2023 7:16,pre_market,0.600000024,0.620000005,469.3299866,470.980011,0.0333333,0.003515702,0.029817598,long,long,
277,326,BCDA,"BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023",https://www.globenewswire.com/news-release/2023/08/02/2716675/0/en/BioCardia-to-Host-Q2-2023-Financial-Results-and-Corporate-Update-Conference-Call-on-August-9-2023.html,Conference Calls/ Webcasts,8/2/2023 7:00,pre_market,0.970000029,1.009999991,456.480011,453.25,0.041237073,-0.007075909,0.048312982,long,long,
278,327,BCDA,BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval,https://www.globenewswire.com/news-release/2023/11/29/2787607/0/en/BioCardia-Shares-Update-from-Japan-PMDA-Consultation-on-CardiAMP-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure-Foreign-Data-Expected-to-be-Sufficient-for-Product-Approval.html,Other News,11/29/2023 7:00,pre_market,0.689999998,0.660000026,454.9299927,457.1499939,-0.04347822,0.004879874,-0.048358094,short,long,
279,349,BICX,"BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder",https://www.globenewswire.com/news-release/2022/06/30/2472213/0/en/BioCorRx-Announces-First-Subject-Dosed-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html,Health,6/30/2022 9:00,pre_market,2.329999924,2.480000019,380.3399963,376.2399902,0.064377725,-0.010779845,0.07515757,long,long,
280,328,BCDA,BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results,https://www.globenewswire.com/news-release/2023/03/29/2636648/0/en/BioCardia-Reports-Fourth-Quarter-and-Full-Year-2022-Business-Highlights-and-Financial-Results.html,Conference Calls/ Webcasts,3/29/2023 8:15,pre_market,2.170000076,2.170000076,395.6000061,399.9299927,0,0.010945365,-0.010945365,short,short,
281,329,BCDA,BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II,https://www.globenewswire.com/news-release/2023/10/11/2758144/0/en/BioCardia-Announces-Completion-of-Enrollment-in-Phase-III-CardiAMP-HF-Trial-and-Plans-for-CardiAMP-HF-Trial-II.html,Clinical Study,10/11/2023 6:00,pre_market,0.389999986,0.409999996,434.5400085,435.6400146,0.051282081,0.002531427,0.048750654,long,long,
282,337,BICX,"BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder",https://www.globenewswire.com/news-release/2023/01/19/2591804/0/en/BioCorRx-Announces-Completion-of-Treatment-Phase-of-Study-Subjects-and-Preliminary-Safety-Data-from-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treat.html,Company Announcement,1/19/2023 8:30,pre_market,1.230000019,1.269999981,391.4899902,389.3599854,0.032520294,-0.005440765,0.037961058,long,long,
283,338,BICX,BioCorRx Provides Business Update for the First Quarter of 2023,https://www.globenewswire.com/news-release/2023/05/16/2669960/0/en/BioCorRx-Provides-Business-Update-for-the-First-Quarter-of-2023.html,Company Announcement,5/16/2023 8:30,pre_market,1.850000024,1.909999967,413.0100098,411.8599854,0.032432401,-0.002784495,0.035216896,long,long,
284,339,BICX,BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting,https://www.globenewswire.com/news-release/2023/03/07/2622532/0/en/BioCorRx-Announced-Interim-Positive-Safety-and-Pharmacokinetic-Results-of-Phase-1-Clinical-Trial-at-4th-Annual-NIH-HEAL-Initiative-Investigator-Meeting.html,Clinical Study,3/7/2023 15:13,market_open,1.559999943,1.554999948,404.4200134,398.269989,-0.003205125,-0.015207023,0.012001898,long,long,
285,340,BICX,BioCorRx to Present at Sequire Biotechnology Conference on February 2nd,https://www.globenewswire.com/news-release/2023/01/27/2596906/0/en/BioCorRx-to-Present-at-Sequire-Biotechnology-Conference-on-February-2nd.html,Press releases,1/27/2023 8:30,pre_market,1.299999952,1.383000016,404.75,403.6600037,0.063846205,-0.002693011,0.066539217,long,long,
286,341,BICX,"BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder",https://www.globenewswire.com/news-release/2022/10/13/2533867/0/en/BioCorRx-Completes-Final-Subject-Enrollment-in-Phase-I-Clinical-Trial-of-BICX104-an-Implantable-Naltrexone-Pellet-for-the-Treatment-of-Opioid-Use-Disorder.html,Clinical Study,10/13/2022 8:30,pre_market,1.995000005,2,356.5599976,349.2099915,0.002506263,-0.020613659,0.023119922,long,long,
287,342,BICX,"BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder",https://www.globenewswire.com/news-release/2023/07/18/2706412/0/en/BioCorRx-Submits-Fast-Track-Application-to-FDA-for-BICX104-an-Implantable-Biodegradable-Naltrexone-Pellet-for-The-Treatment-of-Opioid-Use-Disorder.html,Press releases,7/18/2023 8:30,pre_market,1.860000014,2.019999981,450.8399963,450.5,0.086021487,-0.00075414,0.086775627,long,long,
288,343,BICX,BioCorRx Provides Business Update for the Third Quarter of 2022,https://www.globenewswire.com/news-release/2022/11/15/2556294/0/en/BioCorRx-Provides-Business-Update-for-the-Third-Quarter-of-2022.html,Earnings Releases and Operating Results,11/15/2022 9:00,pre_market,1.840000033,1.840000033,395.1199951,401.1499939,0,0.015261184,-0.015261184,short,short,
289,344,BICX,BioCorRx Provides Business Update for the Second Quarter of 2022,https://www.globenewswire.com/news-release/2022/08/16/2499080/0/en/BioCorRx-Provides-Business-Update-for-the-Second-Quarter-of-2022.html,Company Announcement,8/16/2022 8:30,pre_market,2.269999981,2.269999981,428.8599854,427.730011,0,-0.002634833,0.002634833,long,long,
290,345,BICX,BioCorRx Provides Business Update for 2022,https://www.globenewswire.com/news-release/2023/04/03/2639586/0/en/BioCorRx-Provides-Business-Update-for-2022.html,Annual report,4/3/2023 8:30,pre_market,1.769999981,1.769999981,409.3900146,408.8500061,0,-0.001319057,0.001319057,long,long,
291,346,BICX,BioCorRx Reports Business Update for the Third Quarter of 2023,https://www.globenewswire.com/news-release/2023/11/14/2780399/0/en/BioCorRx-Reports-Business-Update-for-the-Third-Quarter-of-2023.html,Earnings Releases and Operating Results,11/14/2023 12:52,market_open,1.440000057,1.230000019,446.3200073,448.730011,-0.145833354,0.005399721,-0.151233075,short,short,
292,347,BICX,BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors,https://www.globenewswire.com/news-release/2023/01/24/2594325/0/en/BioCorRx-Appoints-Pharmaceutical-Finance-Veteran-Harsha-Murthy-to-the-Board-of-Directors.html,Directors and Officers,1/24/2023 9:00,pre_market,1.100000024,1.200000048,400.6300049,398.8800049,0.090909111,-0.00436812,0.095277231,long,long,
293,348,BICX,BioCorRx Featured on LiveNOW from FOX,https://www.globenewswire.com/news-release/2022/06/17/2464706/0/en/BioCorRx-Featured-on-LiveNOW-from-FOX.html,Press releases,6/17/2022 9:00,pre_market,2.220000029,2.220000029,366.6499939,365.5100098,0,-0.003109189,0.003109189,long,long,
294,331,BCDA,BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction,https://www.globenewswire.com/news-release/2023/12/19/2798416/0/en/BioCardia-Doses-First-Patient-in-CardiALLO-Phase-I-II-Clinical-Trial-of-BCDA-03-Allogeneic-Mesenchymal-Stem-Cells-for-the-Treatment-of-Ischemic-Heart-Failure-of-Reduced-Ejection-Fr.html,Clinical Study,12/19/2023 7:00,pre_market,0.649999976,0.649999976,471.9700012,472.5299988,0,0.001186511,-0.001186511,short,short,
295,332,BCDA,BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders,https://www.globenewswire.com/news-release/2024/01/03/2803155/0/en/BioCardia-Biotherapeutic-Delivery-and-Morph-Access-Innovations-Business-Development-Update-for-Shareholders.html,Major shareholder announcements,1/3/2024 7:00,pre_market,0.660000026,0.639999986,472.6499939,470.4299927,-0.030303091,-0.004696924,-0.025606166,short,short,
296,333,BCDA,BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA,https://www.globenewswire.com/news-release/2024/02/08/2825876/0/en/BioCardia-Announces-Activation-of-CardiAMP-Heart-Failure-II-Phase-3-Pivotal-Study-Recently-Approved-by-FDA.html,Clinical Study,2/8/2024 7:00,pre_market,0.449999988,0.409999996,498.1000061,498.1000061,-0.088888873,0,-0.088888873,short,long,
297,334,BCDA,BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference,https://www.globenewswire.com/news-release/2024/01/31/2820965/0/en/BioCardia-Announces-Two-Scientific-Abstracts-Have-Been-Accepted-at-the-2024-Technology-and-Heart-Failure-Therapeutics-Conference.html,Calendar of Events,1/31/2024 7:00,pre_market,0.479999989,0.479999989,490.8900146,488.6199951,0,-0.004624294,0.004624294,long,long,
298,356,BIIB,Biogen Appoints Adam Keeney as Head of Corporate Development,https://www.globenewswire.com/news-release/2023/04/04/2640516/0/en/Biogen-Appoints-Adam-Keeney-as-Head-of-Corporate-Development.html,Directors and Officers,4/4/2023 7:30,pre_market,277.3399963,277.1099854,410.9500122,411.6199951,-0.000829347,0.001630327,-0.002459674,short,long,
299,357,BIIB,New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/03/29/2636687/0/en/New-Data-Presented-at-AD-PD-2023-Show-Biogen-s-BIIB080-MAPT-ASO-Substantially-Reduced-Tau-Protein-Levels-in-Patients-with-Early-stage-Alzheimer-s-Disease.html,Clinical Study,3/29/2023 8:45,pre_market,270.25,271.1199951,395.6000061,399.9299927,0.003219223,0.010945365,-0.007726142,short,short,
300,358,BIIB,Biogen Appoints Jane Grogan as Head of Research,https://www.globenewswire.com/news-release/2023/09/06/2738268/0/en/Biogen-Appoints-Jane-Grogan-as-Head-of-Research.html,Management Changes,9/6/2023 7:30,pre_market,266.2900085,266.4700012,449.2399902,448.3999939,0.000675927,-0.001869817,0.002545744,long,short,
301,359,BIIB,Biogen Appoints Monish Patolawala to its Board of Directors,https://www.globenewswire.com/news-release/2023/11/06/2773981/0/en/Biogen-Appoints-Monish-Patolawala-to-its-Board-of-Directors.html,Directors and Officers,11/6/2023 7:30,pre_market,249.5,249.5,434.6900024,435.4700012,0,0.001794379,-0.001794379,short,short,
302,360,BIIB,"FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS",https://www.globenewswire.com/news-release/2023/04/25/2654404/0/en/FDA-Grants-Accelerated-Approval-for-QALSODY-tofersen-for-SOD1-ALS-a-Major-Scientific-Advancement-as-the-First-Treatment-to-Target-a-Genetic-Cause-of-ALS.html,Clinical Study,4/25/2023 15:04,market_open,291.0499878,282.4100037,410.5799866,406.0799866,-0.029685568,-0.010960106,-0.018725462,short,short,
303,361,BIIB,Biogen Completes Acquisition of Reata Pharmaceuticals,https://www.globenewswire.com/news-release/2023/09/26/2749581/0/en/Biogen-Completes-Acquisition-of-Reata-Pharmaceuticals.html,Mergers and Acquisitions,9/26/2023 8:59,pre_market,255.0200043,254.9700012,432.230011,429.0899963,-0.000196075,-0.007264685,0.00706861,long,long,
304,362,BIIB,Biogen to Acquire Reata Pharmaceuticals,https://www.globenewswire.com/news-release/2023/07/28/2713028/0/en/Biogen-to-Acquire-Reata-Pharmaceuticals.html,Health,7/28/2023 7:05,pre_market,262.7900085,263.2999878,452.4899902,455.8800049,0.001940634,0.007491911,-0.005551277,short,short,
305,363,BIIB,Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting,https://www.globenewswire.com/news-release/2023/10/19/2763066/0/en/Biogen-to-Present-New-Data-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-2023-Meeting.html,Clinical Study,10/19/2023 7:30,pre_market,263.5,263.4500122,430.2099915,430.9500122,-0.000189707,0.001720139,-0.001909846,short,short,
306,350,BICX,BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States,https://www.globenewswire.com/news-release/2022/12/07/2569398/0/en/BioCorRx-Partners-with-Government-Plus-to-Expand-its-Beat-Addiction-Recovery-Program-in-the-United-States.html,Partnerships,12/7/2022 9:00,pre_market,1.759999991,2,393.8299866,392.9400024,0.136363643,-0.002259818,0.138623461,long,long,
307,351,BICX,"BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.",https://www.globenewswire.com/news-release/2022/11/22/2560932/0/en/BioCorRx-Board-of-Directors-Approves-Exploration-of-Potential-Spin-Off-of-BioCorRx-Pharmaceuticals-Inc.html,Company Announcement,11/22/2022 9:00,pre_market,1.850000024,1.850000024,394.5899963,396.6300049,0,0.005169945,-0.005169945,short,short,
308,352,BICX,BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data,https://www.globenewswire.com/news-release/2023/02/23/2614329/0/en/BioCorRx-Attended-4th-Annual-NIH-HEAL-Initiative-Investigator-Meeting-Shares-Update-on-BICX104-Data.html,Company Announcement,2/23/2023 8:30,pre_market,2,2,398.5400085,401.5599976,0,0.007577631,-0.007577631,short,short,
309,353,BICX,BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President,https://www.globenewswire.com/news-release/2024/01/09/2806288/0/en/BioCorRx-Appoints-Renowned-Investment-and-Capital-Markets-Executive-Louis-Lucido-as-President.html,Directors and Officers,1/9/2024 8:30,pre_market,0.671999991,0.720000029,474.6000061,471.8699951,0.071428628,-0.005752236,0.077180864,long,long,
310,364,BIIB,Biogen to Realign Resources for Alzheimer's Disease Franchise,https://www.globenewswire.com/news-release/2024/01/31/2821003/0/en/Biogen-to-Realign-Resources-for-Alzheimer-s-Disease-Franchise.html,Clinical Study,1/31/2024 7:30,pre_market,247.0800018,247.6699982,490.8900146,488.6199951,0.002387876,-0.004624294,0.007012169,long,long,
311,365,BIIB,Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission,https://www.globenewswire.com/news-release/2023/12/19/2798443/0/en/Centralized-Marketing-Authorizations-of-Generic-Versions-of-TECFIDERA-are-Revoked-by-the-European-Commission.html,Product / Services Announcement,12/19/2023 7:30,pre_market,250.3300018,250.3300018,471.9700012,472.5299988,0,0.001186511,-0.001186511,short,short,
312,354,BICX,BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors,https://www.globenewswire.com/news-release/2024/02/08/2826159/0/en/BioCorRx-Pharmaceuticals-Inc-Appoints-Neuroscientist-Dr-Kate-DeVarney-to-the-Board-of-Directors.html,Directors and Officers,2/8/2024 9:52,market_open,0.759999991,0.814999998,498.1000061,498.3200073,0.072368431,0.000441681,0.071926751,long,long,
313,366,BIIB,"ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.",https://www.globenewswire.com/news-release/2023/12/14/2796102/0/en/ZURZUVAE-zuranolone-CIV-a-Landmark-Oral-Treatment-for-Women-with-Postpartum-Depression-PPD-is-Now-Available-in-the-U-S.html,Product / Services Announcement,12/14/2023 6:30,pre_market,255.5599976,257,470.5,472.5,0.005634694,0.004250797,0.001383897,long,long,
314,369,BIOR,Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform,https://www.globenewswire.com/news-release/2023/08/03/2717952/0/en/Biora-Therapeutics-Announces-New-Patents-Covering-its-BioJet-Systemic-Oral-Delivery-Platform.html,Patents,8/3/2023 8:00,pre_market,3.849999905,3.829999924,450.1300049,448.0400085,-0.0051948,-0.004643095,-0.000551706,short,short,
315,377,BIOR,Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update,https://www.globenewswire.com/news-release/2023/05/08/2663346/0/en/Biora-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html,Conference Calls/ Webcasts,5/8/2023 9:00,pre_market,2.569999933,2.559999943,412.6300049,412.9700012,-0.003891047,0.000823974,-0.004715021,short,short,
316,371,BIOR,Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program,https://www.globenewswire.com/news-release/2023/09/25/2748572/0/en/Biora-Therapeutics-Announces-Submission-of-IND-Application-to-the-U-S-FDA-for-BT-600-Program.html,Health,9/25/2023 8:00,pre_market,2.130000114,2.130000114,430.4200134,429.1700134,0,-0.00290414,0.00290414,long,long,
317,372,BIOR,Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update,https://www.globenewswire.com/news-release/2023/11/06/2774028/0/en/Biora-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html,Conference Calls/ Webcasts,11/6/2023 8:00,pre_market,1.889999986,1.909999967,434.6900024,435.4700012,0.010582001,0.001794379,0.008787621,long,short,
318,373,BIOR,Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform,https://www.globenewswire.com/news-release/2023/07/27/2712117/0/en/Biora-Therapeutics-Announces-Clinical-Device-Performance-Study-Results-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html,Clinical Study,7/27/2023 8:00,pre_market,3.660000086,3.630000114,455.5100098,459.019989,-0.008196713,0.007705603,-0.015902316,short,short,
319,379,BIOR,Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer,https://www.globenewswire.com/news-release/2023/05/01/2658330/0/en/Biora-Therapeutics-Appoints-Dr-Ariella-Kelman-as-Chief-Medical-Officer.html,Management Changes,5/1/2023 9:00,pre_market,2.430000067,2.400000095,415.9299927,415.4700012,-0.012345667,-0.001105935,-0.011239732,short,short,
320,374,BIOR,Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/11/2740775/0/en/Biora-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/11/2023 8:01,pre_market,2.869999886,2.920000076,445.519989,448.2399902,0.01742167,0.006105228,0.011316442,long,long,
321,375,BIOR,Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure,https://www.globenewswire.com/news-release/2023/09/19/2745527/0/en/Biora-Therapeutics-Reduces-Debt-and-Largest-Shareholder-Increases-Equity-Exposure.html,Interim information,9/19/2023 8:00,pre_market,2.089999914,2.210000038,443.6300049,442.6799927,0.05741633,-0.002141452,0.059557781,long,long,
322,376,BIOR,Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update,https://www.globenewswire.com/news-release/2023/07/17/2705252/0/en/Biora-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html,Calendar of Events,7/17/2023 6:00,pre_market,4,4.010000229,449.2799988,449.1300049,0.002500057,-0.000333854,0.002833911,long,long,
323,378,BIOR,Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions,https://www.globenewswire.com/news-release/2023/06/26/2694235/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-American-Diabetes-Association-83rd-Scientific-Sessions.html,Clinical Study,6/26/2023 6:00,pre_market,3.809999943,3.799999952,433.2099915,432.6199951,-0.00262467,-0.001361918,-0.001262752,short,short,
324,380,BIOR,Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform,https://www.globenewswire.com/news-release/2023/06/28/2696172/0/en/Biora-Therapeutics-Announces-New-Patents-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html,Patents,6/28/2023 8:30,pre_market,3.549999952,3.549999952,436.1700134,435.0499878,0,-0.002567865,0.002567865,long,long,
325,381,BIOR,Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes,https://www.globenewswire.com/news-release/2023/10/05/2755345/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html,Health,10/5/2023 8:00,pre_market,2.180000067,2.190000057,424.6600037,424.3599854,0.004587151,-0.000706491,0.005293642,long,long,
326,382,BIOR,Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/06/13/2687091/0/en/Biora-Therapeutics-Announces-8-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,Initial Public Offerings,6/13/2023 8:00,pre_market,6.230000019,5,433.7999878,435.3200073,-0.197431784,0.003503964,-0.200935748,short,short,
327,383,BIOR,Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium,https://www.globenewswire.com/news-release/2024/02/08/2825975/0/en/Biora-Therapeutics-Announces-Participation-in-Canaccord-Genuity-Inflammatory-Bowel-Disease-Symposium.html,Calendar of Events,2/8/2024 8:00,pre_market,0.856999993,0.839999974,498.1000061,498.1000061,-0.019836662,0,-0.019836662,short,long,
328,384,BIOR,Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform,https://www.globenewswire.com/news-release/2023/12/11/2793791/0/en/Biora-Therapeutics-Announces-New-Research-Collaboration-for-the-BioJet-Systemic-Oral-Delivery-Platform.html,Product / Services Announcement,12/11/2023 8:00,pre_market,1.169999957,1.200000048,460.2000122,459.6900024,0.025641104,-0.001108235,0.026749339,long,long,
329,385,BIOR,Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.,https://www.globenewswire.com/news-release/2024/01/22/2812999/0/en/Biora-Therapeutics-Announces-Participation-in-Fireside-Chat-Hosted-by-H-C-Wainwright-Co.html,Conference Calls/ Webcasts,1/22/2024 8:00,pre_market,0.912000001,0.898000002,482.4299927,484.0100098,-0.015350876,0.003275122,-0.018625998,short,long,
330,397,BIVI,BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association,https://www.globenewswire.com/news-release/2023/06/21/2691942/0/en/BioVie-To-Present-of-NE3017-in-Alzheimer-s-Disease-Data-at-83rd-Scientific-Sessions-of-the-American-Diabetes-Association.html,Product / Services Announcement,6/21/2023 8:00,pre_market,5.510000229,5.519999981,437.1799927,436.1600037,0.001814837,-0.00233311,0.004147947,long,long,
331,398,BIVI,BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023,https://www.globenewswire.com/news-release/2023/11/13/2779020/0/en/BioVie-Presents-Positive-Clinical-Safety-Data-from-Phase-2b-Trial-of-BIV201-in-Refractory-Ascites-at-the-American-Association-for-the-Study-of-Liver-Disease-AASLD-The-Liver-Meeting.html,Clinical Study,11/13/2023 8:00,pre_market,3.279999971,3.130000114,440.6099854,439.230011,-0.045731664,-0.003131963,-0.042599701,short,short,
332,399,BIVI,BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting,https://www.globenewswire.com/news-release/2023/04/20/2650993/0/en/BioVie-To-Present-Data-from-NE3107-Phase-2-Open-Label-Trial-at-Society-of-Biological-Psychiatry-Annual-Meeting.html,Clinical Study,4/20/2023 8:30,pre_market,8.18999958,8.130000114,414.1400146,411.2099915,-0.007325943,-0.007074958,-0.000250985,short,short,
333,400,BIVI,BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023,https://www.globenewswire.com/news-release/2023/10/26/2767473/0/en/BioVie-Announces-Late-Breaking-Abstract-Presenting-Clinical-Safety-Data-from-the-Company-s-Ascites-Phase-2-Trial-Accepted-for-Presentation-at-AASLD-The-Liver-Meeting-2023.html,Calendar of Events,10/26/2023 8:00,pre_market,3.150000095,3.039999962,417.5499878,416.4500122,-0.034920676,-0.002634357,-0.03228632,short,short,
334,401,BIVI,BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023,https://www.globenewswire.com/news-release/2023/04/17/2647867/0/en/BioVie-Announces-Data-Abstracts-from-NE3107-Phase-2-Trials-Accepted-for-Presentation-at-AAN-2023.html,Trade Show,4/17/2023 8:00,pre_market,7.949999809,7.909999847,412.4599915,412.3699951,-0.005031442,-0.000218194,-0.004813248,short,short,
335,402,BIVI,BioVie to Participate in the Truist Securities BioPharma Symposium,https://www.globenewswire.com/news-release/2023/11/02/2772222/0/en/BioVie-to-Participate-in-the-Truist-Securities-BioPharma-Symposium.html,Calendar of Events,11/2/2023 8:00,pre_market,4.599999905,4.550000191,422.6600037,426.5799866,-0.010869503,0.009274554,-0.020144057,short,long,
336,389,BIOS.BR,"Correction: BioSenic S.A.  : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS",https://www.globenewswire.com/news-release/2023/10/17/2761355/0/en/Correction-BioSenic-S-A-Transparency-notifications-received-from-Fran%C3%A7ois-Rieger-V%C3%A9ronique-Pomi-FA-Di%C3%A8se-3-SAS-and-Capital-Grand-Est-SAS.html,European Regulatory News,10/17/2023 7:00,pre_market,0.061000001,0.061000001,436.0400085,432.8099976,0,-0.007407602,0.007407602,long,long,
337,390,BIOS.BR,BioSenic soutient la prochaine conférence européenne sur la maladie du greffon contre l'hôte,https://www.globenewswire.com/news-release/2024/01/31/2820799/0/fr/BioSenic-soutient-la-prochaine-conf%C3%A9rence-europ%C3%A9enne-sur-la-maladie-du-greffon-contre-l-h%C3%B4te.html,European Regulatory News,1/31/2024 4:30,pre_market,0.041999999,0.0438,490.8900146,488.6199951,0.042857159,-0.004624294,0.047481453,long,long,
338,391,BIOS.BR,"BioSenic signe un nouvel accord de souscription pour un maximum de 1,2 M€ en obligations convertibles",https://www.globenewswire.com/news-release/2024/01/08/2805699/0/fr/BioSenic-signe-un-nouvel-accord-de-souscription-pour-un-maximum-de-1-2-M-en-obligations-convertibles.html,European Regulatory News,1/8/2024 12:00,market_open,0.064000003,0.064199999,468.4299927,474.6000061,0.003124936,0.013171687,-0.010046751,short,short,
339,386,BIOR,Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform,https://www.globenewswire.com/news-release/2023/12/19/2798488/0/en/Biora-Therapeutics-Announces-New-Patent-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html,Patents,12/19/2023 8:00,pre_market,1.190000057,1.210000038,471.9700012,472.5299988,0.016806706,0.001186511,0.015620195,long,long,
340,392,BIOS.BR,BioSenic lève 500 000 euros dans le cadre d'un placement privé d'actions nouvelles auprès de nouveaux investisseurs établis,https://www.globenewswire.com/news-release/2024/02/02/2822980/0/fr/BioSenic-l%C3%A8ve-500-000-euros-dans-le-cadre-d-un-placement-priv%C3%A9-d-actions-nouvelles-aupr%C3%A8s-de-nouveaux-investisseurs-%C3%A9tablis.html,European Regulatory News,2/2/2024 11:30,market_open,0.041000001,0.041000001,489.6499939,494.3500061,0,0.009598718,-0.009598718,short,short,
341,393,BIOS.BR,BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds,https://www.globenewswire.com/news-release/2024/01/08/2805699/0/en/BioSenic-signs-a-new-subscription-agreement-for-a-maximum-of-EUR-1-2M-in-convertible-bonds.html,European Regulatory News,1/8/2024 12:00,market_open,0.064000003,0.064199999,468.4299927,474.6000061,0.003124936,0.013171687,-0.010046751,short,short,
342,394,BIOS.BR,BioSenic provides support to forthcoming European conference on graft-versus-host disease,https://www.globenewswire.com/news-release/2024/01/31/2820799/0/en/BioSenic-provides-support-to-forthcoming-European-conference-on-graft-versus-host-disease.html,European Regulatory News,1/31/2024 4:30,pre_market,0.041999999,0.0438,490.8900146,488.6199951,0.042857159,-0.004624294,0.047481453,long,long,
343,395,BIOS.BR,"BioSenic raises €500,000 in private placement of new shares with established new investors",https://www.globenewswire.com/news-release/2024/02/02/2822980/0/en/BioSenic-raises-500-000-in-private-placement-of-new-shares-with-established-new-investors.html,European Regulatory News,2/2/2024 11:30,market_open,0.041000001,0.041000001,489.6499939,494.3500061,0,0.009598718,-0.009598718,short,long,
344,387,BIOR,Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600,https://www.globenewswire.com/news-release/2024/01/08/2805368/0/en/Biora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-BT-600.html,Clinical Study,1/8/2024 8:00,pre_market,1.350000024,1.379999995,467.9200134,468.4299927,0.022222201,0.001089886,0.021132315,long,long,
345,388,BIOR,Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors,https://www.globenewswire.com/news-release/2023/12/18/2797800/0/en/Biora-Therapeutics-Accelerates-Debt-Reduction-and-Raises-Capital-with-Large-Institutional-Investors.html,Health,12/18/2023 8:00,pre_market,1.360000014,1.230000019,469.3299866,470.980011,-0.095588231,0.003515702,-0.099103933,short,short,
346,404,BIVI,BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023,https://www.globenewswire.com/news-release/2023/03/21/2631261/0/en/BioVie-Announces-Data-from-Phase-2-Parkinson-s-Disease-Trial-Accepted-for-Presentation-at-AD-PD-2023.html,Health,3/21/2023 8:01,pre_market,9.239999771,9.420000076,393.7399902,397.2399902,0.019480553,0.008889115,0.010591438,long,long,
347,405,BIVI,BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD,https://www.globenewswire.com/news-release/2023/10/19/2763073/0/en/BioVie-to-Present-Blinded-Data-on-NE3107-in-the-Treatment-of-Mild-to-Moderate-Alzheimer-s-Disease-at-CTAD.html,Clinical Study,10/19/2023 7:30,pre_market,3.170000076,3.109999895,430.2099915,430.9500122,-0.018927502,0.001720139,-0.02064764,short,short,
348,406,BIVI,"BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023",https://www.globenewswire.com/news-release/2023/09/07/2739254/0/en/BioVie-Hosting-Virtual-KOL-Event-on-NE3107-in-Alzheimer-s-Disease-Today-September-7-2023.html,Conference Calls/ Webcasts,9/7/2023 8:00,pre_market,3.329999924,3.329999924,446.2200012,443.1099854,0,-0.006969692,0.006969692,long,long,
349,407,BIVI,BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/06/26/2694368/0/en/BioVie-Presents-Data-Highlighting-Role-of-Insulin-Resistance-and-Neuroinflammation-in-the-Development-of-Mild-to-Moderate-in-Alzheimer-s-Disease.html,Calendar of Events,6/26/2023 8:00,pre_market,5.829999924,5.579999924,433.2099915,432.6199951,-0.042881647,-0.001361918,-0.04151973,short,short,
350,408,BIVI,BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders,https://www.globenewswire.com/news-release/2023/08/28/2732542/0/en/BioVie-Presents-Data-for-NE3107-at-2023-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html,Health,8/28/2023 8:00,pre_market,3.369999886,3.380000114,439.9700012,442.2399902,0.002967427,0.005159418,-0.002191991,short,short,
351,410,BIVI,BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/19/2745513/0/en/BioVie-to-Participate-in-the-Cantor-Fitzgerald-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,9/19/2023 8:00,pre_market,3.200000048,3.210000038,443.6300049,442.6799927,0.003124997,-0.002141452,0.005266449,long,long,
352,411,BIVI,BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/11/29/2787674/0/en/BioVie-Announces-Efficacy-Data-from-Phase-3-Trial-of-NE3107-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html,Clinical Study,11/29/2023 8:00,pre_market,4.989999771,1.620000005,454.9299927,457.1499939,-0.675350686,0.004879874,-0.68023056,short,short,
353,412,BIVI,"BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET",https://www.globenewswire.com/news-release/2023/10/30/2769132/0/en/BioVie-to-Host-Conference-Call-and-Webcast-Wednesday-November-1-2023-at-8-00-AM-ET.html,Conference Calls/ Webcasts,10/30/2023 8:00,pre_market,3.190000057,3.130000114,410.6799927,413.5599976,-0.018808759,0.007012771,-0.025821531,short,short,
354,413,BIVI,"BioVie Announces Registration Details for ""BioVie Day"" Webinar",https://www.globenewswire.com/news-release/2023/03/14/2626541/0/en/BioVie-Announces-Registration-Details-for-BioVie-Day-Webinar.html,Calendar of Events,3/14/2023 8:00,pre_market,8.260000229,8.539999962,385.3599854,390.5,0.033898272,0.013338216,0.020560056,long,long,
355,414,BIVI,BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease,https://www.globenewswire.com/news-release/2023/09/11/2740752/0/en/BioVie-Presents-Data-Highlighting-Baseline-Characteristics-of-Study-Population-in-Phase-3-Trial-of-NE3107-in-Mild-to-Moderate-Alzheimer-s-Disease.html,Clinical Study,9/11/2023 8:00,pre_market,3.440000057,3.579999924,445.519989,448.2399902,0.040697635,0.006105228,0.034592407,long,short,
356,415,BIVI,BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference,https://www.globenewswire.com/news-release/2023/03/09/2624028/0/en/BioVie-to-Participate-in-the-Oppenheimer-33rd-Annual-Healthcare-Conference.html,Conference Calls/ Webcasts,3/9/2023 8:00,pre_market,8.909999847,8.800000191,398.9200134,399.7399902,-0.012345641,0.002055492,-0.014401133,short,short,
357,416,BIVI,"BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial",https://www.globenewswire.com/news-release/2023/03/13/2625654/0/en/BioVie-Announces-the-Pausing-of-Patient-Enrollment-in-Ascites-Phase-2b-Trial-Encouraging-Efficacy-Data-is-Announced-Initiating-FDA-Discussions-to-Conduct-Pivotal-Registrational-Tri.html,Product / Services Announcement,3/13/2023 8:00,pre_market,8.149999619,7.949999809,385.9100037,381.8099976,-0.024539855,-0.010624255,-0.013915601,short,short,
358,417,BIVI,BioVie Issues Letter to Shareholders,https://www.globenewswire.com/news-release/2023/07/18/2706267/0/en/BioVie-Issues-Letter-to-Shareholders.html,Advisory,7/18/2023 7:00,pre_market,5.059999943,5.25,450.8399963,450.5,0.037549419,-0.00075414,0.038303559,long,long,
359,418,BIVI,BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease,https://www.globenewswire.com/news-release/2023/09/26/2749457/0/en/BioVie-Announces-Completion-of-Last-Patient-Treatment-Visit-in-Phase-3-Trial-of-NE3107-in-Mild-to-Moderate-Alzheimer-s-Disease.html,Clinical Study,9/26/2023 8:00,pre_market,3.25,3.269999981,432.230011,429.0899963,0.00615384,-0.007264685,0.013418525,long,short,
360,419,BIVI,BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease,https://www.globenewswire.com/news-release/2023/07/17/2705478/0/en/BioVie-Presents-Data-Showing-How-NE3107-May-Potentially-Regulate-DNA-Methylation-of-Specific-Genes-in-a-Manner-Highly-Correlated-to-Observed-Improvements-in-Cognition-and-Biomarker.html,Clinical Study,7/17/2023 7:00,pre_market,5.050000191,5.019999981,449.2799988,449.1300049,-0.005940635,-0.000333854,-0.005606781,short,short,
361,423,BMRA,Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock,https://www.globenewswire.com/news-release/2023/03/03/2620157/0/en/Biomerica-Announces-Pricing-of-8-Million-Underwritten-Public-Offering-of-Common-Stock.html,Prospectus/Announcement of Prospectus,3/3/2023 7:30,pre_market,2.779999971,2.5,397.8099976,399.7099915,-0.100719415,0.004776134,-0.105495549,short,short,
362,454,BNOX,Bionomics Provides a Review of 2023 and of 2024 Plans,https://www.globenewswire.com/news-release/2024/01/22/2812832/0/en/Bionomics-Provides-a-Review-of-2023-and-of-2024-Plans.html,Clinical Study,1/22/2024 6:00,pre_market,1.049999952,1,482.4299927,484.0100098,-0.047619004,0.003275122,-0.050894126,short,short,
363,425,BMRA,Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores,https://www.globenewswire.com/news-release/2022/10/14/2534713/0/en/Walmart-to-Expand-Sales-of-Biomerica-s-Aware-Breast-Self-Exam-Product-will-now-be-available-in-over-2400-Walmart-stores.html,Product / Services Announcement,10/14/2022 9:18,pre_market,3.960000038,5,365.9700012,368.5499878,0.262626251,0.007049722,0.255576529,long,long,
364,426,BMRA,"Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board",https://www.globenewswire.com/news-release/2023/01/10/2586154/0/en/Biomerica-Appoints-Mayo-Clinic-Gastroenterologist-Dr-Brian-E-Lacy-to-the-Company-s-Scientific-Advisory-Board.html,Health,1/10/2023 8:19,pre_market,3.400000095,3.460000038,387.8599854,387.25,0.017647042,-0.001572695,0.019219736,long,long,
365,427,BMRA,Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients,https://www.globenewswire.com/news-release/2023/06/21/2691993/0/en/Biomerica-Receives-Notice-of-Patent-Allowance-in-China-for-a-Potential-Innovative-Technology-That-Includes-an-Artificial-Intelligence-AI-Claim-for-Predicting-Foods-That-Contain-Ing.html,Patents,6/21/2023 8:19,pre_market,1.629999995,1.730000019,437.1799927,436.1600037,0.061349708,-0.00233311,0.063682818,long,long,
366,428,BMRA,Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE,https://www.globenewswire.com/news-release/2022/12/08/2570250/0/en/Biomerica-Receives-KFDA-and-Ministry-of-Health-Approval-for-Colorectal-Screening-and-Breast-Screening-Tests-in-Saudi-Arabia-and-UAE.html,Product / Services Announcement,12/8/2022 8:19,pre_market,3.74000001,3.819999933,393.1600037,395.1400146,0.021390354,0.005036146,0.016354208,long,long,
367,430,BMRA,REPEAT - Biomerica Reports First Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2023/10/13/2760118/0/en/REPEAT-Biomerica-Reports-First-Quarter-2024-Financial-Results.html,Earnings Releases and Operating Results,10/13/2023 13:10,market_open,0.720000029,0.74000001,435.2099915,431.5,0.02777775,-0.008524601,0.036302351,long,long,
368,431,BMRA,Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting,https://www.globenewswire.com/news-release/2022/11/02/2546506/0/en/Biomerica-InFoods-IBS-Data-Presented-at-the-2022-American-College-of-Gastroenterology-ACG-Annual-Scientific-Meeting.html,Clinical Study,11/2/2022 8:19,pre_market,3.400000095,3.380000114,384.519989,383.8999939,-0.005882347,-0.001612387,-0.00426996,short,short,
369,432,BMRA,"Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).",https://www.globenewswire.com/news-release/2023/04/17/2647830/0/en/Biomerica-s-inFoods-IBS-test-is-now-available-at-Gastro-Health-providing-a-revolutionary-new-treatment-for-patients-suffering-from-Irritable-Bowel-Syndrome-IBS.html,Product / Services Announcement,4/17/2023 7:47,pre_market,1.679999948,1.659999967,412.4599915,412.3699951,-0.011904751,-0.000218194,-0.011686557,short,short,
370,433,BMRA,inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology,https://www.globenewswire.com/news-release/2023/05/18/2671867/0/en/inFoods-IBS-Test-Now-Validated-for-Use-with-Simple-Finger-Stick-Whole-Blood-Collection-Technology.html,Clinical Study,5/18/2023 8:19,pre_market,1.200000048,1.139999986,415.230011,414.8999939,-0.05000005,-0.000794781,-0.049205268,short,short,
371,434,BMRA,Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16,https://www.globenewswire.com/news-release/2023/11/10/2778299/0/en/Biomerica-to-Participate-in-14th-Annual-Craig-Hallum-Alpha-Select-Conference-on-November-16.html,Calendar of Events,11/10/2023 8:19,pre_market,0.910000026,0.939999998,433.8399963,435.980011,0.032967001,0.004932728,0.028034273,long,long,
372,435,BMRA,Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors,https://www.globenewswire.com/news-release/2023/08/28/2732577/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Joins-Biomerica-s-Board-of-Directors.html,Directors and Officers,8/28/2023 8:19,pre_market,1.149999976,1.149999976,439.9700012,442.2399902,0,0.005159418,-0.005159418,short,short,
373,436,BMRA,Biomerica Reports First Quarter 2024 Financial Results,https://www.globenewswire.com/news-release/2023/10/13/2759856/0/en/Biomerica-Reports-First-Quarter-2024-Financial-Results.html,Earnings Releases and Operating Results,10/13/2023 6:39,pre_market,0.75,0.720000029,433.6600037,435.2099915,-0.039999962,0.003574201,-0.043574162,short,short,
374,420,BIVI,"BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023",https://www.globenewswire.com/news-release/2023/08/31/2735173/0/en/BioVie-to-Host-Virtual-KOL-Event-on-NE3107-in-Alzheimer-s-Disease-on-September-7-2023.html,Health,8/31/2023 8:00,pre_market,3.329999924,3.359999895,451.0100098,451.6499939,0.009009001,0.001419002,0.007589999,long,long,
375,421,BIVI,BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/06/2824283/0/en/BioVie-to-Participate-in-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,Conference Calls/ Webcasts,2/6/2024 8:00,pre_market,1.029999971,1.039999962,492.5499878,493.519989,0.009708729,0.001969346,0.007739383,long,long,
376,452,BNOX,Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210,https://www.globenewswire.com/news-release/2023/08/23/2730217/0/en/Bionomics-Completes-Last-Patient-Last-Visit-in-the-Phase-2b-ATTUNE-Study-for-Post-Traumatic-Stress-Disorder-PTSD-and-Confirms-Expected-2023-Milestones-with-its-Lead-Asset-BNC210.html,Product / Services Announcement,8/23/2023 6:00,pre_market,1.200000048,1.269999981,438.1499939,439.25,0.058333275,0.00251057,0.055822706,long,long,
377,450,BNOX,Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD),https://www.globenewswire.com/news-release/2023/04/27/2656035/0/en/Bionomics-Announces-the-Completion-of-Enrollment-in-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html,Clinical Study,4/27/2023 6:00,pre_market,2.160000086,2.160000086,404.3599854,407,0,0.006528872,-0.006528872,short,short,
378,448,BNOX,Quarterly Activities and Cashflow Report,https://www.globenewswire.com/news-release/2023/07/31/2714666/0/en/Quarterly-Activities-and-Cashflow-Report.html,Management statements,7/31/2023 6:00,pre_market,1.909999967,1.460000038,456.9200134,457.4100037,-0.235602061,0.001072376,-0.236674437,short,short,
379,437,BMRA,Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed,https://www.globenewswire.com/news-release/2023/03/08/2623008/0/en/Biomerica-announces-the-Launch-of-InFoods-IBS-as-a-Laboratory-Developed-Test-LDT-First-patient-samples-have-been-processed.html,Health,3/8/2023 8:19,pre_market,2.289999962,2.329999924,398.269989,398.3900146,0.017467233,0.000301368,0.017165865,long,long,
380,444,BNOX,Quarterly Activities and Cashflow Report,https://www.globenewswire.com/news-release/2023/04/28/2657250/0/en/Quarterly-Activities-and-Cashflow-Report.html,Management statements,4/28/2023 6:00,pre_market,2.259999991,2.259999991,412.4100037,411.4899902,0,-0.002230822,0.002230822,long,short,
381,453,BNOX,Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting,https://www.globenewswire.com/news-release/2023/12/06/2791725/0/en/Bionomics-Presents-Detailed-Data-on-the-Validity-and-Reliability-of-the-Subjective-Units-of-Distress-Scale-at-the-2023-American-College-of-Neuropsychopharmacology-Annual-Meeting.html,Health,12/6/2023 8:00,pre_market,1.179999948,1.220000029,456.6000061,458.8099976,0.033898375,0.004840104,0.029058271,long,long,
382,443,BNOX,Bionomics to Present at Upcoming June Investor Conferences,https://www.globenewswire.com/news-release/2023/06/15/2688829/0/en/Bionomics-to-Present-at-Upcoming-June-Investor-Conferences.html,Calendar of Events,6/15/2023 8:00,pre_market,2.450000048,2.5,437.1799927,436.3299866,0.020408143,-0.001944293,0.022352437,long,long,
383,442,BNOX,Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting,https://www.globenewswire.com/news-release/2022/12/02/2566521/0/en/Bionomics-Announces-Accepted-Abstract-and-Upcoming-Poster-Presentations-at-the-American-College-of-Neuropsychopharmacology-ACNP-2022-Annual-Meeting.html,Health,12/2/2022 6:00,pre_market,6.949999809,7,407.3800049,402.25,0.007194272,-0.012592677,0.019786949,long,long,
384,447,BNOX,Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth,https://www.globenewswire.com/news-release/2023/07/03/2698382/0/en/Bionomics-Announces-Key-Leadership-Updates-to-Drive-U-S-Focused-Transformation-and-Next-Stage-of-Strategic-Growth.html,Management Changes,7/3/2023 6:00,pre_market,2.200000048,2.200000048,443.2799988,442.9200134,0,-0.000812095,0.000812095,long,long,
385,445,BNOX,Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD,https://www.globenewswire.com/news-release/2023/09/14/2743067/0/en/Bionomics-Announces-Update-on-the-%CE%B17-Nicotinic-Acetylcholine-Receptor-nAChR-Positive-Allosteric-Modulator-PAM-Collaboration-with-MSD.html,Product / Services Announcement,9/14/2023 6:00,pre_market,1.789999962,1.450000048,446.5100098,449.0700073,-0.18994409,0.005733349,-0.195677439,short,long,
386,446,BNOX,Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD),https://www.globenewswire.com/news-release/2023/09/28/2751004/0/en/Bionomics-Announces-Positive-Topline-Results-from-the-Phase-2b-ATTUNE-Clinical-Trial-of-BNC210-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html,Clinical Study,9/28/2023 6:00,pre_market,0.985000014,5.71999979,426.0499878,425.480011,4.807106302,-0.001337817,4.808444118,long,long,
387,449,BNOX,Bionomics Limited to Participate in Upcoming November Investor Conferences,https://www.globenewswire.com/news-release/2022/11/02/2546246/0/en/Bionomics-Limited-to-Participate-in-Upcoming-November-Investor-Conferences.html,Calendar of Events,11/2/2022 6:00,pre_market,8.25,7.46600008,384.519989,383.8999939,-0.095030293,-0.001612387,-0.093417906,short,long,
388,451,BNOX,Bionomics’ Half-Year Report,https://www.globenewswire.com/news-release/2023/02/23/2614019/0/en/Bionomics-Half-Year-Report.html,Earnings Releases and Operating Results,2/23/2023 6:00,pre_market,2.640000105,2.779999971,398.5400085,401.5599976,0.05303025,0.007577631,0.04545262,long,short,
389,438,BMRA,Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica,https://www.globenewswire.com/news-release/2024/01/23/2814070/0/en/Diagnostics-Industry-Leader-Jack-Kenny-Appointed-as-Chairman-of-the-Board-at-Biomerica.html,Directors and Officers,1/23/2024 8:19,pre_market,0.910000026,0.910000026,483.4500122,484.0100098,0,0.001158336,-0.001158336,short,short,
390,439,BMRA,Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population,https://www.globenewswire.com/news-release/2023/12/18/2797746/0/en/Biomerica-Received-US-FDA-510-k-Clearance-for-Their-Hp-Detect-ELISA-Test-Product-Designed-to-Detect-the-Presence-of-the-H-pylori-Bacteria-That-infects-Approximately-35-of-the-U-S-P.html,Product / Services Announcement,12/18/2023 7:47,pre_market,0.99000001,1.509999991,469.3299866,470.980011,0.525252501,0.003515702,0.521736799,long,long,
391,468,BNTX,BioNTech schließt Übernahme von InstaDeep ab,https://www.globenewswire.com/news-release/2023/07/31/2714822/0/de/BioNTech-schlie%C3%9Ft-%C3%9Cbernahme-von-InstaDeep-ab.html,Press releases,7/31/2023 8:00,pre_market,107.4199982,107.5999985,456.9200134,457.4100037,0.001675669,0.001072376,0.000603292,long,long,
392,464,BNTX,Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron XBB.1.5 angepassten COVID-19-Impfstoff in der Europäischen Union,https://www.globenewswire.com/news-release/2023/08/30/2734517/0/de/Pfizer-und-BioNTech-erhalten-positive-CHMP-Empfehlung-f%C3%BCr-an-Omikron-XBB-1-5-angepassten-COVID-19-Impfstoff-in-der-Europ%C3%A4ischen-Union.html,Company Announcement,8/30/2023 10:00,market_open,122.5,125.0800018,449.5100098,451.0100098,0.021061239,0.003336967,0.017724273,long,long,
393,457,BNTX,BioNTech Presents Positive Phase 1/2 Data Update for  CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023,https://www.globenewswire.com/news-release/2023/10/23/2764948/0/en/BioNTech-Presents-Positive-Phase-1-2-Data-Update-for-CAR-T-Cell-Therapy-Candidate-BNT211-in-Advanced-Solid-Tumors-at-ESMO-Congress-2023.html,Company Announcement,10/23/2023 11:30,market_open,88.87000275,92.51999664,419.6099854,420.4599915,0.041071158,0.002025705,0.039045453,long,long,
394,466,BNTX,Pfizer and BioNTech Receive Health Canada Authorization for  XBB.1.5-Adapted Monovalent COVID-19 Vaccine,https://www.globenewswire.com/news-release/2023/09/28/2751493/0/en/Pfizer-and-BioNTech-Receive-Health-Canada-Authorization-for-XBB-1-5-Adapted-Monovalent-COVID-19-Vaccine.html,Company Announcement,9/28/2023 12:24,market_open,103.3399963,102.0299988,425.480011,428.519989,-0.012676578,0.00714482,-0.019821398,short,short,
395,458,BNTX,BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie  in neuer Krebsindikation,https://www.globenewswire.com/news-release/2023/10/19/2763018/0/de/BioNTech-erweitert-fortgeschrittenes-klinisches-Onkologie-Portfolio-Weiterer-Phase-2-Studienstart-mit-mRNA-basierter-individualisierter-Neoantigen-spezifischer-Immuntherapie-in-neu.html,Press releases,10/19/2023 6:45,pre_market,94.37999725,94,430.2099915,430.9500122,-0.004026248,0.001720139,-0.005746386,short,short,
396,456,BNTX,BioNTech veröffentlicht am 6. November 2023 Ergebnisse des dritten Quartals und informiert zur Geschäftsentwicklung und lädt zum „Innovation Series Day“ am 7. November 2023 ein,https://www.globenewswire.com/news-release/2023/10/23/2764554/0/de/BioNTech-ver%C3%B6ffentlicht-am-6-November-2023-Ergebnisse-des-dritten-Quartals-und-informiert-zur-Gesch%C3%A4ftsentwicklung-und-l%C3%A4dt-zum-Innovation-Series-Day-am-7-November-2023-ein.html,Press releases,10/23/2023 6:45,pre_market,90.91000366,88.87000275,421.1900024,419.6099854,-0.022439785,-0.003751317,-0.018688468,short,short,
397,459,BNTX,Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19,https://www.globenewswire.com/news-release/2023/10/26/2767318/0/en/Pfizer-and-BioNTech-Announce-Positive-Topline-Data-for-mRNA-based-Combination-Vaccine-Program-Against-Influenza-and-COVID-19.html,Company Announcement,10/26/2023 6:45,pre_market,95.25,96.19000244,417.5499878,416.4500122,0.009868792,-0.002634357,0.012503149,long,long,
398,461,BNTX,BioNTech veröffentlicht Ergebnisse des dritten Quartals 2023 und Informationen zur Geschäftsentwicklung,https://www.globenewswire.com/news-release/2023/11/06/2773898/0/de/BioNTech-ver%C3%B6ffentlicht-Ergebnisse-des-dritten-Quartals-2023-und-Informationen-zur-Gesch%C3%A4ftsentwicklung.html,Earnings Releases and Operating Results,11/6/2023 6:45,pre_market,95.77999878,101.2799988,434.6900024,435.4700012,0.057423262,0.001794379,0.055628883,long,long,
399,463,BNTX,BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023,https://www.globenewswire.com/news-release/2023/10/23/2764948/0/de/BioNTech-pr%C3%A4sentiert-positives-Daten-Update-aus-der-Phase-1-2-Studie-mit-dem-CAR-T-Zelltherapiekandidat-BNT211-bei-fortgeschrittenen-soliden-Tumoren-auf-dem-ESMO-Kongress-2023.html,Company Announcement,10/23/2023 11:30,market_open,88.87000275,92.51999664,419.6099854,420.4599915,0.041071158,0.002025705,0.039045453,long,long,
400,460,BNTX,BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission,https://www.globenewswire.com/news-release/2023/09/18/2744601/0/en/BioNTech-and-CEPI-Announce-Partnership-to-Advance-mRNA-Mpox-Vaccine-Development-and-Support-CEPI-s-100-Days-Mission.html,Company Announcement,9/18/2023 6:45,pre_market,113.0599976,113.0599976,443.3699951,443.0499878,0,-0.000721761,0.000721761,long,long,
401,467,BNTX,BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt,https://www.globenewswire.com/news-release/2023/09/18/2744601/0/de/BioNTech-und-CEPI-geben-Partnerschaft-zur-Entwicklung-eines-mRNA-Mpox-Impfstoffs-und-zur-Unterst%C3%BCtzung-von-CEPIs-100-Tage-Ziel-bekannt.html,Company Announcement,9/18/2023 6:45,pre_market,113.0599976,113.0599976,443.3699951,443.0499878,0,-0.000721761,0.000721761,long,long,
402,469,BNTX,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union,https://www.globenewswire.com/news-release/2023/08/30/2734517/0/en/Pfizer-and-BioNTech-Receive-Positive-CHMP-Opinion-for-Omicron-XBB-1-5-adapted-COVID-19-Vaccine-in-the-European-Union.html,Company Announcement,8/30/2023 10:00,market_open,122.5,125.0800018,449.5100098,451.0100098,0.021061239,0.003336967,0.017724273,long,long,
403,455,BNOX,Bionomics to Present at Biotech Showcase™ 2024,https://www.globenewswire.com/news-release/2024/01/05/2804526/0/en/Bionomics-to-Present-at-Biotech-Showcase-2024.html,Calendar of Events,1/5/2024 6:00,pre_market,1.299999952,1.409999967,467.2799988,467.4899902,0.084615399,0.000449391,0.084166008,long,long,
404,470,BNTX,BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer,https://www.globenewswire.com/news-release/2023/08/14/2724220/0/en/BioNTech-Expands-Management-Board-by-Appointing-James-Ryan-as-Chief-Legal-Officer.html,Company Announcement,8/14/2023 6:45,pre_market,106.9199982,106.8099976,445.6499939,444.7000122,-0.001028812,-0.002131677,0.001102864,long,long,
405,471,BNTX,BioNTech Completes Acquisition of InstaDeep,https://www.globenewswire.com/news-release/2023/07/31/2714822/0/en/BioNTech-Completes-Acquisition-of-InstaDeep.html,Press releases,7/31/2023 8:00,pre_market,107.4199982,107.5999985,456.9200134,457.4100037,0.001675669,0.001072376,0.000603292,long,long,
406,474,BNTX,BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs,https://www.globenewswire.com/news-release/2023/12/21/2799939/0/de/BioNTech-und-DualityBio-erhalten-Breakthrough-Therapy-Status-der-FDA-f%C3%BCr-ADC-Kandidaten-BNT323-DB-1303-zur-Behandlung-von-Geb%C3%A4rmutterkrebs.html,Press releases,12/21/2023 8:00,pre_market,102.8000031,103.4899979,468.2600098,471.3299866,0.006712012,0.006556137,0.000155875,long,long,
407,473,BNTX,BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/11/06/2773898/0/en/BioNTech-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update.html,Earnings Releases and Operating Results,11/6/2023 6:45,pre_market,95.77999878,101.2799988,434.6900024,435.4700012,0.057423262,0.001794379,0.055628883,long,long,
408,475,BNTX,BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme,https://www.globenewswire.com/news-release/2024/02/08/2825809/0/de/BioNTech-und-Autolus-schlie%C3%9Fen-strategische-Kollaboration-zur-Weiterentwicklung-der-Pipeline-und-Ausbau-fortgeschrittener-CAR-T-Zelltherapie-Programme.html,Press releases,2/8/2024 5:45,pre_market,95.05000305,95.19999695,498.1000061,498.1000061,0.001578053,0,0.001578053,long,long,
409,476,BNTX,BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer,https://www.globenewswire.com/news-release/2023/12/21/2799939/0/en/BioNTech-and-DualityBio-Receive-FDA-Breakthrough-Therapy-Designation-for-Antibody-Drug-Conjugate-Candidate-BNT323-DB-1303-in-Endometrial-Cancer.html,Press releases,12/21/2023 8:00,pre_market,102.8000031,103.4899979,468.2600098,471.3299866,0.006712012,0.006556137,0.000155875,long,long,
410,477,BNTX,BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/09/2806101/0/en/BioNTech-Outlines-2024-Strategic-Priorities-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Company Announcement,1/9/2024 6:45,pre_market,111.8799973,109.0999985,474.6000061,471.8699951,-0.024848041,-0.005752236,-0.019095806,short,short,
411,478,BNTX,BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda,https://www.globenewswire.com/news-release/2023/12/18/2798070/0/en/BioNTech-Achieves-Milestone-at-mRNA-based-Vaccine-Manufacturing-Site-in-Rwanda.html,Company Announcement,12/18/2023 13:15,market_open,101.9800034,103.5699997,470.980011,471.9700012,0.015591256,0.002101979,0.013489277,long,long,
412,479,BNTX,BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305,https://www.globenewswire.com/news-release/2024/01/31/2820922/0/de/BioNTech-und-DualityBio-erhalten-Fast-Track-Status-der-FDA-f%C3%BCr-innovativen-Antik%C3%B6rper-Wirkstoff-Konjugat-Kandidat-BNT325-DB-1305.html,Company Announcement,1/31/2024 6:45,pre_market,94.98000336,94,490.8900146,488.6199951,-0.010317997,-0.004624294,-0.005693703,short,short,
413,480,BNTX,BioNTech erreicht Meilenstein in der Errichtung einer Produktionsstätte für mRNA-basierte Impfstoffe in Ruanda,https://www.globenewswire.com/news-release/2023/12/18/2798070/0/de/BioNTech-erreicht-Meilenstein-in-der-Errichtung-einer-Produktionsst%C3%A4tte-f%C3%BCr-mRNA-basierte-Impfstoffe-in-Ruanda.html,Company Announcement,12/18/2023 13:15,market_open,101.9800034,103.5699997,470.980011,471.9700012,0.015591256,0.002101979,0.013489277,long,long,
414,481,BNTX,BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305,https://www.globenewswire.com/news-release/2024/01/31/2820922/0/en/BioNTech-and-DualityBio-Receive-FDA-Fast-Track-Designation-for-Next-Generation-Antibody-Drug-Conjugate-Candidate-BNT325-DB-1305.html,Company Announcement,1/31/2024 6:45,pre_market,94.98000336,94,490.8900146,488.6199951,-0.010317997,-0.004624294,-0.005693703,short,short,
415,482,BNTX,BioNTech weiht am 18. Dezember 2023 ersten afrikanischen Standort ein,https://www.globenewswire.com/news-release/2023/12/12/2794577/0/de/BioNTech-weiht-am-18-Dezember-2023-ersten-afrikanischen-Standort-ein.html,Press releases,12/12/2023 6:45,pre_market,100.4899979,100.2300034,461.9899902,461.6300049,-0.002587268,-0.000779206,-0.001808062,short,short,
416,483,BNTX,BioNTech and DualityBio Initiate Pivotal Phase 3 Trial  Of Antibody-Drug Conjugate Candidate BNT323/DB-1303  in Metastatic Breast Cancer,https://www.globenewswire.com/news-release/2024/01/22/2812878/0/en/BioNTech-and-DualityBio-Initiate-Pivotal-Phase-3-Trial-Of-Antibody-Drug-Conjugate-Candidate-BNT323-DB-1303-in-Metastatic-Breast-Cancer.html,Company Announcement,1/22/2024 6:45,pre_market,98.22000122,98.38999939,482.4299927,484.0100098,0.00173079,0.003275122,-0.001544332,short,short,
417,485,BNTX,BioNTech stellt strategische Prioritäten für 2024 auf der 42. jährlichen J.P. Morgan Healthcare-Konferenz vor,https://www.globenewswire.com/news-release/2024/01/09/2806101/0/de/BioNTech-stellt-strategische-Priorit%C3%A4ten-f%C3%BCr-2024-auf-der-42-j%C3%A4hrlichen-J-P-Morgan-Healthcare-Konferenz-vor.html,Company Announcement,1/9/2024 6:45,pre_market,111.8799973,109.0999985,474.6000061,471.8699951,-0.024848041,-0.005752236,-0.019095806,short,short,
418,486,BNTX,"BioNTech to Inaugurate First African Site on December 18, 2023",https://www.globenewswire.com/news-release/2023/12/12/2794577/0/en/BioNTech-to-Inaugurate-First-African-Site-on-December-18-2023.html,Press releases,12/12/2023 6:45,pre_market,100.4899979,100.2300034,461.9899902,461.6300049,-0.002587268,-0.000779206,-0.001808062,short,long,
419,487,BNTX,BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs,https://www.globenewswire.com/news-release/2024/02/08/2825809/0/en/BioNTech-and-Autolus-Announce-Strategic-CAR-T-Cell-Therapy-Collaboration-to-Advance-Pipeline-and-Expand-Late-Stage-Programs.html,Press releases,2/8/2024 5:45,pre_market,95.05000305,95.19999695,498.1000061,498.1000061,0.001578053,0,0.001578053,long,long,
420,489,BTAI,BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights,https://www.globenewswire.com/news-release/2023/03/09/2623898/0/en/BioXcel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Operational-Highlights.html,Earnings Releases and Operating Results,3/9/2023 7:00,pre_market,28.36000061,26.92000008,398.9200134,399.7399902,-0.050775758,0.002055492,-0.05283125,short,short,
421,490,BTAI,BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site,https://www.globenewswire.com/news-release/2023/10/25/2766353/0/en/BioXcel-Therapeutics-Announces-Positive-Findings-from-Independent-Third-Party-Audit-of-Data-Integrity-at-TRANQUILITY-II-Phase-3-Trial-Site.html,Clinical Study,10/25/2023 7:00,pre_market,2.339999914,3.069999933,423.6300049,421.8900146,0.311965832,-0.004107335,0.316073166,long,long,
422,492,BTAI,"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer",https://www.globenewswire.com/news-release/2023/10/10/2757315/0/en/BioXcel-Therapeutics-Reports-Positive-Overall-Survival-Results-from-Single-Arm-Open-Label-Phase-2-Trial-of-BXCL701-in-Patients-with-Small-Cell-Neuroendocrine-Prostate-Cancer.html,Clinical Study,10/10/2023 7:00,pre_market,2.74000001,2.789999962,432.2900085,432.9400024,0.018248158,0.001503606,0.016744552,long,long,
423,519,BXRX,Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/16/2726283/0/en/Baudax-Bio-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,8/16/2023 8:00,pre_market,0.575100005,0.589999974,442.8900146,442.4599915,0.025908484,-0.000970948,0.026879432,long,long,
424,493,BTAI,BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/06/01/2680145/0/en/BioXcel-Therapeutics-to-Participate-at-Two-Upcoming-Investor-Conferences.html,Calendar of Events,6/1/2023 7:00,pre_market,17.94000053,17.92000008,417.8500061,418.0899963,-0.001114853,0.000574345,-0.001689198,short,short,
425,494,BTAI,"BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023",https://www.globenewswire.com/news-release/2023/07/31/2714718/0/en/BioXcel-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-on-August-14-2023.html,Conference Calls/ Webcasts,7/31/2023 7:00,pre_market,9.579999924,9.680000305,456.9200134,457.4100037,0.010438453,0.001072376,0.009366077,long,long,
426,495,BTAI,BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia,https://www.globenewswire.com/news-release/2023/05/25/2675983/0/en/BioXcel-Therapeutics-Announces-Promising-Topline-Results-from-Part-1-of-Pivotal-SERENITY-III-Trial-of-BXCL501-for-At-Home-Use-in-Acute-Treatment-of-Agitation-in-Bipolar-Disorders-o.html,Health,5/25/2023 7:00,pre_market,25.93000031,25.92000008,411.0899963,414.7399902,-0.000385663,0.00887882,-0.009264482,short,long,
427,496,BTAI,"BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results",https://www.globenewswire.com/news-release/2023/11/14/2779919/0/en/BioXcel-Therapeutics-Aligns-with-FDA-Recommendation-for-Phase-3-Trial-for-TRANQUILITY-Program-Provides-Update-on-Strategic-Financing-and-Reports-Third-Quarter-2023-Financial-Result.html,Conference Calls/ Webcasts,11/14/2023 7:00,pre_market,5.510000229,3.559999943,440.1900024,446.3200073,-0.353902034,0.013925816,-0.367827849,short,short,
428,497,BTAI,BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights,https://www.globenewswire.com/news-release/2023/05/08/2663157/0/en/BioXcel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Operational-Highlights.html,Earnings Releases and Operating Results,5/8/2023 7:00,pre_market,23.17000008,21,412.6300049,412.9700012,-0.093655592,0.000823974,-0.094479566,short,short,
429,498,BTAI,BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference,https://www.globenewswire.com/news-release/2023/05/02/2658961/0/en/BioXcel-Therapeutics-to-Present-at-the-BofA-Securities-2023-Health-Care-Conference.html,Trade Show,5/2/2023 7:00,pre_market,20.80999947,20.80999947,415.5100098,414.769989,0,-0.001780994,0.001780994,long,long,
430,499,BTAI,BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer,https://www.globenewswire.com/news-release/2023/01/11/2586890/0/en/BioXcel-Therapeutics-Announces-Promising-Top-Line-Results-from-Phase-2-Trial-of-BXCL701-in-Aggressive-Form-of-Rare-Prostate-Cancer.html,Clinical Study,1/11/2023 7:00,pre_market,23.65999985,23.78000069,390.5799866,392.230011,0.005071887,0.004224549,0.000847337,long,long,
431,500,BTAI,BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program,https://www.globenewswire.com/news-release/2023/05/16/2669821/0/en/BioXcel-Therapeutics-Announces-Positive-Top-Line-Data-from-Repeat-Dosing-of-BXCL501-in-Phase-1b-Multiple-Ascending-Dose-Trial-in-Healthy-Volunteers-for-Major-Depressive-Disorder-MD.html,Health,5/16/2023 7:00,pre_market,27.22999954,27.26000023,413.0100098,411.8599854,0.001101751,-0.002784495,0.003886247,long,long,
432,501,BTAI,"BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023",https://www.globenewswire.com/news-release/2023/10/31/2769984/0/en/BioXcel-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-on-November-14-2023.html,Calendar of Events,10/31/2023 7:00,pre_market,3.99000001,3.920000076,415.5899963,416.1799927,-0.017543843,0.00141966,-0.018963503,short,short,
433,502,BTAI,BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease,https://www.globenewswire.com/news-release/2022/12/19/2576149/0/en/BioXcel-Therapeutics-Announces-First-Patient-Dosed-in-TRANQUILITY-III-Phase-3-Trial-for-Acute-Treatment-of-Agitation-in-Patients-with-Alzheimer-s-Disease.html,Clinical Study,12/19/2022 7:00,pre_market,20.04999924,20.25,383.269989,383.4700012,0.009975101,0.000521857,0.009453244,long,long,
434,518,BXRX,"Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000",https://www.globenewswire.com/news-release/2023/06/07/2683858/0/en/Baudax-Bio-Announces-Additional-Positive-Top-Line-Results-From-Phase-2-Randomized-Clinical-Trial-of-BX1000.html,Clinical Study,6/7/2023 9:21,pre_market,0.559899986,0.600000024,428.0299988,428.4400024,0.071620002,0.000957885,0.070662117,long,long,
435,520,BXRX,"Baudax Bio Acquires TeraImmune, Inc.",https://www.globenewswire.com/news-release/2023/06/30/2697710/0/en/Baudax-Bio-Acquires-TeraImmune-Inc.html,Mergers and Acquisitions,6/30/2023 8:00,pre_market,0.520200014,0.639999986,438.1099854,441.4400024,0.230295979,0.00760087,0.222695109,long,long,
436,505,BTAI,BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services,https://www.globenewswire.com/news-release/2023/10/30/2769033/0/en/BioXcel-Therapeutics-Receives-Permanent-J-Code-for-IGALMI-dexmedetomidine-Sublingual-Film-from-Centers-for-Medicare-Medicaid-Services.html,Health,10/30/2023 7:00,pre_market,3.029999971,3.049999952,410.6799927,413.5599976,0.006600654,0.007012771,-0.000412118,short,long,
437,506,BTAI,BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD),https://www.globenewswire.com/news-release/2023/11/06/2773940/0/en/BioXcel-Therapeutics-Announces-Update-on-NIDA-funded-Trial-of-BXCL501-sublingual-dexmedetomidine-for-Potential-Treatment-of-Opioid-Use-Disorder-OUD.html,Health,11/6/2023 7:00,pre_market,4.639999867,4.820000172,434.6900024,435.4700012,0.03879317,0.001794379,0.036998791,long,long,
438,507,BTAI,"BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023",https://www.globenewswire.com/news-release/2023/11/30/2788461/0/en/BioXcel-Therapeutics-to-Host-Virtual-Neuroscience-R-D-Day-on-Dec-12-2023.html,Conference Calls/ Webcasts,11/30/2023 7:00,pre_market,3.900000095,3.859999895,454.6099854,455.480011,-0.010256461,0.001913785,-0.012170246,short,long,
439,508,BTAI,"BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023",https://www.globenewswire.com/news-release/2023/02/23/2614089/0/en/BioXcel-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-March-9-2023.html,Calendar of Events,2/23/2023 7:00,pre_market,28.60000038,29.12999916,398.5400085,401.5599976,0.018531426,0.007577631,0.010953795,long,long,
440,509,BTAI,"BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023",https://www.globenewswire.com/news-release/2023/04/24/2652526/0/en/BioXcel-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-on-May-8-2023.html,Conference Calls/ Webcasts,4/24/2023 7:00,pre_market,22.15999985,21.98999977,412.2000122,411.9899902,-0.007671484,-0.000509515,-0.007161969,short,short,
441,510,BTAI,BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2022/12/22/2578481/0/en/BioXcel-Therapeutics-to-Present-at-41st-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/22/2022 7:00,pre_market,21.11000061,20.95999908,386.230011,383.0499878,-0.007105709,-0.008233496,0.001127787,long,long,
442,511,BTAI,"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype",https://www.globenewswire.com/news-release/2023/11/08/2776064/0/en/BioXcel-Therapeutics-Reports-Positive-Overall-Survival-Results-from-Single-Arm-Open-Label-Phase-2-Trial-of-BXCL701-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-.html,Clinical Study,11/8/2023 7:00,pre_market,4.840000153,4.900000095,436.9299927,437.5499878,0.012396682,0.00141898,0.010977702,long,long,
443,512,BTAI,BioXcel Therapeutics Announces Termination of Proposed Public Offering,https://www.globenewswire.com/news-release/2024/02/13/2828330/0/en/BioXcel-Therapeutics-Announces-Termination-of-Proposed-Public-Offering.html,Financing Agreements,2/13/2024 9:00,pre_market,1.950000048,2.559999943,500.980011,494.5299988,0.312820451,-0.01287479,0.325695241,long,long,
444,513,BTAI,BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs,https://www.globenewswire.com/news-release/2023/12/11/2793729/0/en/BioXcel-Therapeutics-Strengthens-Clinical-Development-Leadership-to-Advance-Late-Stage-Programs.html,Corporate Action,12/11/2023 7:00,pre_market,3.170000076,3.269999981,460.2000122,459.6900024,0.031545711,-0.001108235,0.032653946,long,long,
445,514,BTAI,BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today,https://www.globenewswire.com/news-release/2023/12/12/2794604/0/en/BioXcel-Therapeutics-Hosting-Virtual-Neuroscience-R-D-Day-Today.html,Product / Services Announcement,12/12/2023 7:00,pre_market,3.11500001,3.130000114,461.9899902,461.6300049,0.004815443,-0.000779206,0.005594649,long,long,
446,515,BTAI,BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC),https://www.globenewswire.com/news-release/2024/02/12/2827423/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL701-for-Treatment-of-Small-Cell-Neuroendocrine-Prostate-Cancer-SCNC.html,Health,2/12/2024 7:14,pre_market,2.109999895,2.400000095,501.2000122,501.1700134,0.13744086,-5.99E-05,0.137500714,long,long,
447,516,BTAI,BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine,https://www.globenewswire.com/news-release/2024/02/05/2823402/0/en/BioXcel-Therapeutics-Announces-USPTO-s-Allowance-of-Patent-Application-for-Method-of-Treating-Agitation-in-Alzheimer-s-Disease-Using-Oromucosal-Formulations-of-Dexmedetomidine.html,Patents,2/5/2024 7:00,pre_market,3.059999943,3.349999905,494.3500061,493.7000122,0.094771231,-0.001314846,0.096086077,long,long,
448,517,BTAI,BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®,https://www.globenewswire.com/news-release/2024/02/06/2824137/0/en/BioXcel-Therapeutics-Announces-Completion-of-Patient-Enrollment-in-Safety-Portion-of-Investigator-Sponsored-Phase-2-Relapsed-Pancreatic-Cancer-Trial-of-BXCL701-in-Combination-with-.html,Clinical Study,2/6/2024 7:00,pre_market,3.710000038,3.589999914,492.5499878,493.519989,-0.032345047,0.001969346,-0.034314392,short,short,
449,528,CADL,Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference,https://www.globenewswire.com/news-release/2023/08/02/2716816/0/en/Candel-Therapeutics-to-Participate-in-the-Canaccord-Genuity-43rd-Annual-Growth-Conference.html,Health,8/2/2023 8:00,pre_market,1.049999952,1.070000053,456.480011,453.25,0.019047715,-0.007075909,0.026123624,long,long,
450,529,CADL,Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting,https://www.globenewswire.com/news-release/2023/05/19/2672581/0/en/Candel-Therapeutics-Announces-New-Data-from-Ongoing-Phase-1-Clinical-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-26th-Annual.html,Clinical Study,5/19/2023 9:00,pre_market,1.708999991,1.720000029,419.230011,420.1700134,0.006436534,0.002242212,0.004194323,long,long,
451,530,CADL,Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2738304/0/en/Candel-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Conference Calls/ Webcasts,9/6/2023 8:00,pre_market,1.159999967,1.139000058,449.2399902,448.3999939,-0.01810337,-0.001869817,-0.016233553,short,short,
452,531,CADL,"Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409",https://www.globenewswire.com/news-release/2023/11/28/2787049/0/en/Candel-Therapeutics-Announces-Restructuring-to-Prioritize-Resources-on-Key-Value-Drivers-for-Expanded-Development-of-CAN-3110-the-enLIGHTEN-Discovery-Platform-and-Key-Clinical-Read.html,Clinical Study,11/28/2023 9:00,pre_market,0.980000019,1.019999981,454.480011,454.0799866,0.040816287,-0.00088018,0.041696467,long,long,
453,533,CADL,Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference,https://www.globenewswire.com/news-release/2023/06/05/2681910/0/en/Candel-Therapeutics-to-Participate-in-the-2023-Jefferies-Healthcare-Conference.html,Calendar of Events,6/5/2023 8:00,pre_market,1.529999971,1.559999943,427.9200134,428.2799988,0.019607825,0.000841245,0.01876658,long,long,
454,534,CADL,Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer,https://www.globenewswire.com/news-release/2023/04/17/2647879/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Non-Small-Cell-Lung-Cancer.html,Regulatory information,4/17/2023 8:00,pre_market,1.419999957,1.559999943,412.4599915,412.3699951,0.098591542,-0.000218194,0.098809736,long,long,
455,535,CADL,Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024,https://www.globenewswire.com/news-release/2023/06/13/2687074/0/en/Candel-Therapeutics-Announces-It-Expects-to-Report-Topline-Data-from-its-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Small-Cell-Lung-Cancer-in-the-Second-Quarter-of-2024.html,Clinical Study,6/13/2023 8:00,pre_market,1.659999967,1.623000026,433.7999878,435.3200073,-0.022289122,0.003503964,-0.025793085,short,short,
456,536,CADL,"Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors",https://www.globenewswire.com/news-release/2023/06/08/2684701/0/en/Candel-Therapeutics-Appoints-Experienced-Manufacturing-Leader-Nicoletta-Loggia-PhD-RPh-to-its-Board-of-Directors.html,Directors and Officers,6/8/2023 8:00,pre_market,1.509999991,1.539999962,426.5499878,426.6199951,0.019867531,0.000164125,0.019703406,long,long,
457,537,CADL,Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day,https://www.globenewswire.com/news-release/2023/02/01/2599407/0/en/Candel-Therapeutics-to-Participate-in-Guggenheim-Healthcare-Talks-2023-Oncology-Day.html,Conference Calls/ Webcasts,2/1/2023 8:00,pre_market,2.569999933,2.599999905,406.480011,405.2099915,0.011673141,-0.003124433,0.014797574,long,long,
458,521,BXRX,Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors,https://www.globenewswire.com/news-release/2023/09/28/2751180/0/en/Baudax-Bio-Announces-Orphan-Drug-Designation-Granted-by-U-S-FDA-for-TI-168-for-the-Treatment-of-Hemophilia-A-with-Inhibitors.html,"Environmental, Social, and Governance Criteria",9/28/2023 8:00,pre_market,0.300000012,0.562699974,426.0499878,425.480011,0.875666504,-0.001337817,0.877004321,long,long,
459,522,BXRX,Baudax Bio Announces Date of Reconvened Annual Meeting,https://www.globenewswire.com/news-release/2023/06/06/2682905/0/en/Baudax-Bio-Announces-Date-of-Reconvened-Annual-Meeting.html,Calendar of Events,6/6/2023 9:00,pre_market,0.540000022,0.550000012,427.1000061,426.6700134,0.0185185,-0.001006773,0.019525273,long,long,
460,523,BXRX,Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/08/17/2727199/0/en/Baudax-Bio-Announces-1-9-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html,Warrants and Certificates,8/17/2023 8:00,pre_market,0.560000002,0.521200001,439.6400146,441.1600037,-0.069285716,0.003457349,-0.072743065,short,short,
461,524,BXRX,Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/07/2739292/0/en/Baudax-Bio-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html,Calendar of Events,9/7/2023 8:00,pre_market,0.400000006,0.389999986,446.2200012,443.1099854,-0.02500005,-0.006969692,-0.018030359,short,short,
462,525,BXRX,Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock,https://www.globenewswire.com/news-release/2023/08/23/2730353/0/en/Baudax-Bio-Announces-Distribution-of-Series-C-Preferred-Stock-to-Holders-of-its-Common-Stock.html,Dividend Reports and Estimates,8/23/2023 8:00,pre_market,0.448000014,0.474999994,438.1499939,439.25,0.060267811,0.00251057,0.057757241,long,long,
463,526,BXRX,Baudax Bio Announces Corporate Update,https://www.globenewswire.com/news-release/2023/10/18/2762296/0/en/Baudax-Bio-Announces-Corporate-Update.html,Corporate Action,10/18/2023 8:00,pre_market,0.200000003,0.276899993,436.019989,434.1900024,0.384499947,-0.004197025,0.388696971,long,long,
464,553,CAPR,"Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors",https://www.globenewswire.com/news-release/2023/07/13/2704319/0/en/Capricor-Therapeutics-Announces-Appointment-of-Paul-Auwaerter-M-D-to-its-Board-of-Directors.html,Directors and Officers,7/13/2023 8:30,pre_market,4.420000076,4.5,446.019989,447.8999939,0.01809953,0.004215069,0.013884461,long,long,
465,547,CADL,"Candel Therapeutics to Host Virtual R&D Day on December 6, 2022",https://www.globenewswire.com/news-release/2022/11/29/2563926/0/en/Candel-Therapeutics-to-Host-Virtual-R-D-Day-on-December-6-2022.html,Calendar of Events,11/29/2022 8:00,pre_market,1.710000038,1.799999952,395.9100037,396.0499878,0.052631528,0.000353576,0.052277952,long,long,
466,539,CADL,Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer,https://www.globenewswire.com/news-release/2023/09/26/2749459/0/en/Candel-Therapeutics-Reports-Encouraging-Initial-Survival-Data-from-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Small-Cell-Lung-Cancer.html,Clinical Study,9/26/2023 8:00,pre_market,1.120000005,1.139999986,432.230011,429.0899963,0.017857126,-0.007264685,0.02512181,long,long,
467,540,CADL,Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2023/08/10/2722588/0/en/Candel-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,Earnings Releases and Operating Results,8/10/2023 8:00,pre_market,1.100000024,1,445.75,448.1900024,-0.090909111,0.005473926,-0.096383036,short,short,
468,542,CADL,Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2023/11/09/2777291/0/en/Candel-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,Clinical Study,11/9/2023 8:00,pre_market,1,1.080000043,437.25,438.4299927,0.080000043,0.002698668,0.077301375,long,long,
469,543,CADL,Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer,https://www.globenewswire.com/news-release/2023/11/03/2773326/0/en/Candel-Therapeutics-Announces-Initial-Positive-Interim-Data-from-Randomized-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html,Clinical Study,11/3/2023 12:00,market_open,0.899999976,0.675000012,433.1400146,434.6900024,-0.249999967,0.003578491,-0.253578458,short,short,
470,544,CADL,Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/09/27/2750513/0/en/Candel-Therapeutics-Announces-Three-Abstracts-Accepted-for-Poster-Presentations-at-SITC-2023-Annual-Meeting.html,Clinical Study,9/27/2023 9:40,market_open,1,0.910000026,427.0899963,426.0499878,-0.089999974,-0.002435104,-0.08756487,short,short,
471,545,CADL,Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights,https://www.globenewswire.com/news-release/2023/05/11/2666694/0/en/Candel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,Earnings Releases and Operating Results,5/11/2023 8:00,pre_market,1.779999971,1.700000048,412.8500061,411.9500122,-0.044943778,-0.002179954,-0.042763824,short,short,
472,546,CADL,Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma,https://www.globenewswire.com/news-release/2022/11/11/2554350/0/en/Candel-Therapeutics-Announces-Late-Breaking-Oral-Presentation-at-SITC-Annual-Meeting-with-Data-on-CAN-2409-in-Combination-with-Nivolumab-in-a-Phase-1-Mechanistic-Clinical-Trial-in-.html,Product / Services Announcement,11/11/2022 12:00,market_open,1.580000043,1.621000052,395.5899963,398.5100098,0.025949372,0.007381414,0.018567958,long,long,
473,571,CBAY,CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants,https://www.globenewswire.com/news-release/2023/09/11/2740591/37067/en/CymaBay-Announces-Proposed-150-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html,Warrants and Certificates,9/11/2023 6:00,pre_market,16.23999977,16.03000069,445.519989,448.2399902,-0.012930978,0.006105228,-0.019036207,short,short,
474,548,CADL,Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference,https://www.globenewswire.com/news-release/2023/01/12/2587826/0/en/Candel-Therapeutics-to-Participate-in-Upcoming-B-Riley-Oncology-Conference.html,Conference Calls/ Webcasts,1/12/2023 8:00,pre_market,1.919999957,1.980000019,395.519989,396.6700134,0.031250033,0.002907627,0.028342407,long,long,
475,549,CADL,Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts,https://www.globenewswire.com/news-release/2024/02/05/2823461/0/en/Candel-Therapeutics-Sets-Path-to-Success-Recent-Achievements-Pave-the-Way-for-a-Promising-2024-Propelled-by-Key-Value-Drivers-and-Catalysts.html,Product / Services Announcement,2/5/2024 8:00,pre_market,1.299999952,1.338000059,494.3500061,493.7000122,0.029230853,-0.001314846,0.030545698,long,long,
476,550,CADL,Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer,https://www.globenewswire.com/news-release/2023/12/12/2794671/0/en/Candel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-CAN-2409-in-Pancreatic-Cancer.html,Product / Services Announcement,12/12/2023 8:00,pre_market,0.869000018,1.350000024,461.9899902,461.6300049,0.553509777,-0.000779206,0.554288983,long,long,
477,551,CADL,CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma,https://www.globenewswire.com/news-release/2024/02/13/2828140/0/en/CAN-3110-Receives-FDA-Fast-Track-Designation-for-Treatment-of-Recurrent-High-Grade-Glioma.html,Health,2/13/2024 7:30,pre_market,1.389999986,1.49000001,500.980011,494.5299988,0.071942464,-0.01287479,0.084817254,long,long,
478,569,CBAY,CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference,https://www.globenewswire.com/news-release/2023/02/06/2602017/37067/en/CymaBay-Therapeutics-to-Present-at-the-SVB-Securities-Global-Biopharma-Conference.html,Conference Calls/ Webcasts,2/6/2023 8:00,pre_market,8.550000191,8.550000191,412.3500061,409.7900085,0,-0.006208312,0.006208312,long,long,
479,570,CBAY,CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference,https://www.globenewswire.com/news-release/2023/03/01/2618131/37067/en/CymaBay-Therapeutics-to-Present-at-the-Oppenheimer-33rd-Annual-Healthcare-Conference.html,Trade Show,3/1/2023 8:00,pre_market,8,8.069999695,396.2600098,395.4100037,0.008749962,-0.002145072,0.010895034,long,short,
480,555,CAPR,Capricor Therapeutics Appoints Michael Kelliher to Board of Directors,https://www.globenewswire.com/news-release/2023/09/06/2738485/0/en/Capricor-Therapeutics-Appoints-Michael-Kelliher-to-Board-of-Directors.html,Directors and Officers,9/6/2023 9:00,pre_market,6.139999867,6.170000076,449.2399902,448.3999939,0.004886028,-0.001869817,0.006755844,long,short,
481,556,CAPR,Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy,https://www.globenewswire.com/news-release/2023/09/29/2751919/0/en/Capricor-Therapeutics-Announces-Positive-Type-B-Meeting-with-the-FDA-to-Discuss-Pathway-to-BLA-for-CAP-1002-in-Duchenne-Muscular-Dystrophy.html,Conference Calls/ Webcasts,9/29/2023 7:30,pre_market,5.820000172,3.849999905,428.519989,431.6700134,-0.338488008,0.007350939,-0.345838948,short,short,
482,557,CAPR,Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14,https://www.globenewswire.com/news-release/2023/11/07/2775233/0/en/Capricor-Therapeutics-to-Present-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Update-on-November-14.html,Conference Calls/ Webcasts,11/7/2023 9:15,pre_market,2.859999895,2.839999914,435.6900024,435.6900024,-0.006993001,0,-0.006993001,short,short,
483,558,CAPR,Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15,https://www.globenewswire.com/news-release/2023/03/08/2623124/0/en/Capricor-Therapeutics-to-Present-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Corporate-Update-on-March-15.html,Conference Calls/ Webcasts,3/8/2023 9:00,pre_market,4.760000229,4.809999943,398.269989,398.3900146,0.010504141,0.000301368,0.010202774,long,long,
484,559,CAPR,Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform,https://www.globenewswire.com/news-release/2023/04/27/2656431/0/en/Capricor-Announces-Peer-Reviewed-Publication-Demonstrating-the-Therapeutic-Potential-of-Exosome-Based-Multivalent-Vaccine-Developed-from-its-StealthX-Platform.html,Product / Services Announcement,4/27/2023 9:00,pre_market,3.950000048,3.980000019,404.3599854,407,0.007594929,0.006528872,0.001066057,long,long,
485,560,CAPR,Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society,https://www.globenewswire.com/news-release/2023/10/10/2757546/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentations-at-28th-Annual-Congress-of-the-World-Muscle-Society.html,Health,10/10/2023 9:00,pre_market,2.779999971,2.759999991,432.2900085,432.9400024,-0.007194238,0.001503606,-0.008697844,short,short,
486,561,CAPR,Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11,https://www.globenewswire.com/news-release/2023/05/04/2661614/0/en/Capricor-Therapeutics-to-Present-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Update-on-May-11.html,Calendar of Events,5/4/2023 9:00,pre_market,3.839999914,3.809999943,408.019989,406.9299927,-0.007812493,-0.002671429,-0.005141064,short,short,
487,562,CAPR,Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy,https://www.globenewswire.com/news-release/2023/06/13/2687234/0/en/Capricor-Therapeutics-to-Present-24-Month-Results-from-Ongoing-HOPE-2-Open-Label-Extension-Study-of-CAP-1002-in-Duchenne-Muscular-Dystrophy.html,Conference Calls/ Webcasts,6/13/2023 9:15,pre_market,4.650000095,4.679999828,433.7999878,435.3200073,0.006451555,0.003503964,0.002947591,long,long,
488,563,CAPR,"Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors",https://www.globenewswire.com/news-release/2023/07/24/2709506/0/en/Capricor-Therapeutics-Announces-Appointment-of-Philip-J-Gotwals-Ph-D-to-its-Board-of-Directors.html,Management Changes,7/24/2023 8:30,pre_market,4.550000191,4.619999886,452.1799927,453.3699951,0.015384548,0.002631701,0.012752847,long,short,
489,564,CAPR,Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award,https://www.globenewswire.com/news-release/2023/03/02/2619446/0/en/Capricor-Therapeutics-Receives-Clinical-Research-Forum-s-2023-Top-Ten-Clinical-Research-Achievement-Award.html,Contests/Awards,3/2/2023 9:15,pre_market,5.03000021,5.050000191,394.7399902,392.6799927,0.003976139,-0.005218619,0.009194758,long,long,
490,565,CAPR,Capricor Therapeutics Announces $23 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2023/09/29/2751922/0/en/Capricor-Therapeutics-Announces-23-Million-Registered-Direct-Offering.html,Partnerships,9/29/2023 7:35,pre_market,5.820000172,3.849999905,428.519989,431.6700134,-0.338488008,0.007350939,-0.345838948,short,short,
491,566,CAPR,Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2,https://www.globenewswire.com/news-release/2024/01/24/2815446/0/en/Capricor-Therapeutics-Announces-Collaboration-with-the-National-Institutes-of-Health-for-Clinical-Trial-of-Novel-Exosome-Based-Multivalent-Vaccine-for-SARS-CoV-2.html,Clinical Study,1/24/2024 9:15,pre_market,4.130000114,4.21999979,484.8599854,487.8099976,0.021791688,0.006084256,0.015707433,long,long,
492,567,CAPR,Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis,https://www.globenewswire.com/news-release/2023/12/11/2793907/0/en/Capricor-Therapeutics-Announces-Continuation-of-Phase-3-HOPE-3-Trial-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-Based-on-Completion-of-Interim-Futility-Analysis.html,Product / Services Announcement,12/11/2023 9:00,pre_market,3.690000057,3.710000038,460.2000122,459.6900024,0.005420049,-0.001108235,0.006528284,long,long,
493,584,CCCC,"C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors",https://www.globenewswire.com/news-release/2022/08/02/2490309/0/en/C4-Therapeutics-Appoints-Experienced-Clinical-Development-Leaders-Laura-Bessen-M-D-and-Donna-Grogan-M-D-to-Board-of-Directors.html,Directors and Officers,8/2/2022 8:00,pre_market,9.479999542,9.289999962,410.769989,409.1199951,-0.020042151,-0.004016832,-0.016025319,short,short,
494,585,CCCC,C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/05/04/2661295/0/en/C4-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,Earnings Releases and Operating Results,5/4/2023 7:00,pre_market,3.140000105,3.150000095,408.019989,406.9299927,0.00318471,-0.002671429,0.005856139,long,long,
495,586,CCCC,"C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma",https://www.globenewswire.com/news-release/2023/10/11/2758207/0/en/C4-Therapeutics-Announces-Upcoming-Data-Presentations-for-CFT8634-an-Orally-Bioavailable-BiDAC-Degrader-in-Development-for-Synovial-Sarcoma-and-SMARCB1-Null-Tumors-and-CFT7455-an-O.html,Health,10/11/2023 7:00,pre_market,1.889999986,1.919999957,434.5400085,435.6400146,0.015873001,0.002531427,0.013341574,long,long,
496,587,CCCC,C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022,https://www.globenewswire.com/news-release/2022/09/26/2522365/0/en/C4-Therapeutics-to-Present-at-Bank-of-America-Securities-Precision-Oncology-Conference-2022.html,Calendar of Events,9/26/2022 7:00,pre_market,8.56000042,8.56000042,367.9500122,366.4100037,0,-0.004185374,0.004185374,long,long,
497,572,CBAY,Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis,https://www.globenewswire.com/news-release/2023/10/23/2764648/37067/en/Seladelpar-Granted-Revised-Breakthrough-Therapy-Designation-for-the-Treatment-of-Primary-Biliary-Cholangitis-Including-Pruritus-in-Patients-Without-Cirrhosis-or-With-Compensated-Ci.html,Research Analysis and Reports,10/23/2023 8:00,pre_market,13.60999966,13.59000015,421.1900024,419.6099854,-0.001469471,-0.003751317,0.002281845,long,long,
498,573,CBAY,CymaBay Names Harish Shantharam Chief Financial Officer,https://www.globenewswire.com/news-release/2023/05/09/2664385/37067/en/CymaBay-Names-Harish-Shantharam-Chief-Financial-Officer.html,Directors and Officers,5/9/2023 8:00,pre_market,10.18999958,10.07999992,412.7399902,411.1300049,-0.010794864,-0.003900725,-0.006894138,short,short,
499,574,CBAY,CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023,https://www.globenewswire.com/news-release/2023/10/18/2762280/37067/en/CymaBay-s-RESPONSE-Phase-3-Data-Evaluating-Seladelpar-for-Primary-Biliary-Cholangitis-to-be-Featured-in-an-Oral-Late-Breaking-Presentation-at-The-Liver-Meeting-2023.html,Clinical Study,10/18/2023 8:00,pre_market,14.35000038,14.21000004,436.019989,434.1900024,-0.009756121,-0.004197025,-0.005559097,short,short,
500,575,CBAY,"CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023",https://www.globenewswire.com/news-release/2023/05/10/2665485/37067/en/CymaBay-Therapeutics-to-Report-First-Quarter-of-2023-Financial-Results-on-Monday-May-15-2023.html,Calendar of Events,5/10/2023 8:00,pre_market,10.43000031,10.44999981,410.9299927,413.8800049,0.001917498,0.007178868,-0.00526137,short,long,
501,576,CBAY,"CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)",https://www.globenewswire.com/news-release/2023/04/21/2651878/37067/en/CymaBay-Therapeutics-Announces-Publication-of-Results-From-the-ENHANCE-Phase-3-Study-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis-PBC.html,Research Analysis and Reports,4/21/2023 8:00,pre_market,10.27999973,10.35000038,411.8800049,412.1900024,0.006809402,0.000752641,0.006056761,long,long,
502,577,CBAY,CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ,https://www.globenewswire.com/news-release/2023/04/17/2647862/37067/en/CymaBay-Therapeutics-to-Present-at-the-H-C-Wainwright-BioConnect-Investor-Conference-at-NASDAQ.html,Trade Show,4/17/2023 8:00,pre_market,8.909999847,8.979999542,412.4599915,412.3699951,0.007856307,-0.000218194,0.008074501,long,short,
503,578,CBAY,CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis,https://www.globenewswire.com/news-release/2023/11/01/2771113/37067/en/CymaBay-Announces-Publication-of-Two-year-Safety-and-Efficacy-Results-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis.html,Clinical Study,11/1/2023 8:00,pre_market,16.37999916,16.39999962,418.2000122,419.2000122,0.001221029,0.0023912,-0.001170171,short,short,
504,579,CBAY,CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/15/2743947/37067/en/CymaBay-Therapeutics-to-Present-at-the-Cantor-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,9/15/2023 8:00,pre_market,16.92000008,16.96999931,450.3599854,447.1400146,0.002955038,-0.007149771,0.010104809,long,long,
505,580,CBAY,"CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis",https://www.globenewswire.com/news-release/2023/09/21/2747218/37067/en/CymaBay-Initiates-AFFIRM-a-Phase-3b-4-Study-Evaluating-the-Effect-of-Seladelpar-on-Clinical-Outcomes-in-Patients-with-Cirrhosis-due-to-Primary-Biliary-Cholangitis.html,Clinical Study,9/21/2023 8:00,pre_market,14.64000034,14.39999962,438.6400146,435.7000122,-0.016393492,-0.006702541,-0.009690951,short,short,
506,581,CBAY,CymaBay Therapeutics to Participate in Upcoming Investment Conferences,https://www.globenewswire.com/news-release/2024/01/31/2821052/37067/en/CymaBay-Therapeutics-to-Participate-in-Upcoming-Investment-Conferences.html,Conference Calls/ Webcasts,1/31/2024 8:00,pre_market,23.64999962,23.76000023,490.8900146,488.6199951,0.004651189,-0.004624294,0.009275482,long,long,
507,588,CCCC,C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/11/01/2770978/0/en/C4-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,Earnings Releases and Operating Results,11/1/2023 7:00,pre_market,1.49000001,1.620000005,418.2000122,419.2000122,0.087248318,0.0023912,0.084857118,long,long,
508,589,CCCC,C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2022/08/04/2492273/0/en/C4-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html,Earnings Releases and Operating Results,8/4/2022 8:00,pre_market,10.93999958,10.85000038,414.4500122,414.3699951,-0.008226618,-0.000193068,-0.00803355,short,short,
509,591,CCCC,C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/02/23/2614105/0/en/C4-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Recent-Business-Highlights.html,Calendar of Events,2/23/2023 7:00,pre_market,5.920000076,5.840000153,398.5400085,401.5599976,-0.013513501,0.007577631,-0.021091131,short,short,
510,592,CCCC,"C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers",https://www.globenewswire.com/news-release/2022/09/29/2525008/0/en/C4-Therapeutics-Receives-Study-May-Proceed-Letter-from-U-S-FDA-to-Initiate-Phase-1-2-Clinical-Trial-of-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Cance.html,Regulatory information,9/29/2022 7:00,pre_market,8.989999771,8.890000343,370.5299988,366.8099976,-0.011123407,-0.010039676,-0.001083731,short,short,
511,593,CCCC,C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),https://www.globenewswire.com/news-release/2023/07/17/2705168/0/en/C4-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,Management statements,7/17/2023 7:00,pre_market,3.349999905,3.349999905,449.2799988,449.1300049,0,-0.000333854,0.000333854,long,short,
512,594,CCCC,C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment,https://www.globenewswire.com/news-release/2023/11/20/2783101/0/en/C4-Therapeutics-Strengthens-Board-of-Directors-with-Owen-Hughes-Appointment.html,Directors and Officers,11/20/2023 7:00,pre_market,1.809999943,1.850000024,450.7900085,450.5299988,0.022099493,-0.000576787,0.02267628,long,long,
513,595,CCCC,C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines,https://www.globenewswire.com/news-release/2023/01/09/2585029/0/en/C4-Therapeutics-Announces-2023-Strategic-Priorities-to-Advance-Portfolio-of-Targeted-Protein-Degradation-Medicines.html,Research Analysis and Reports,1/9/2023 7:00,pre_market,6.71999979,6.78000021,388.0799866,390.3699951,0.008928634,0.005900867,0.003027767,long,long,
514,596,CCCC,C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma,https://www.globenewswire.com/news-release/2023/11/28/2786797/0/en/C4-Therapeutics-to-Host-Webcast-to-Present-New-Dose-Escalation-Data-from-CFT7455-Phase-1-Study-in-Relapsed-Refractory-Multiple-Myeloma.html,Clinical Study,11/28/2023 7:00,pre_market,1.5,1.519999981,454.480011,454.0799866,0.013333321,-0.00088018,0.014213501,long,long,
515,597,CCCC,"C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors",https://www.globenewswire.com/news-release/2023/01/30/2597422/0/en/C4-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CFT1946-an-Orally-Bioavailable-BiDAC-Degrader-in-BRAF-V600-Mutant-Solid-Tumors.html,Clinical Study,1/30/2023 7:00,pre_market,7.840000153,7.78000021,405.6799927,402.7999878,-0.007653054,-0.007099204,-0.00055385,short,short,
516,598,CCCC,C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2022/11/03/2547375/0/en/C4-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Recent-Business-Highlights.html,Earnings Releases and Operating Results,11/3/2022 7:00,pre_market,9.699999809,9.399999619,374.8699951,371.4700012,-0.030927855,-0.009069795,-0.021858061,short,long,
517,599,CCCC,C4 Therapeutics to Present at Two Virtual February 2023 Conferences,https://www.globenewswire.com/news-release/2023/02/08/2603789/0/en/C4-Therapeutics-to-Present-at-Two-Virtual-February-2023-Conferences.html,Calendar of Events,2/8/2023 7:00,pre_market,6.309999943,6.309999943,415.1900024,413.1300049,0,-0.004961578,0.004961578,long,long,
518,600,CCCC,C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs),https://www.globenewswire.com/news-release/2023/12/12/2794588/0/en/C4-Therapeutics-Announces-License-and-Research-Collaboration-with-Merck-to-Discover-and-Develop-Degrader-Antibody-Conjugates-DACs.html,Product / Services Announcement,12/12/2023 7:00,pre_market,1.179999948,1.820000053,461.9899902,461.6300049,0.542372994,-0.000779206,0.5431522,long,long,
519,601,CCCC,C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/04/2803847/0/en/C4-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Conference Calls/ Webcasts,1/4/2024 7:00,pre_market,5.78000021,5.929999828,468.7900085,468.2999878,0.02595149,-0.001045288,0.026996779,long,short,
520,610,CDTX,"Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B",https://www.globenewswire.com/news-release/2023/06/22/2692856/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-CD388-a-Novel-Drug-Fc-Conjugate-Targeting-Influenza-A-and-B.html,Product / Services Announcement,6/22/2023 8:00,pre_market,1.100000024,1.210000038,434.9400024,433.9500122,0.100000011,-0.002276154,0.102276164,long,long,
521,611,CDTX,Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023,https://www.globenewswire.com/news-release/2023/09/27/2750330/0/en/Cidara-Therapeutics-to-Present-New-Data-on-Novel-drug-Fc-conjugate-CD388-at-IDWeek-2023.html,Calendar of Events,9/27/2023 8:00,pre_market,0.980000019,0.97299999,425.8800049,427.0899963,-0.007142887,0.002841156,-0.009984043,short,short,
522,612,CDTX,Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1),https://www.globenewswire.com/news-release/2023/10/13/2760048/0/en/Cidara-Therapeutics-and-Mundipharma-receive-positive-CHMP-opinion-for-rezafungin-for-the-treatment-of-Invasive-Candidiasis-in-adults-1.html,Product / Services Announcement,10/13/2023 10:34,market_open,0.885999978,0.920000017,435.2099915,431.5,0.038374763,-0.008524601,0.046899364,long,long,
523,613,CDTX,Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress,https://www.globenewswire.com/news-release/2023/11/30/2788520/0/en/Cidara-Therapeutics-to-Present-New-Preclinical-Data-on-Novel-Dual-Acting-Drug-Fc-Conjugates-at-ESMO-Immuno-Oncology-Annual-Congress.html,Product / Services Announcement,11/30/2023 8:00,pre_market,0.690999985,0.709999979,454.6099854,455.480011,0.027496374,0.001913785,0.025582589,long,long,
524,614,CDTX,Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/03/23/2633001/0/en/Cidara-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,Earnings Releases and Operating Results,3/23/2023 7:12,pre_market,1.899999976,1.700000048,392.1099854,395.0899963,-0.105263122,0.007599937,-0.112863058,short,long,
525,615,CDTX,Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit,https://www.globenewswire.com/news-release/2023/06/20/2691268/0/en/Cidara-Therapeutics-to-Present-Ongoing-Development-of-Drug-Fc-Conjugates-DFC-Including-CD73-Targeting-DFC-From-Its-Cloudbreak-Platform-at-Adenosine-Pathway-Targeted-Cancer-Immunoth.html,Clinical Study,6/20/2023 9:55,market_open,1.100000024,1.129999995,437.4500122,437.1799927,0.027272701,-0.000617258,0.027889959,long,long,
526,616,CDTX,Cidara Therapeutics Named as a San Diego Metro Area Top Workplace,https://www.globenewswire.com/news-release/2023/11/20/2783213/0/en/Cidara-Therapeutics-Named-as-a-San-Diego-Metro-Area-Top-Workplace.html,Contests/Awards,11/20/2023 8:00,pre_market,0.779999971,0.769999981,450.7900085,450.5299988,-0.012820501,-0.000576787,-0.012243714,short,short,
527,617,CDTX,Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit,https://www.globenewswire.com/news-release/2023/06/13/2687061/0/en/Cidara-Therapeutics-to-Present-at-Adenosine-Pathway-Targeted-Cancer-Immunotherapy-Summit.html,Health,6/13/2023 8:00,pre_market,1.230000019,1.220000029,433.7999878,435.3200073,-0.008130073,0.003503964,-0.011634037,short,short,
528,618,CDTX,Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza,https://www.globenewswire.com/news-release/2023/09/06/2738348/0/en/Cidara-Therapeutics-Announces-Janssen-s-Election-to-Proceed-Under-its-License-Agreement-Relating-to-Novel-Drug-Fc-Conjugates-Targeting-Influenza.html,Business Contracts,9/6/2023 8:00,pre_market,0.792999983,0.939999998,449.2399902,448.3999939,0.185372028,-0.001869817,0.187241844,long,long,
529,619,CDTX,"Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023",https://www.globenewswire.com/news-release/2023/09/07/2739260/0/en/Cidara-Therapeutics-to-Host-Virtual-Research-Development-Day-on-its-Cloudbreak-Development-Pipeline-on-September-21-2023.html,Calendar of Events,9/7/2023 8:00,pre_market,1,0.976000011,446.2200012,443.1099854,-0.023999989,-0.006969692,-0.017030297,short,short,
530,620,CDTX,Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023,https://www.globenewswire.com/news-release/2023/10/11/2758360/0/en/Cidara-Therapeutics-Presents-New-Preclinical-and-Clinical-Data-on-Novel-Drug-Fc-Conjugate-CD388-at-IDWeek-2023.html,Health,10/11/2023 8:30,pre_market,0.964999974,0.99000001,434.5400085,435.6400146,0.025906774,0.002531427,0.023375347,long,long,
531,605,CDMO,Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers,https://www.globenewswire.com/news-release/2023/04/04/2640637/0/en/Avid-Bioservices-Unveils-Completed-Mammalian-Cell-Facilities-Expansion-Providing-Significantly-Increased-Capacity-for-Existing-and-Future-Customers.html,Health,4/4/2023 8:05,pre_market,18.75,18.98999977,410.9500122,411.6199951,0.012799988,0.001630327,0.011169661,long,long,
532,621,CDTX,Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™,https://www.globenewswire.com/news-release/2023/04/24/2652645/0/en/Cidara-Therapeutics-Receives-20-Million-Milestone-Payment-Following-FDA-Approval-of-REZZAYO.html,Product / Services Announcement,4/24/2023 8:00,pre_market,1.129999995,1.129999995,412.2000122,411.9899902,0,-0.000509515,0.000509515,long,long,
533,606,CDMO,Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs,https://www.globenewswire.com/news-release/2023/11/08/2776212/0/en/Avid-Bioservices-Partners-With-California-Institute-for-Regenerative-Medicine-CIRM-to-Provide-CDMO-Services-for-Cell-and-Gene-Therapy-CGT-Programs.html,Product / Services Announcement,11/8/2023 8:05,pre_market,5.869999886,5.880000114,436.9299927,437.5499878,0.001703617,0.00141898,0.000284636,long,long,
534,607,CDMO,"Avid Bioservices Appoints Oksana Lukash as Vice President, People",https://www.globenewswire.com/news-release/2022/11/16/2557167/0/en/Avid-Bioservices-Appoints-Oksana-Lukash-as-Vice-President-People.html,Management statements,11/16/2022 8:05,pre_market,15.64000034,15.48999977,398.4899902,396.7799988,-0.009590829,-0.004291178,-0.005299651,short,short,
535,629,CELU,Celularity Inc. Announces $6 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2023/04/05/2641778/0/en/Celularity-Inc-Announces-6-Million-Registered-Direct-Offering.html,Financing Agreements,4/5/2023 9:00,pre_market,0.735000014,0.643999994,408.6700134,407.9100037,-0.123809549,-0.001859715,-0.121949834,short,short,
536,630,CELU,Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification,https://www.globenewswire.com/news-release/2023/10/18/2762428/0/en/Celularity-Announces-Commercial-Biomaterial-Products-Receive-Saudi-Food-and-Drug-Authority-SFDA-Product-Classification.html,Regulatory information,10/18/2023 9:00,pre_market,0.32100001,0.319999993,436.019989,434.1900024,-0.003115317,-0.004197025,0.001081707,long,long,
537,631,CELU,Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health,https://www.globenewswire.com/news-release/2023/04/03/2639651/0/en/Celularity-Receives-U-S-Food-And-Drug-Administration-FDA-Preliminary-Assessment-For-Celularity-s-Investigational-Fuse-Bone-Void-Filler-To-Be-Regulated-As-A-Device-By-FDA-s-Center-F.html,Product / Services Announcement,4/3/2023 9:00,pre_market,0.620000005,0.629999995,409.3900146,408.8500061,0.016129017,-0.001319057,0.017448073,long,long,
538,632,CELU,Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”,https://www.globenewswire.com/news-release/2023/04/12/2645388/0/en/Celularity-s-Dr-Robert-Hariri-To-Co-Chair-The-2023-International-Precision-Medicine-Center-IPMC-Conference-Beyond-Longevity-Live-120-Like-50.html,Calendar of Events,4/12/2023 9:00,pre_market,0.652999997,0.699999988,409.7200012,411.8699951,0.071975484,0.005247471,0.066728013,long,long,
539,633,CELU,Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing,https://www.globenewswire.com/news-release/2023/11/24/2785689/0/en/Celularity-Inc-Announces-Receipt-of-Nasdaq-Notice-Regarding-Late-Form-10-Q-Filing.html,Exchange Members,11/24/2023 13:15,market_open,0.200000003,0.214000002,455.0700073,455.2999878,0.069999992,0.000505374,0.069494618,long,short,
540,634,CELU,Celularity Announces Clinical Data on  Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia,https://www.globenewswire.com/news-release/2023/04/27/2656412/0/en/Celularity-Announces-Clinical-Data-on-Human-Placental-Derived-Unmodified-Allogeneic-Natural-Killer-Cell-Therapy-Candidate-Cynk-001-in-Adult-Patients-With-Relapsed-Refractory-and-Me.html,Clinical Study,4/27/2023 9:00,pre_market,0.634999991,0.649999976,404.3599854,407,0.023622025,0.006528872,0.017093153,long,long,
541,635,CELU,Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications,https://www.globenewswire.com/news-release/2023/07/27/2712254/0/en/Celularity-and-Vers%C3%A9a-Ophthalmics-Announce-Exclusive-U-S-Commercialization-Agreement-to-Distribute-Biovance-and-Biovance-3l-Ocular-For-Ophthalmic-Applications.html,Product / Services Announcement,7/27/2023 9:00,pre_market,0.349999994,0.344999999,455.5100098,459.019989,-0.014285701,0.007705603,-0.021991304,short,short,
542,636,CELU,Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting,https://www.globenewswire.com/news-release/2023/04/04/2640787/0/en/Celularity-Announces-Acceptance-of-Poster-Presentation-at-2023-Society-for-Biomaterials-Annual-Meeting.html,Calendar of Events,4/4/2023 9:00,pre_market,0.74000001,0.759999991,410.9500122,411.6199951,0.027027001,0.001630327,0.025396674,long,long,
543,637,CELU,Celularity Inc. Announces $3 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2023/07/27/2712276/0/en/Celularity-Inc-Announces-3-Million-Registered-Direct-Offering.html,Stock Market News,7/27/2023 9:07,pre_market,0.349999994,0.344999999,455.5100098,459.019989,-0.014285701,0.007705603,-0.021991304,short,short,
544,622,CDTX,"Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development",https://www.globenewswire.com/news-release/2023/08/16/2726300/0/en/Cidara-Therapeutics-Announces-Appointment-of-Nicole-Davarpanah-M-D-J-D-as-Senior-Vice-President-of-Translational-Research-Development.html,Company Announcement,8/16/2023 8:00,pre_market,0.907999992,0.90200001,442.8900146,442.4599915,-0.00660791,-0.000970948,-0.005636962,short,short,
545,623,CDTX,Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress,https://www.globenewswire.com/news-release/2023/12/07/2792476/0/en/Cidara-Therapeutics-Presents-New-Promising-Preclincal-Data-on-Novel-Dual-Acting-Drug-Fc-Conjugates-at-ESMO-Immuno-Oncology-Annual-Congress.html,Clinical Study,12/7/2023 8:00,pre_market,0.759000003,0.800000012,454.7600098,456.9100037,0.054018456,0.004727755,0.049290701,long,long,
546,624,CDTX,Cidara Therapeutics to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/03/31/2638585/0/en/Cidara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,Calendar of Events,3/31/2023 8:00,pre_market,1.279999971,1.259999991,403.7000122,404.6600037,-0.015624985,0.002377982,-0.018002968,short,short,
547,625,CDTX,Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China,https://www.globenewswire.com/news-release/2023/12/06/2791705/0/en/Cidara-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-Restore-Trial-of-Rezafungin-in-China.html,Product / Services Announcement,12/6/2023 8:00,pre_market,0.779999971,0.774999976,456.6000061,458.8099976,-0.006410251,0.004840104,-0.011250354,short,short,
548,626,CDTX,Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO,https://www.globenewswire.com/news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html,Health,2/12/2024 8:00,pre_market,0.727999985,0.730000019,501.2000122,501.1700134,0.002747299,-5.99E-05,0.002807153,long,long,
549,627,CDTX,Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults,https://www.globenewswire.com/news-release/2023/12/22/2800553/0/en/Cidara-Therapeutics-Announces-European-Approval-of-REZZAYO-rezafungin-for-the-Treatment-of-Invasive-Candidiasis-in-Adults.html,Clinical Study,12/22/2023 7:30,pre_market,0.737999976,0.878000021,472.7000122,473.8599854,0.189701965,0.002453931,0.187248034,long,long,
550,650,CERT,Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software,https://www.globenewswire.com/news-release/2023/09/19/2745582/0/en/Certara-Announces-300th-Regulatory-Submission-Milestone-Using-its-Technology-enabled-Services-and-Software.html,Management statements,9/19/2023 8:15,pre_market,13.97999954,13.98999977,443.6300049,442.6799927,0.000715324,-0.002141452,0.002856776,long,long,
551,652,CERT,Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase,https://www.globenewswire.com/news-release/2022/11/07/2549670/0/en/Arsenal-Capital-Partners-Increases-Investment-in-Global-Biosimulation-Leader-Certara-with-449M-Stock-Purchase.html,Changes in company's own shares,11/7/2022 8:00,pre_market,10.64999962,12.02000046,376.3500061,377.7099915,0.128638581,0.003613619,0.125024963,long,long,
552,653,CERT,Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year,https://www.globenewswire.com/news-release/2023/04/27/2656261/0/en/Certara-Customers-Received-90-Percent-of-US-FDA-Novel-Drug-Approvals-for-9th-Consecutive-Year.html,Health,4/27/2023 8:00,pre_market,23.95000076,24.15999985,404.3599854,407,0.008768229,0.006528872,0.002239357,long,long,
553,638,CELU,Celularity Human Placental-Derived  Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies,https://www.globenewswire.com/news-release/2023/07/18/2706479/0/en/Celularity-Human-Placental-Derived-Advanced-Biomaterials-Demonstrate-Superior-Biocompatibility-and-Better-Support-Differentiated-Cell-Functions-in-Studies.html,Clinical Study,7/18/2023 9:00,pre_market,0.49000001,0.492000014,450.8399963,450.5,0.004081641,-0.00075414,0.004835781,long,long,
554,639,CELU,Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron,https://www.globenewswire.com/news-release/2023/08/29/2733451/0/en/Celularity-Announces-Multi-Year-Research-Collaboration-Services-Agreement-With-Regeneron.html,Calendar of Events,8/29/2023 9:00,pre_market,0.286000013,0.326000005,442.7600098,442.6499939,0.139860104,-0.000248477,0.140108582,long,long,
555,640,CELU,Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products,https://www.globenewswire.com/news-release/2023/05/10/2665590/0/en/Celularity-Announces-Advisory-Guidance-From-Tamer-Group-Regarding-Anticipated-2023-Purchase-Orders-for-Celularity-Branded-Halal-Certified-Biomaterial-Products.html,Management statements,5/10/2023 9:00,pre_market,0.423000008,0.444999993,410.9299927,413.8800049,0.05200942,0.007178868,0.044830552,long,long,
556,641,CELU,Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt,https://www.globenewswire.com/news-release/2023/03/28/2635736/0/en/Celularity-Announces-Agreement-with-AD-Ports-Group-for-Exclusive-Product-Distribution-in-Various-Territories-in-the-Gulf-Cooperation-Council-Regions-and-Egypt.html,Partnerships,3/28/2023 9:00,pre_market,0.558000028,0.623000026,396.4899902,395.769989,0.116487445,-0.001815938,0.118303383,long,long,
557,642,CELU,Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated  as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH),https://www.globenewswire.com/news-release/2023/02/02/2600378/0/en/Correcting-Replacing-Celularity-Receives-Preliminary-Assessment-of-Product-Classification-and-Jurisdiction-for-Its-Investigational-Celularity-Tendon-Wrap-CTW-to-be-Regulated-as-a-D.html,Licensing Agreements,2/2/2023 7:53,pre_market,0.912000001,0.897000015,410.7999878,414.8599854,-0.016447353,0.009883149,-0.026330502,short,short,
558,643,CELU,Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability,https://www.globenewswire.com/news-release/2023/06/01/2680450/0/en/Celularity-Tissue-Factor-Gene-Knockout-of-Allogeneic-Stromal-Cells-Significantly-Lowers-Thrombotic-Effects-Study-Highlights-Critical-Importance-of-Gene-Editing-Capability.html,Clinical Study,6/1/2023 9:15,pre_market,0.759999991,0.779999971,417.8500061,418.0899963,0.026315765,0.000574345,0.025741419,long,long,
559,644,CELU,"Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline",https://www.globenewswire.com/news-release/2024/02/01/2822062/0/en/Celularity-Announces-Net-Sales-Expectations-for-First-Quarter-2024-and-Full-Year-2024-Reiterates-Advanced-Biomaterial-Product-Commercial-and-Development-Pipeline.html,Health,2/1/2024 9:00,pre_market,0.379999995,0.409999996,482.8800049,484.6300049,0.078947373,0.003624089,0.075323284,long,long,
560,645,CELU,Celularity Releases CEO Letter to Shareholders,https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html,Major shareholder announcements,1/18/2024 13:40,market_open,0.27700001,0.289000005,474.0100098,476.4899902,0.043321278,0.005231916,0.038089363,long,long,
561,646,CELU,Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023,https://www.globenewswire.com/news-release/2024/01/03/2803517/0/en/Celularity-Announces-Net-Sales-and-Total-Revenue-Expectations-for-Fourth-Quarter-2023-and-Full-Year-2023.html,Pre-Release Comments,1/3/2024 12:00,market_open,0.280000001,0.280999988,470.4299927,468.7900085,0.003571383,-0.003486139,0.007057521,long,long,
562,647,CELU,Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions,https://www.globenewswire.com/news-release/2024/01/25/2816813/0/en/Celularity-and-Genting-Leaders-Comments-on-Closing-21-Million-Financing-Transactions.html,Financing Agreements,1/25/2024 9:00,pre_market,0.300000012,0.284999996,485.3900146,487.5799866,-0.05000005,0.004511778,-0.054511828,short,short,
563,648,CELU,Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare,https://www.globenewswire.com/news-release/2024/01/04/2804245/0/en/Celularity-Confirms-Commercialization-Agreement-with-BioCellgraft-for-the-Manufacture-and-Distribution-of-Advanced-Biomaterial-Products-for-Use-in-Oral-Healthcare.html,Partnerships,1/4/2024 13:00,market_open,0.300000012,0.254999995,468.2999878,467.2799988,-0.15000005,-0.002178068,-0.147821982,short,short,
564,657,CHRS,Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™,https://www.globenewswire.com/news-release/2023/07/13/2704318/33333/en/Coherus-and-Superior-Biologics-Announce-National-Distribution-Agreement-for-YUSIMRY.html,Product / Services Announcement,7/13/2023 8:30,pre_market,4.46999979,4.505000114,446.019989,447.8999939,0.007830051,0.004215069,0.003614982,long,long,
565,659,CHRS,Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC),https://www.globenewswire.com/news-release/2023/10/27/2768663/33333/en/Coherus-and-Junshi-Biosciences-Announce-FDA-Approval-of-LOQTORZI-toripalimab-tpzi-in-All-Lines-of-Treatment-for-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-NPC.html,Clinical Study,10/27/2023 15:07,market_open,2.809999943,2.640000105,414.1900024,410.6799927,-0.060498164,-0.008474395,-0.052023769,short,long,
566,660,CHRS,Coherus Completes Surface Oncology Acquisition,https://www.globenewswire.com/news-release/2023/09/08/2740124/33333/en/Coherus-Completes-Surface-Oncology-Acquisition.html,Mergers and Acquisitions,9/8/2023 9:05,pre_market,4.889999867,4.949999809,444.8500061,444.8999939,0.012269927,0.00011237,0.012157557,long,long,
567,661,CHRS,Coherus to Acquire Surface Oncology,https://www.globenewswire.com/news-release/2023/06/16/2689648/33333/en/Coherus-to-Acquire-Surface-Oncology.html,Mergers and Acquisitions,6/16/2023 7:01,pre_market,5.389999867,4.739999771,442.6000061,443.019989,-0.120593713,0.0009489,-0.121542612,short,short,
568,662,CHRS,"CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch",https://www.globenewswire.com/news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html,Product / Services Announcement,10/4/2023 8:30,pre_market,3.349999905,3.390000105,421.5899963,422.0700073,0.011940359,0.001138573,0.010801786,long,long,
569,663,CHRS,Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC),https://www.globenewswire.com/news-release/2023/09/27/2750480/33333/en/Coherus-Announces-Three-Presentations-at-the-38th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html,Health,9/27/2023 9:10,pre_market,3.980000019,4.010000229,425.8800049,427.0899963,0.007537741,0.002841156,0.004696585,long,long,
570,654,CERT,"Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation",https://www.globenewswire.com/news-release/2023/01/04/2582816/0/en/Certara-Acquires-Vyasa-an-Artificial-Intelligence-Company-that-Delivers-Predictions-to-Accelerate-Scientific-Innovation.html,Mergers and Acquisitions,1/4/2023 7:31,pre_market,16.23999977,16.67000008,380.8200073,383.1799927,0.026477852,0.006197115,0.020280737,long,long,
571,664,CHRS,Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day,https://www.globenewswire.com/news-release/2023/10/02/2752800/33333/en/Coherus-Applauds-Congressional-Designation-of-September-30th-as-Rare-Cancer-Day.html,Health,10/2/2023 9:00,pre_market,3.74000001,3.799999952,427.480011,426.6199951,0.016042765,-0.002011827,0.018054593,long,long,
572,665,CHRS,"Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients",https://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html,Product / Services Announcement,6/1/2023 8:33,pre_market,4.090000153,4.170000076,417.8500061,418.0899963,0.019559883,0.000574345,0.018985537,long,long,
573,655,CERT,Certara Simcyp™ Group Awarded Two New Grants from US FDA,https://www.globenewswire.com/news-release/2023/08/29/2733376/0/en/Certara-Simcyp-Group-Awarded-Two-New-Grants-from-US-FDA.html,Health,8/29/2023 8:15,pre_market,15.92000008,15.89999962,442.7600098,442.6499939,-0.00125631,-0.000248477,-0.001007833,short,short,
574,666,CHRS,Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™,https://www.globenewswire.com/news-release/2023/10/05/2755393/33333/en/Coherus-Announces-Resubmission-of-Biologics-License-Application-BLA-Supplement-for-UDENYCA-ONBODY.html,Product / Services Announcement,10/5/2023 8:30,pre_market,3.170000076,3.25,424.6600037,424.3599854,0.025236568,-0.000706491,0.025943059,long,long,
575,667,CHRS,Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC),https://www.globenewswire.com/news-release/2023/11/03/2773176/33333/en/Coherus-Presents-Data-from-Next-generation-Immuno-oncology-Programs-at-38th-Annual-Meeting-of-Society-for-Immunotherapy-of-Cancer-SITC.html,Health,11/3/2023 8:30,pre_market,3.319999933,3.369999886,430.7600098,433.1400146,0.015060227,0.00552513,0.009535097,long,long,
576,668,CHRS,"Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association",https://www.globenewswire.com/news-release/2023/11/28/2787206/33333/en/Coherus-and-Junshi-Biosciences-Announce-Publication-of-Positive-Final-Overall-Survival-Results-of-JUPITER-02-a-Phase-3-Trial-Evaluating-LOQTORZI-toripalimab-tpzi-as-Treatment-for-N.html,Clinical Study,11/28/2023 11:16,market_open,1.909999967,2.109999895,454.0799866,454.9299927,0.104712006,0.00187193,0.102840076,long,long,
577,669,CHRS,"Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP",https://www.globenewswire.com/news-release/2024/02/05/2823475/33333/en/Coherus-Amends-Term-Loan-Agreement-with-Pharmakon-Advisors-LP.html,Financing Agreements,2/5/2024 8:00,pre_market,2.059999943,1.99000001,494.3500061,493.7000122,-0.033980551,-0.001314846,-0.032665706,short,short,
578,670,CHRS,"Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress",https://www.globenewswire.com/news-release/2023/12/06/2791515/33333/en/Coherus-Presents-Phase-1-2-Clinical-Data-on-Casdozokitug-a-First-in-Class-IL-27-Targeted-Antibody-at-the-2023-ESMO-Immuno-Oncology-Congress.html,Clinical Study,12/6/2023 4:00,pre_market,2.200000048,2.210000038,456.6000061,458.8099976,0.00454545,0.004840104,-0.000294654,short,short,
579,675,CKPT,Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/21/2747284/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,9/21/2023 8:30,pre_market,1.679999948,1.659999967,438.6400146,435.7000122,-0.011904751,-0.006702541,-0.005202211,short,short,
580,739,CRSP,CRISPR Therapeutics Announces Departure of Board Member,https://www.globenewswire.com/news-release/2023/03/29/2636608/0/en/CRISPR-Therapeutics-Announces-Departure-of-Board-Member.html,Directors and Officers,3/29/2023 8:00,pre_market,43.84999847,44.36000061,395.6000061,399.9299927,0.011630608,0.010945365,0.000685243,long,long,
581,676,CKPT,Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2738401/36989/en/Checkpoint-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/6/2023 8:30,pre_market,2,1.99000001,449.2399902,448.3999939,-0.004999995,-0.001869817,-0.003130179,short,short,
582,677,CKPT,Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2022/12/15/2574533/36989/en/Checkpoint-Therapeutics-Announces-7-5-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,Stock Market News,12/15/2022 8:00,pre_market,4.820000172,4.25,399.3999939,394.2999878,-0.118257293,-0.012769169,-0.105488124,short,short,
583,678,CKPT,Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer,https://www.globenewswire.com/news-release/2023/10/18/2762378/36989/en/Checkpoint-Therapeutics-Announces-Publication-of-Cosibelimab-Pivotal-Trial-Results-in-the-Journal-for-ImmunoTherapy-of-Cancer.html,Clinical Study,10/18/2023 8:30,pre_market,1.940000057,2.019999981,436.019989,434.1900024,0.041237073,-0.004197025,0.045434097,long,long,
584,679,CKPT,Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/05/23/2674331/36989/en/Checkpoint-Therapeutics-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,Stock Market News,5/23/2023 8:30,pre_market,2.890000105,2.789999962,418.7900085,417.0799866,-0.034602124,-0.004083244,-0.03051888,short,short,
585,681,CKPT,Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2022/09/22/2521006/36989/en/Checkpoint-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html,Calendar of Events,9/22/2022 8:30,pre_market,10.89999962,11,377.3900146,376.5799866,0.009174347,-0.002146395,0.011320742,long,long,
586,682,CKPT,Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma,https://www.globenewswire.com/news-release/2023/01/04/2582863/36989/en/Checkpoint-Therapeutics-Submits-Biologics-License-Application-to-FDA-for-Cosibelimab-as-a-Treatment-for-Patients-with-Metastatic-or-Locally-Advanced-Cutaneous-Squamous-Cell-Carcino.html,Company Announcement,1/4/2023 8:00,pre_market,6.139999867,6.369999886,380.8200073,383.1799927,0.037459287,0.006197115,0.031262172,long,long,
587,683,CKPT,Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma,https://www.globenewswire.com/news-release/2023/03/02/2619118/36989/en/Checkpoint-Therapeutics-Announces-FDA-Filing-Acceptance-of-Biologics-License-Application-for-Cosibelimab-in-Metastatic-or-Locally-Advanced-Cutaneous-Squamous-Cell-Carcinoma.html,Health,3/2/2023 7:00,pre_market,4.920000076,5.159999847,394.7399902,392.6799927,0.048780441,-0.005218619,0.053999059,long,long,
588,684,CKPT,Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds,https://www.globenewswire.com/news-release/2023/10/02/2753067/36989/en/Checkpoint-Therapeutics-Announces-Exercise-of-Warrants-for-11-13-Million-in-Gross-Proceeds.html,Financing Agreements,10/2/2023 12:53,market_open,1.75,1.610000014,426.6199951,427.3099976,-0.079999992,0.00161737,-0.081617362,short,short,
589,685,CKPT,Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing,https://www.globenewswire.com/news-release/2023/06/28/2696124/36989/en/Checkpoint-Therapeutics-Announces-Presentation-of-New-Cosibelimab-Pharmacokinetic-Data-Supporting-Extended-Interval-Dosing.html,Clinical Study,6/28/2023 8:00,pre_market,2.349999905,2.359999895,436.1700134,435.0499878,0.004255315,-0.002567865,0.00682318,long,long,
590,686,CKPT,Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference,https://www.globenewswire.com/news-release/2024/01/11/2807906/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-B-Riley-Securities-4th-Annual-Oncology-Conference.html,Health,1/11/2024 8:15,pre_market,1.909999967,1.940000057,476.5599976,477.5899963,0.015706854,0.00216132,0.013545534,long,long,
591,671,CHRS,Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx,https://www.globenewswire.com/news-release/2023/12/11/2793856/33333/en/Coherus-Announces-Updated-NCCN-Clinical-Practice-Guidelines-Positioning-LOQTORZI-toripalimab-tpzi-as-Preferred-Category-1-Regimen-for-First-Line-Treatment-of-Cancer-of-the-Nasophar.html,Clinical Study,12/11/2023 8:30,pre_market,2.220000029,2.230000019,460.2000122,459.6900024,0.0045045,-0.001108235,0.005612735,long,long,
592,672,CHRS,Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803378/33333/en/Coherus-BioSciences-Management-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Conference Calls/ Webcasts,1/3/2024 9:00,pre_market,3.140000105,3.099999905,472.6499939,470.4299927,-0.012738917,-0.004696924,-0.008041993,short,short,
593,694,CNTG,CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders,https://www.globenewswire.com/news-release/2023/04/11/2644190/0/en/CENTOGENE-Extends-Strategic-Partnership-With-Takeda-to-Continue-Providing-Access-to-Genetic-Testing-for-Patients-With-Lysosomal-Storage-Disorders.html,Clinical Study,4/11/2023 6:30,pre_market,0.649999976,0.731000006,409.6099854,410.2600098,0.124615435,0.001586935,0.1230285,long,long,
594,687,CKPT,Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance,https://www.globenewswire.com/news-release/2023/12/05/2790924/36989/en/Checkpoint-Therapeutics-Strengthens-Intellectual-Property-Protection-for-Cosibelimab-with-New-U-S-Patent-Issuance.html,Patents,12/5/2023 8:30,pre_market,2.890000105,2.880000114,456.6900024,455.2600098,-0.003460204,-0.003131211,-0.000328993,short,long,
595,693,CNTG,"CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment",https://www.globenewswire.com/news-release/2023/06/27/2695202/0/en/CENTOGENE-and-Lifera-a-Biopharma-Company-Owned-by-the-PIF-Enter-Strategic-Collaboration-Forming-Saudi-Arabian-Joint-Venture-to-Increase-Access-to-Leading-Data-Driven-Multiomic-Test.html,Financing Agreements,6/27/2023 7:30,pre_market,0.782000005,1.110000014,431.4400024,432.3500061,0.419437349,0.002109224,0.417328125,long,long,
596,816,DBVT,Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF,https://www.globenewswire.com/news-release/2024/01/16/2810343/0/en/Half-Year-Report-on-the-DBV-Technologies-Liquidity-Contract-with-ODDO-BHF.html,European Regulatory News,1/16/2024 16:30,after_hours,,,,,,,,,long,
597,695,CNTG,"CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline",https://www.globenewswire.com/news-release/2023/04/26/2655078/0/en/CENTOGENE-Accelerates-Global-Genetic-Data-Interpretation-Launching-FilterTool-Application-as-Accessory-to-CentoCloud-Bioinformatics-Pipeline.html,Product / Services Announcement,4/26/2023 8:30,pre_market,1.629999995,1.649999976,406.0799866,406.7200012,0.012269927,0.00157608,0.010693847,long,long,
598,696,CNTG,CENTOGENE to Participate in Upcoming Conferences in April,https://www.globenewswire.com/news-release/2023/04/14/2647012/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-April.html,Calendar of Events,4/14/2023 8:00,pre_market,0.680000007,0.680000007,413.4700012,412.8099976,0,-0.001596255,0.001596255,long,long,
599,703,CNTG,CENTOGENE Regains Compliance With Nasdaq Listing Requirements,https://www.globenewswire.com/news-release/2023/07/14/2704894/0/en/CENTOGENE-Regains-Compliance-With-Nasdaq-Listing-Requirements.html,Stock Market News,7/14/2023 6:30,pre_market,1.480000019,1.5,449.5599976,450.480011,0.013513501,0.002046475,0.011467025,long,long,
600,700,CNTG,CENTOGENE Receives Nasdaq Non-Compliance Notice,https://www.globenewswire.com/news-release/2023/04/28/2657282/0/en/CENTOGENE-Receives-Nasdaq-Non-Compliance-Notice.html,Stock Market News,4/28/2023 6:30,pre_market,1.210000038,0.976999998,412.4100037,411.4899902,-0.192562011,-0.002230822,-0.190331188,short,short,
601,688,CKPT,U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer,https://www.globenewswire.com/news-release/2023/12/18/2797694/36989/en/U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Cosibelimab-Solely-Due-to-Inspection-Findings-at-Third-Party-Manufacturer.html,Clinical Study,12/18/2023 7:00,pre_market,3.319999933,1.539999962,469.3299866,470.980011,-0.536144581,0.003515702,-0.539660283,short,short,
602,697,CNTG,CENTOGENE to Participate in Upcoming Conferences in August,https://www.globenewswire.com/news-release/2023/08/07/2719533/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-August.html,Health,8/7/2023 6:30,pre_market,1.029999971,1,446.8099976,448.7099915,-0.029126187,0.004252353,-0.03337854,short,short,
603,702,CNTG,"CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism",https://www.globenewswire.com/news-release/2023/11/14/2780103/0/en/CENTOGENE-University-College-London-and-Global-Team-of-Researchers-Discover-Gene-Associated-With-New-Neurodevelopmental-Disease-Linked-to-Early-Onset-Dystonia-and-Parkinsonism.html,Clinical Study,11/14/2023 8:30,pre_market,1.169999957,1.289999962,440.1900024,446.3200073,0.10256411,0.013925816,0.088638295,long,long,
604,692,CNTG,CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering,https://www.globenewswire.com/news-release/2023/10/10/2757274/0/en/CENTOGENE-Expands-Multiomic-Diagnostic-Portfolio-With-Newly-Launched-Transcriptomic-Offering.html,Product / Services Announcement,10/10/2023 6:30,pre_market,1.029999971,1.023000002,432.2900085,432.9400024,-0.006796087,0.001503606,-0.008299693,short,short,
605,701,CNTG,CENTOGENE to Participate in Upcoming Conferences in May,https://www.globenewswire.com/news-release/2023/05/05/2662386/0/en/CENTOGENE-to-Participate-in-Upcoming-Conferences-in-May.html,Conference Calls/ Webcasts,5/5/2023 6:30,pre_market,0.739000022,0.717000008,405.1300049,408.9100037,-0.029769979,0.009330335,-0.039100314,short,short,
606,689,CKPT,Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market,https://www.globenewswire.com/news-release/2024/01/29/2818873/36989/en/Checkpoint-Therapeutics-Announces-14-Million-Registered-Direct-Offering-Priced-At-the-Market.html,Financing Agreements,1/29/2024 8:00,pre_market,1.679999948,1.690000057,487.4100037,487.730011,0.005952446,0.000656547,0.0052959,long,short,
607,712,CRBP,"Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020",https://www.globenewswire.com/news-release/2020/11/03/2119282/0/en/Corbus-Pharmaceuticals-to-Report-Third-Quarter-Results-on-November-10-2020.html,Press releases,11/3/2020 8:05,pre_market,30.60000038,30.89999962,330.2000122,333.6900024,0.009803897,0.010569322,-0.000765425,short,short,
608,713,CRBP,Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/07/2775041/0/en/Corbus-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,11/7/2023 8:00,pre_market,5.039999962,4.679999828,435.6900024,435.6900024,-0.071428599,0,-0.071428599,short,short,
609,714,CRBP,Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis,https://www.globenewswire.com/news-release/2020/11/09/2122759/0/en/Corbus-Pharmaceuticals-Presents-Additional-Data-from-RESOLVE-1-Study-in-Systemic-Sclerosis.html,Press releases,11/9/2020 8:05,pre_market,33.90000153,34.79999924,350.1600037,363.9700012,0.026548604,0.039439106,-0.012890502,short,short,
610,715,CRBP,"Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021",https://www.globenewswire.com/news-release/2021/03/08/2188695/0/en/Corbus-Pharmaceuticals-to-Report-Fourth-Quarter-and-Year-End-2020-Results-on-March-15-2021.html,Press releases,3/8/2021 8:05,pre_market,56.09999847,56.09999847,383.6300049,384.6600037,0,0.002684875,-0.002684875,short,short,
611,716,CRBP,CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING,https://www.globenewswire.com/news-release/2021/05/19/2232608/0/en/CORBUS-PHARMACEUTICALS-ANNOUNCES-ADJOURNMENT-OF-ANNUAL-MEETING.html,Press releases,5/19/2021 9:20,pre_market,48.90000153,46.79999924,411.9400024,406.9200134,-0.042944831,-0.012186214,-0.030758617,short,short,
612,717,CRBP,Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress,https://www.globenewswire.com/news-release/2021/05/25/2235486/0/en/Corbus-Pharmaceuticals-Announces-Publication-of-Two-Abstracts-at-EULAR-2021-Virtual-Congress.html,Press releases,5/25/2021 8:05,pre_market,50.70000076,50.70000076,419.1700134,420.3299866,0,0.00276731,-0.00276731,short,short,
613,718,CRBP,Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases,https://www.globenewswire.com/news-release/2021/01/20/2161391/0/en/Corbus-Pharmaceuticals-Announces-Presentations-at-the-New-York-Academy-of-Sciences-Webinar-on-Targeting-the-Endocannabinoid-System-to-Treat-Human-Diseases.html,Press releases,1/20/2021 8:05,pre_market,51.90000153,51.90000153,378.6499939,381.1099854,0,0.006496742,-0.006496742,short,short,
614,719,CRBP,Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2021/03/09/2189519/0/en/Corbus-Pharmaceuticals-to-Present-at-Two-Upcoming-Investor-Conferences.html,Press releases,3/9/2021 8:05,pre_market,55.79999924,57.59999847,381.7200012,385.8500061,0.032258051,0.010819462,0.02143859,long,long,
615,720,CRBP,Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2021/05/11/2227201/0/en/Corbus-Pharmaceuticals-to-Present-at-Three-Upcoming-Investor-Conferences.html,Press releases,5/11/2021 8:05,pre_market,47.09999847,42.59999847,417.9400024,413.1000061,-0.095541404,-0.011580601,-0.083960804,short,long,
616,721,CRBP,Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701,https://www.globenewswire.com/news-release/2023/10/16/2760607/0/en/Corbus-Pharmaceuticals-Presents-the-First-Pre-Clinical-Characterization-of-its-Next-Generation-Nectin-4-ADC-CRB-701.html,Health,10/16/2023 8:00,pre_market,6.03000021,6.179999828,431.5,433.8200073,0.024875558,0.00537661,0.019498948,long,long,
617,704,CNTG,CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients,https://www.globenewswire.com/news-release/2023/09/01/2735986/0/en/CENTOGENE-Announces-Publication-Establishing-Lyso-Gb1-as-a-Predictive-Biomarker-for-Gaucher-Disease-Patients.html,Clinical Study,9/1/2023 8:00,pre_market,1.190000057,1.200000048,450.3500061,453.1700134,0.008403353,0.006261813,0.00214154,long,long,
618,705,CNTG,CENTOGENE Announces Voting Results of Extraordinary General Meeting,https://www.globenewswire.com/news-release/2023/12/19/2798385/0/en/CENTOGENE-Announces-Voting-Results-of-Extraordinary-General-Meeting.html,Annual Meetings & Shareholder Rights,12/19/2023 6:30,pre_market,1.159999967,1.139999986,471.9700012,472.5299988,-0.017241363,0.001186511,-0.018427874,short,short,
619,706,CNTG,CENTOGENE Announces Preliminary Full Year 2023 Revenue,https://www.globenewswire.com/news-release/2024/01/18/2811370/0/en/CENTOGENE-Announces-Preliminary-Full-Year-2023-Revenue.html,Management statements,1/18/2024 6:30,pre_market,1.24000001,1.210000038,472.2900085,474.0100098,-0.024193525,0.003641833,-0.027835358,short,short,
620,707,CNTG,"CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone",https://www.globenewswire.com/news-release/2023/12/13/2795390/0/en/CENTOGENE-s-Frontotemporal-Dementia-FTD-Genetic-Study-EFRONT-Reaches-Initial-Patient-Enrollment-Milestone.html,Clinical Study,12/13/2023 6:30,pre_market,1.269999981,1.210000038,464.1000061,464.4899902,-0.04724405,0.000840302,-0.048084352,short,long,
621,708,CNTG,CENTOGENE Receives French Research Tax Credit Accreditation,https://www.globenewswire.com/news-release/2024/01/24/2815050/0/en/CENTOGENE-Receives-French-Research-Tax-Credit-Accreditation.html,Management statements,1/24/2024 6:30,pre_market,1.25,1.220000029,484.8599854,487.8099976,-0.023999977,0.006084256,-0.030084233,short,short,
622,709,CNTG,CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration,https://www.globenewswire.com/news-release/2024/01/25/2816524/0/en/CENTOGENE-and-the-Laboratory-of-Human-Genetics-of-Infectious-Diseases-at-Institut-Imagine-Announce-Rare-Disease-Research-Collaboration.html,Health,1/25/2024 6:30,pre_market,1.200000048,1.169999957,485.3900146,487.5799866,-0.025000075,0.004511778,-0.029511852,short,long,
623,710,CNTG,CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics,https://www.globenewswire.com/news-release/2024/01/23/2813910/0/en/CENTOGENE-and-The-Michael-J-Fox-Foundation-Announce-Research-Project-to-Validate-Genetic-Risk-Factors-of-Parkinson-s-Disease-Using-Multiomics.html,Clinical Study,1/23/2024 6:30,pre_market,1.25,1.25,483.4500122,484.0100098,0,0.001158336,-0.001158336,short,short,
624,723,CRBP,"Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023",https://www.globenewswire.com/news-release/2023/10/03/2753553/0/en/Corbus-Pharmaceuticals-to-Host-Virtual-Meet-the-Expert-Series-Session-2-on-CRB-701-on-October-10-2023.html,Calendar of Events,10/3/2023 8:00,pre_market,6.440000057,6.440000057,427.3099976,425.0599976,0,-0.005265498,0.005265498,long,long,
625,724,CRBP,Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results,https://www.globenewswire.com/news-release/2021/03/15/2192661/0/en/Corbus-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2020-Financial-Results.html,Press releases,3/15/2021 7:05,pre_market,69.90000153,72.30000305,394.0599976,394.3299866,0.034334785,0.000685147,0.033649638,long,long,
626,726,CRBP,Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020,https://www.globenewswire.com/news-release/2020/10/23/2113631/0/en/Corbus-Pharmaceuticals-Announces-Presentation-of-Data-from-its-Phase-2b-Study-in-Cystic-Fibrosis-at-NACFC-2020.html,Press releases,10/23/2020 8:05,pre_market,31.20000076,30.75,344.6099854,345.9299927,-0.014423101,0.003830438,-0.018253539,short,short,
627,727,CRBP,Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates,https://www.globenewswire.com/news-release/2021/05/13/2229088/0/en/Corbus-Pharmaceuticals-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates.html,Press releases,5/13/2021 8:05,pre_market,44.70000076,44.40000153,405.4100037,407.0700073,-0.006711392,0.004094629,-0.010806022,short,short,
628,728,CRBP,Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates,https://www.globenewswire.com/news-release/2020/11/10/2123642/0/en/Corbus-Pharmaceuticals-Reports-Third-Quarter-Financial-Results-and-Provides-Corporate-Updates.html,Press releases,11/10/2020 7:05,pre_market,36.59999847,35.63999939,354.5599976,353.4899902,-0.026229484,-0.003017846,-0.023211639,short,short,
629,729,CRBP,Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting,https://www.globenewswire.com/news-release/2023/11/02/2772252/0/en/Corbus-Pharmaceuticals-Presents-Results-of-Two-Pre-Clinical-Studies-on-its-Anti-%CE%B1V%CE%B28-Monoclonal-Antibody-CRB-601-at-the-2023-SITC-Annual-Meeting.html,Clinical Study,11/2/2023 8:00,pre_market,5.050000191,5.236000061,422.6600037,426.5799866,0.036831656,0.009274554,0.027557102,long,long,
630,730,CRBP,Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates,https://www.globenewswire.com/news-release/2021/08/12/2279756/0/en/Corbus-Pharmaceuticals-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates.html,Press releases,8/12/2021 8:05,pre_market,39.90000153,39.59999847,443.7799988,443.6199951,-0.007518873,-0.000360547,-0.007158326,short,short,
631,1819,ORPHA.CO,Insiders handel med selskabets aktier,https://www.globenewswire.com/news-release/2023/12/08/2793205/0/da/Insiders-handel-med-selskabets-aktier.html,European Regulatory News,12/8/2023 8:40,pre_market,676.7999878,676,458.230011,457.4599915,-0.001182015,-0.001680421,0.000498406,long,long,
632,731,CRBP,Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE),https://www.globenewswire.com/news-release/2021/04/20/2213251/0/en/Corbus-Pharmaceuticals-Announces-Completion-of-Enrollment-in-NIH-Sponsored-Phase-2-Study-of-Lenabasum-for-Treatment-of-Systemic-Lupus-Erythematosus-SLE.html,Press releases,4/20/2021 8:05,pre_market,49.20000076,49.20000076,415.2099915,413.9100037,0,-0.003130917,0.003130917,long,short,
633,732,CRBP,Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference,https://www.globenewswire.com/news-release/2020/11/12/2125597/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Jefferies-Virtual-London-Healthcare-Conference.html,Press releases,11/12/2020 8:05,pre_market,36.59999847,36.59999847,356.6700134,355.5799866,0,-0.003056121,0.003056121,long,long,
634,733,CRBP,Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU,https://www.globenewswire.com/news-release/2024/01/23/2814050/0/en/Phase-1-Clinical-Data-for-SYS6002-CRB-701-to-be-presented-at-2024-ASCO-GU.html,Clinical Study,1/23/2024 8:00,pre_market,7.599999905,7.989999771,483.4500122,484.0100098,0.051315773,0.001158336,0.050157437,long,long,
635,734,CRBP,Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/06/2824475/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,Conference Calls/ Webcasts,2/6/2024 9:50,market_open,25.04000092,26,493.519989,493.980011,0.03833862,0.000932124,0.037406496,long,long,
636,735,CRBP,CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024,https://www.globenewswire.com/news-release/2024/01/26/2817869/0/en/CRB-701-SYS6002-A-Next-Generation-Nectin-4-Targeting-Antibody-Drug-Conjugate-Demonstrates-Encouraging-Safety-and-Efficacy-in-Patients-with-Nectin-4-Positive-Tumors-in-First-In-Huma.html,Clinical Study,1/26/2024 7:30,pre_market,8.43999958,16.80999947,488.0299988,487.5899963,0.991706197,-0.000901589,0.992607786,long,long,
637,736,CRBP,Corbus Pharmaceuticals Announces Pricing of Public Offering,https://www.globenewswire.com/news-release/2024/01/31/2821248/0/en/Corbus-Pharmaceuticals-Announces-Pricing-of-Public-Offering.html,Changes in company's own shares,1/31/2024 9:19,pre_market,25.15999985,28.45000076,490.8900146,488.6199951,0.130763153,-0.004624294,0.135387447,long,long,
638,737,CRBP,Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601),https://www.globenewswire.com/news-release/2024/01/09/2806222/0/en/Corbus-Pharmaceuticals-Announces-FDA-Clearance-of-IND-Application-for-its-anti-%CE%B1v%CE%B28-monoclonal-antibody-CRB-601.html,Product / Services Announcement,1/9/2024 8:00,pre_market,7.159999847,7.400000095,474.6000061,471.8699951,0.033519588,-0.005752236,0.039271824,long,long,
639,738,CRBP,Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU,https://www.globenewswire.com/news-release/2023/12/18/2797790/0/en/Corbus-Pharmaceuticals-Announces-Abstract-Accepted-for-Presentation-at-2024-ASCO-GU.html,Product / Services Announcement,12/18/2023 8:00,pre_market,5.5,5.510000229,469.3299866,470.980011,0.001818223,0.003515702,-0.001697479,short,short,
640,740,CRSP,CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference,https://www.globenewswire.com/news-release/2022/12/01/2565896/0/en/CRISPR-Therapeutics-to-Present-at-the-2022-BMO-Growth-ESG-Conference.html,Calendar of Events,12/1/2022 8:00,pre_market,54.79000092,54.18000031,407.6799927,408.769989,-0.01113343,0.002673657,-0.013807086,short,short,
641,741,CRSP,CRISPR Therapeutics to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/02/08/2603890/0/en/CRISPR-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,Calendar of Events,2/8/2023 8:00,pre_market,55.66500092,55.66999817,415.1900024,413.1300049,8.97737e-05,-0.004961578,0.005051352,long,long,
642,742,CRSP,CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference,https://www.globenewswire.com/news-release/2023/02/27/2616052/0/en/CRISPR-Therapeutics-to-Participate-in-the-43rd-Annual-Cowen-Health-Care-Conference.html,Health,2/27/2023 8:00,pre_market,48.02000046,49.18999863,396.3800049,399.8699951,0.02436481,0.008804658,0.015560152,long,long,
643,743,CRSP,CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,https://www.globenewswire.com/news-release/2023/09/27/2750466/0/en/CRISPR-Therapeutics-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html,Calendar of Events,9/27/2023 9:01,pre_market,46.11000061,46.86000061,425.8800049,427.0899963,0.016265452,0.002841156,0.013424296,long,short,
644,744,CRSP,CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference,https://www.globenewswire.com/news-release/2023/01/11/2586996/0/en/CRISPR-Therapeutics-to-Participate-in-B-Riley-Securities-3rd-Annual-Oncology-Conference.html,Conference Calls/ Webcasts,1/11/2023 8:00,pre_market,48.24000168,48.59000015,390.5799866,392.230011,0.007255358,0.004224549,0.003030809,long,long,
645,745,CRSP,CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/06/13/2687207/0/en/CRISPR-Therapeutics-to-Participate-in-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,6/13/2023 9:00,pre_market,59.90000153,60,433.7999878,435.3200073,0.001669424,0.003503964,-0.00183454,short,short,
646,746,CRSP,CRISPR Therapeutics Announces Leadership Transition,https://www.globenewswire.com/news-release/2023/09/07/2739361/0/en/CRISPR-Therapeutics-Announces-Leadership-Transition.html,Directors and Officers,9/7/2023 8:30,pre_market,51.09000015,48.99000168,446.2200012,443.1099854,-0.041103904,-0.006969692,-0.034134213,short,short,
647,747,CRSP,CRISPR Therapeutics Proposes New Appointment to the Board of Directors,https://www.globenewswire.com/news-release/2023/10/16/2760571/0/en/CRISPR-Therapeutics-Proposes-New-Appointment-to-the-Board-of-Directors.html,Directors and Officers,10/16/2023 8:00,pre_market,44.31000137,44.31000137,431.5,433.8200073,0,0.00537661,-0.00537661,short,long,
648,748,CRSP,CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference,https://www.globenewswire.com/news-release/2023/08/30/2734284/0/en/CRISPR-Therapeutics-to-Participate-in-Citi-s-18th-Annual-Biopharma-Conference.html,Calendar of Events,8/30/2023 8:00,pre_market,50.56999969,50.56000137,449.1600037,449.5100098,-0.000197713,0.000779246,-0.000976958,short,short,
649,749,CRSP,CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®,https://www.globenewswire.com/news-release/2022/12/12/2572040/0/en/CRISPR-Therapeutics-Provides-Update-on-Its-Ongoing-Phase-1-CARBON-Trial-of-CTX110.html,Clinical Study,12/12/2022 10:00,market_open,49.22999954,51.06000137,394.1099854,398.9500122,0.037172493,0.012280904,0.02489159,long,long,
650,750,CRSP,"CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development",https://www.globenewswire.com/news-release/2022/12/19/2576318/0/en/CRISPR-Therapeutics-Announces-the-Appointment-of-Alex-Harding-M-D-M-B-A-as-Head-of-Business-Development.html,Directors and Officers,12/19/2022 8:30,pre_market,46.40999985,46.5,383.269989,383.4700012,0.001939241,0.000521857,0.001417383,long,long,
651,754,CRSP,CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit,https://www.globenewswire.com/news-release/2024/02/15/2829970/0/en/CRISPR-Therapeutics-to-Present-at-the-Citi-2024-Virtual-Oncology-Leadership-Summit.html,Calendar of Events,2/15/2024 8:30,pre_market,79.04000092,79.75,498.5700073,499.2900085,0.008982782,0.001444133,0.007538649,long,long,
652,752,CRSP,CRISPR Therapeutics to Participate Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/05/02/2659065/0/en/CRISPR-Therapeutics-to-Participate-Upcoming-Investor-Conferences.html,Conference Calls/ Webcasts,5/2/2023 8:00,pre_market,49.08000183,49.06999969,415.5100098,414.769989,-0.000203793,-0.001780994,0.001577201,long,long,
653,751,CRSP,CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023,https://www.globenewswire.com/news-release/2023/11/06/2773808/0/en/CRISPR-Therapeutics-Announces-Preclinical-Data-at-the-American-Heart-Association-AHA-Scientific-Sessions-2023.html,Product / Services Announcement,11/6/2023 5:01,pre_market,50.99000168,53.20000076,434.6900024,435.4700012,0.043341812,0.001794379,0.041547433,long,long,
654,755,CRSP,CRISPR Therapeutics Announces $280 Million Registered Direct Offering,https://www.globenewswire.com/news-release/2024/02/13/2828258/0/en/CRISPR-Therapeutics-Announces-280-Million-Registered-Direct-Offering.html,Changes in company's own shares,2/13/2024 8:30,pre_market,76.44000244,72.38999939,500.980011,494.5299988,-0.05298277,-0.01287479,-0.04010798,short,short,
655,756,CRSP,CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803326/0/en/CRISPR-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Conference Calls/ Webcasts,1/3/2024 8:30,pre_market,66.05999756,64.58000183,472.6499939,470.4299927,-0.022403811,-0.004696924,-0.017706887,short,short,
656,757,CRSP,CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook,https://www.globenewswire.com/news-release/2024/01/08/2805274/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-2024-Outlook.html,Clinical Study,1/8/2024 7:00,pre_market,60.66999817,60.54999924,467.9200134,468.4299927,-0.001977896,0.001089886,-0.003067781,short,long,
657,768,CTMX,CytomX Therapeutics to Present at Upcoming November Investor Conferences,https://www.globenewswire.com/news-release/2023/11/01/2771110/37704/en/CytomX-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html,Calendar of Events,11/1/2023 8:00,pre_market,1.100000024,1.090000033,418.2000122,419.2000122,-0.0090909,0.0023912,-0.011482101,short,short,
658,760,CTKB,Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward,https://www.globenewswire.com/news-release/2023/05/16/2669891/0/en/Cytek-Biosciences-Marks-Shipment-of-Its-100th-Cell-Sorter-as-the-Company-Continues-to-Lead-Cell-Analysis-Forward.html,Product / Services Announcement,5/16/2023 8:00,pre_market,7.28000021,7.150000095,413.0100098,411.8599854,-0.017857158,-0.002784495,-0.015072663,short,short,
659,761,CTKB,Cytek Biosciences Announces $50 Million Stock Repurchase Program,https://www.globenewswire.com/news-release/2023/05/19/2672579/0/en/Cytek-Biosciences-Announces-50-Million-Stock-Repurchase-Program.html,Stock Market News,5/19/2023 9:00,pre_market,6.690000057,6.880000114,419.230011,420.1700134,0.028400606,0.002242212,0.026158395,long,short,
660,769,CTMX,CytomX Therapeutics Announces New Employment Inducement Grants,https://www.globenewswire.com/news-release/2023/07/20/2708270/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html,Changes in company's own shares,7/20/2023 9:00,pre_market,1.820000053,1.840000033,455.2000122,454.1700134,0.010989,-0.002262739,0.013251739,long,long,
661,770,CTMX,CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.,https://www.globenewswire.com/news-release/2023/06/30/2697718/37704/en/CytomX-Therapeutics-Announces-30-Million-Private-Placement-from-BVF-Partners-L-P.html,Management statements,6/30/2023 8:00,pre_market,1.409999967,1.639999986,438.1099854,441.4400024,0.163120585,0.00760087,0.155519715,long,long,
662,762,CTKB,Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe,https://www.globenewswire.com/news-release/2023/09/20/2746504/0/en/Cytek-Biosciences-Cell-Analysis-Solutions-Take-Center-Stage-at-Upcoming-Clinical-Conferences-in-the-US-and-Europe.html,Health,9/20/2023 9:00,pre_market,6.420000076,6.449999809,442.7099915,444.0100098,0.004672856,0.002936501,0.001736355,long,long,
663,771,CTMX,CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas,https://www.globenewswire.com/news-release/2023/01/26/2595893/37704/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-Probody-T-Cell-Engaging-Bispecific-TCB-Collaboration-with-Astellas.html,Health,1/26/2023 7:00,pre_market,2.619999886,2.74000001,400.3500061,403.1300049,0.045801576,0.006943921,0.038857655,long,long,
664,772,CTMX,CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/10/30/2769158/37704/en/CytomX-Therapeutics-to-Present-Preclinical-Data-for-Conditionally-Activated-Interferon-Alpha-2b-at-the-SITC-2023-Annual-Meeting.html,Calendar of Events,10/30/2023 8:00,pre_market,1.070000053,1.100000024,410.6799927,413.5599976,0.028037355,0.007012771,0.021024584,long,long,
665,763,CTKB,Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed,https://www.globenewswire.com/news-release/2023/02/28/2617240/0/en/Sale-of-Flow-Cytometry-and-Imaging-Business-From-DiaSorin-to-Cytek-Biosciences-Completed.html,Mergers and Acquisitions,2/28/2023 9:21,pre_market,10.53999996,10.53999996,397.730011,397.230011,0,-0.001257134,0.001257134,long,long,
666,773,CTMX,"CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/07/17/2705602/37704/en/CytomX-Therapeutics-Appoints-Yu-Waye-Wayne-Chu-M-D-as-Chief-Medical-Officer.html,Directors and Officers,7/17/2023 8:00,pre_market,1.820000053,1.860000014,449.2799988,449.1300049,0.021978,-0.000333854,0.022311854,long,long,
667,774,CTMX,"CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023",https://www.globenewswire.com/news-release/2023/08/01/2715756/37704/en/CytomX-Therapeutics-to-Report-Second-Quarter-2023-Financial-Results-on-August-8-2023.html,Conference Calls/ Webcasts,8/1/2023 8:00,pre_market,1.74000001,1.730000019,457.7900085,456.269989,-0.005747121,-0.003320342,-0.002426779,short,long,
668,764,CTKB,Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry,https://www.globenewswire.com/news-release/2023/09/14/2743290/0/en/Cytek-Biosciences-Launches-Educational-Roadshow-Focused-on-Spectral-Flow-Cytometry.html,Calendar of Events,9/14/2023 9:00,pre_market,7.260000229,7.329999924,446.5100098,449.0700073,0.009641831,0.005733349,0.003908482,long,long,
669,775,CTMX,"CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023",https://www.globenewswire.com/news-release/2023/10/31/2770106/37704/en/CytomX-Therapeutics-to-Report-Third-Quarter-2023-Financial-Results-on-November-7-2023.html,Conference Calls/ Webcasts,10/31/2023 8:00,pre_market,1.110000014,1.090000033,415.5899963,416.1799927,-0.018018001,0.00141966,-0.01943766,short,short,
670,765,CTKB,Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters,https://www.globenewswire.com/news-release/2023/09/27/2750427/0/en/Cytek-Biosciences-Achieves-ISO-13485-Certification-at-Headquarters.html,Company Announcement,9/27/2023 9:00,pre_market,6.340000153,6.380000114,425.8800049,427.0899963,0.006309142,0.002841156,0.003467986,long,long,
671,766,CTKB,Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results,https://www.globenewswire.com/news-release/2024/01/08/2805518/0/en/Cytek-Biosciences-Announces-Preliminary-Full-Year-2023-Revenue-Results.html,Management statements,1/8/2024 9:00,pre_market,8.069999695,8,467.9200134,468.4299927,-0.008674064,0.001089886,-0.00976395,short,short,
672,767,CTKB,"Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry",https://www.globenewswire.com/news-release/2023/12/21/2800056/0/en/Cytek-Biosciences-Introduces-the-Cytek-Orion-Reagent-Cocktail-Preparation-System-the-First-of-its-Kind-Automated-Cocktail-Preparation-Instrument-for-Flow-Cytometry.html,Product / Services Announcement,12/21/2023 9:00,pre_market,9.329999924,9.399999619,468.2600098,471.3299866,0.007502647,0.006556137,0.00094651,long,long,
673,781,DBVT,DBV Technologies to Participate in Upcoming Investor Conference,https://www.globenewswire.com/news-release/2023/06/06/2683358/0/en/DBV-Technologies-to-Participate-in-Upcoming-Investor-Conference.html,European Regulatory News,6/6/2023 17:00,after_hours,,,,,,,,,long,
674,782,DBVT,Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF,https://www.globenewswire.com/news-release/2023/07/10/2702197/0/fr/Bilan-semestriel-du-contrat-de-liquidit%C3%A9-DBV-Technologies-avec-ODDO-BHF.html,European Regulatory News,7/10/2023 16:30,after_hours,,,,,,,,,long,
675,783,DBVT,DBV Technologies participera au prochain congrès de l’EAACI 2023,https://www.globenewswire.com/news-release/2023/06/08/2685215/0/fr/DBV-Technologies-participera-au-prochain-congr%C3%A8s-de-l-EAACI-2023.html,European Regulatory News,6/8/2023 16:30,after_hours,,,,,,,,,long,
676,784,DBVT,DBV Technologies to Participate in Upcoming EAACI Congress 2023,https://www.globenewswire.com/news-release/2023/06/08/2685215/0/en/DBV-Technologies-to-Participate-in-Upcoming-EAACI-Congress-2023.html,European Regulatory News,6/8/2023 16:30,after_hours,,,,,,,,,long,
677,785,DBVT,DBV Technologies va présenter de nouvelles données à l’ACAAI 2023,https://www.globenewswire.com/news-release/2023/11/02/2772870/0/fr/DBV-Technologies-va-pr%C3%A9senter-de-nouvelles-donn%C3%A9es-%C3%A0-l-ACAAI-2023.html,European Regulatory News,11/2/2023 16:30,after_hours,,,,,,,,,long,
678,786,DBVT,DBV Technologies to Present New Data at ACAAI 2023,https://www.globenewswire.com/news-release/2023/11/02/2772870/0/en/DBV-Technologies-to-Present-New-Data-at-ACAAI-2023.html,European Regulatory News,11/2/2023 16:30,after_hours,,,,,,,,,long,
679,795,DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 octobre 2023,https://www.globenewswire.com/news-release/2023/11/06/2774558/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-octobre-2023.html,European Regulatory News,11/6/2023 16:30,after_hours,,,,,,,,,long,
680,788,DBVT,DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update,https://www.globenewswire.com/news-release/2023/10/27/2768706/0/en/DBV-Technologies-to-Report-Third-Quarter-2023-Financial-Results-and-Business-Update.html,European Regulatory News,10/27/2023 16:30,after_hours,,,,,,,,,long,
681,789,DBVT,DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/10/31/2770671/0/en/DBV-Technologies-Receives-Requested-Feedback-from-FDA-on-Protocol-Design-Elements-for-COMFORT-Safety-Studies-and-Reports-Third-Quarter-2023-Financial-Results.html,European Regulatory News,10/31/2023 16:30,after_hours,,,,,,,,,long,
682,790,DBVT,"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of May 31, 2023",https://www.globenewswire.com/news-release/2023/06/16/2689932/0/en/Monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-May-31-2023.html,European Regulatory News,6/16/2023 16:30,after_hours,,,,,,,,,long,
683,791,DBVT,DBV Technologies a reçu la réponse attendue de la FDA sur certains éléments de conception du protocole pour les études de sécurité COMFORT et publie ses résultats financiers du troisième trimestre 2023,https://www.globenewswire.com/news-release/2023/10/31/2770671/0/fr/DBV-Technologies-a-re%C3%A7u-la-r%C3%A9ponse-attendue-de-la-FDA-sur-certains-%C3%A9l%C3%A9ments-de-conception-du-protocole-pour-les-%C3%A9tudes-de-s%C3%A9curit%C3%A9-COMFORT-et-publie-ses-r%C3%A9sultats-financiers-du-tro.html,European Regulatory News,10/31/2023 16:30,after_hours,,,,,,,,,long,
684,787,DBVT,DBV Technologies annonce la nomination de Virginie Boucinha au poste de Directrice Financière,https://www.globenewswire.com/news-release/2023/10/16/2760299/0/fr/DBV-Technologies-annonce-la-nomination-de-Virginie-Boucinha-au-poste-de-Directrice-Financi%C3%A8re.html,European Regulatory News,10/16/2023 2:00,no_market,,,,,,,,,long,
685,796,DBVT,Information relative au nombre total des droits de vote et  d’actions composant le capital social au 30 novembre 2023,https://www.globenewswire.com/news-release/2023/12/04/2790484/0/fr/Information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-novembre-2023.html,European Regulatory News,12/4/2023 16:30,after_hours,,,,,,,,,long,
686,793,DBVT,DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer,https://www.globenewswire.com/news-release/2023/10/16/2760299/0/en/DBV-Technologies-Announces-Appointment-of-Virginie-Boucinha-as-Chief-Financial-Officer.html,European Regulatory News,10/16/2023 2:00,overnight,,,,,,,,,long,
687,794,DBVT,DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer,https://www.globenewswire.com/news-release/2023/10/16/2760299/0/en/DBV-Technologies-Announces-Appointment-of-Virginie-Boucinha-as-Chief-Financial-Officer.html,European Regulatory News,10/16/2023 2:00,no_market,,,,,,,,,long,
688,902,ELTX,Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split,https://www.globenewswire.com/news-release/2023/06/01/2680276/0/en/Angion-Biomedia-Corp-Announces-1-for-10-Reverse-Stock-Split.html,Major shareholder announcements,6/1/2023 8:00,pre_market,9.800000191,10.60000038,417.8500061,418.0899963,0.081632671,0.000574345,0.081058326,long,long,
689,777,CTMX,CytomX Therapeutics Outlines 2024 Company Priorities and Milestones,https://www.globenewswire.com/news-release/2024/01/04/2803919/37704/en/CytomX-Therapeutics-Outlines-2024-Company-Priorities-and-Milestones.html,Product / Services Announcement,1/4/2024 8:00,pre_market,1.629999995,1.639999986,468.7900085,468.2999878,0.006134964,-0.001045288,0.007180252,long,long,
690,778,CTMX,CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/21/2799945/37704/en/CytomX-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,12/21/2023 8:00,pre_market,1.340000033,1.320000053,468.2600098,471.3299866,-0.014925359,0.006556137,-0.021481496,short,long,
691,779,CTMX,CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference,https://www.globenewswire.com/news-release/2024/01/12/2808578/37704/en/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Conference.html,Calendar of Events,1/12/2024 8:00,pre_market,1.690000057,1.690000057,476.3500061,477.8399963,0,0.003127932,-0.003127932,short,short,
692,804,DBVT,DBV Technologies invitée à participer à une prochaine Conférence Investisseur,https://www.globenewswire.com/news-release/2023/09/05/2737908/0/fr/DBV-Technologies-invit%C3%A9e-%C3%A0-participer-%C3%A0-une-prochaine-Conf%C3%A9rence-Investisseur.html,European Regulatory News,9/5/2023 16:30,after_hours,,,,,,,,,long,
693,805,DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 juin 2023,https://www.globenewswire.com/news-release/2023/07/19/2707774/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-juin-2023.html,European Regulatory News,7/19/2023 16:30,after_hours,,,,,,,,,long,
694,806,DBVT,Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF,https://www.globenewswire.com/news-release/2023/07/10/2702197/0/en/Half-Year-Report-on-the-DBV-Technologies-Liquidity-Contract-with-ODDO-BHF.html,European Regulatory News,7/10/2023 16:30,after_hours,,,,,,,,,long,
695,807,DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 septembre 2023,https://www.globenewswire.com/news-release/2023/10/05/2755807/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-septembre-2023.html,European Regulatory News,10/5/2023 16:30,after_hours,,,,,,,,,long,
696,808,DBVT,DBV Technologies présente ses résultats financiers du premier semestre 2023 et fait le point sur ses activités,https://www.globenewswire.com/news-release/2023/07/25/2710899/0/fr/DBV-Technologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activit%C3%A9s.html,European Regulatory News,7/25/2023 16:30,after_hours,,,,,,,,,long,
697,809,DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 mai 2023,https://www.globenewswire.com/news-release/2023/06/16/2689932/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-mai-2023.html,European Regulatory News,6/16/2023 16:30,after_hours,,,,,,,,,long,
698,810,DBVT,DBV Technologies to Participate in Upcoming Investor Conference,https://www.globenewswire.com/news-release/2023/09/05/2737908/0/en/DBV-Technologies-to-Participate-in-Upcoming-Investor-Conference.html,European Regulatory News,9/5/2023 16:30,after_hours,,,,,,,,,long,
699,811,DBVT,DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers,https://www.globenewswire.com/news-release/2023/05/10/2666153/0/en/DBV-Technologies-Announces-New-England-Journal-of-Medicine-Publication-of-Phase-3-EPITOPE-Trial-Data-Evaluating-Viaskin-Peanut-in-Toddlers.html,European Regulatory News,5/10/2023 17:30,after_hours,,,,,,,,,long,
700,812,DBVT,DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update,https://www.globenewswire.com/news-release/2023/07/25/2710899/0/en/DBV-Technologies-to-Report-First-Half-2023-Financial-Results-and-Provide-a-Corporate-Update.html,European Regulatory News,7/25/2023 16:30,after_hours,,,,,,,,,long,
701,813,DBVT,DBV Technologies invitée à participer à une prochaine Conférence Investisseur,https://www.globenewswire.com/news-release/2023/06/06/2683358/0/fr/DBV-Technologies-invit%C3%A9e-%C3%A0-participer-%C3%A0-une-prochaine-Conf%C3%A9rence-Investisseur.html,European Regulatory News,6/6/2023 17:00,after_hours,,,,,,,,,long,
702,814,DBVT,DBV Technologies présente ses résultats financiers du troisième trimestre 2023 et fait le point sur ses activités,https://www.globenewswire.com/news-release/2023/10/27/2768706/0/fr/DBV-Technologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-du-troisi%C3%A8me-trimestre-2023-et-fait-le-point-sur-ses-activit%C3%A9s.html,European Regulatory News,10/27/2023 16:30,after_hours,,,,,,,,,long,
703,815,DBVT,Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF,https://www.globenewswire.com/news-release/2024/01/16/2810343/0/fr/Bilan-semestriel-du-contrat-de-liquidit%C3%A9-DBV-Technologies-avec-ODDO-BHF.html,European Regulatory News,1/16/2024 16:30,after_hours,,,,,,,,,long,
704,819,DYAI,Dyadic Attends Investor Events in December,https://www.globenewswire.com/news-release/2023/11/30/2788573/0/en/Dyadic-Attends-Investor-Events-in-December.html,Calendar of Events,11/30/2023 8:30,pre_market,1.710000038,1.74000001,454.6099854,455.480011,0.017543843,0.001913785,0.015630058,long,long,
705,821,DYAI,"Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells",https://www.globenewswire.com/news-release/2023/09/26/2749502/0/en/Dyadic-and-bYoRNA-Announce-a-Collaboration-Targeting-the-Production-of-Abundant-Low-Cost-mRNA-From-C1-Cells.html,Partnerships,9/26/2023 8:30,pre_market,2.079999924,2.099999905,432.230011,429.0899963,0.009615376,-0.007264685,0.01688006,long,long,
706,822,DYAI,Dyadic to Present at World Vaccine Congress Washington 2023,https://www.globenewswire.com/news-release/2023/03/30/2637625/0/en/Dyadic-to-Present-at-World-Vaccine-Congress-Washington-2023.html,Calendar of Events,3/30/2023 8:30,pre_market,1.49000001,1.519999981,401.3500061,404.0899963,0.020134209,0.006826935,0.013307274,long,long,
707,823,DYAI,Dyadic to Participate at Two Industry Events in May,https://www.globenewswire.com/news-release/2023/05/10/2665543/0/en/Dyadic-to-Participate-at-Two-Industry-Events-in-May.html,Product / Services Announcement,5/10/2023 8:30,pre_market,1.799999952,1.789999962,410.9299927,413.8800049,-0.00555555,0.007178868,-0.012734419,short,short,
708,824,DYAI,Dyadic to Present at Industry and Investor Events in October,https://www.globenewswire.com/news-release/2023/09/29/2751979/0/en/Dyadic-to-Present-at-Industry-and-Investor-Events-in-October.html,Product / Services Announcement,9/29/2023 8:30,pre_market,1.879999995,1.879999995,428.519989,431.6700134,0,0.007350939,-0.007350939,short,short,
709,825,DYAI,Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin,https://www.globenewswire.com/news-release/2023/08/07/2719707/0/en/Dyadic-Announces-Continued-Progress-Towards-Commercialization-of-Animal-Free-Recombinant-Serum-Albumin.html,Product / Services Announcement,8/7/2023 8:30,pre_market,1.720000029,1.700000048,446.8099976,448.7099915,-0.011627896,0.004252353,-0.015880249,short,long,
710,826,DYAI,Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent,https://www.globenewswire.com/news-release/2023/04/12/2645288/0/en/Dyadic-Announces-Expanded-Licensing-Agreement-to-Develop-and-Commercialize-Vaccines-and-Biologics-for-African-Continent.html,Licensing Agreements,4/12/2023 8:00,pre_market,1.919999957,1.950000048,409.7200012,411.8699951,0.015625048,0.005247471,0.010377576,long,short,
711,827,DYAI,Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate,https://www.globenewswire.com/news-release/2023/11/29/2787745/0/en/Dyadic-Announces-Top-Line-Results-from-its-Successful-Phase-1-Clinical-Trial-for-a-First-in-Human-Filamentous-Fungal-Based-Vaccine-Candidate.html,Clinical Study,11/29/2023 8:30,pre_market,1.769999981,1.75,454.9299927,457.1499939,-0.011299424,0.004879874,-0.016179299,short,short,
712,828,DYAI,Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform,https://www.globenewswire.com/news-release/2023/04/18/2649016/0/en/Dyadic-Receives-U-S-Patent-for-Manufacturing-Seasonal-and-Pandemic-Influenza-Vaccines-from-its-Proprietary-C1-Protein-Production-Platform.html,Patents,4/18/2023 8:30,pre_market,1.820000053,1.879999995,413.9400024,415.5799866,0.032967001,0.003961889,0.029005112,long,long,
713,829,DYAI,Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™,https://www.globenewswire.com/news-release/2023/09/19/2745544/0/en/Dyadic-Announces-Development-and-License-Agreement-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html,Licensing Agreements,9/19/2023 8:00,pre_market,1.840000033,1.809999943,443.6300049,442.6799927,-0.016304397,-0.002141452,-0.014162945,short,short,
714,830,DYAI,Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™,https://www.globenewswire.com/news-release/2023/05/08/2663306/0/en/Dyadic-Announces-Collaboration-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html,Health,5/8/2023 8:30,pre_market,1.649999976,1.690000057,412.6300049,412.9700012,0.024242474,0.000823974,0.0234185,long,long,
715,831,DYAI,Dyadic Appoints Doug Pace to Its Executive Leadership Team,https://www.globenewswire.com/news-release/2023/10/09/2756672/0/en/Dyadic-Appoints-Doug-Pace-to-Its-Executive-Leadership-Team.html,Health,10/9/2023 8:30,pre_market,2.039999962,1.99000001,429.5400085,427.5799866,-0.024509781,-0.004563072,-0.019946709,short,short,
716,832,DYAI,Dyadic to Participate at Upcoming Events in June,https://www.globenewswire.com/news-release/2023/06/01/2680321/0/en/Dyadic-to-Participate-at-Upcoming-Events-in-June.html,Calendar of Events,6/1/2023 8:30,pre_market,2.279999971,2.25,417.8500061,418.0899963,-0.013157882,0.000574345,-0.013732228,short,short,
717,833,DYAI,Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate,https://www.globenewswire.com/news-release/2023/07/24/2709514/0/en/Dyadic-Provides-Phase-1-Clinical-Trial-Update-for-its-Recombinant-Protein-RBD-Vaccine-Candidate.html,Clinical Study,7/24/2023 8:30,pre_market,1.860000014,1.950000048,452.1799927,453.3699951,0.048387114,0.002631701,0.045755414,long,long,
718,834,DYAI,Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity,https://www.globenewswire.com/news-release/2023/06/21/2692028/0/en/Dyadic-Announced-an-MoU-with-Bangladesh-s-State-Owned-Pharmaceutical-Company-to-Facilitate-Biopharmaceutical-Research-and-Biomanufacturing-Capacity.html,Business Contracts,6/21/2023 8:33,pre_market,2.059999943,2.119999886,437.1799927,436.1600037,0.029126187,-0.00233311,0.031459297,long,long,
719,817,DBVT,"Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2023",https://www.globenewswire.com/news-release/2023/12/04/2790484/0/en/Information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-November-30-2023.html,European Regulatory News,12/4/2023 16:30,after_hours,,,,,,,,,long,
720,840,ECOR,electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue,https://www.globenewswire.com/news-release/2023/10/17/2761421/0/en/electroCore-Announces-Two-Year-Extension-of-gammaCore-Device-Listing-in-the-NHS-Supply-Chain-Catalogue.html,Government News,10/17/2023 8:00,pre_market,5.349999905,5.349999905,436.0400085,432.8099976,0,-0.007407602,0.007407602,long,long,
721,841,ECOR,"electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC",https://www.globenewswire.com/news-release/2023/07/13/2704254/0/en/electroCore-Inc-Announces-Distribution-Agreement-with-Reliefband-Technologies-LLC.html,Partnerships,7/13/2023 8:00,pre_market,4.801000118,4.683000088,446.019989,447.8999939,-0.024578219,0.004215069,-0.028793287,short,short,
722,843,ECOR,"electroCore to Announce Second Quarter Financial Results on Wednesday, August 9",https://www.globenewswire.com/news-release/2023/08/01/2715804/0/en/electroCore-to-Announce-Second-Quarter-Financial-Results-on-Wednesday-August-9.html,Conference Calls/ Webcasts,8/1/2023 8:00,pre_market,4.5,4.460000038,457.7900085,456.269989,-0.00888888,-0.003320342,-0.005568538,short,short,
723,844,ECOR,electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference,https://www.globenewswire.com/news-release/2023/10/05/2755341/0/en/electroCore-to-Participate-in-the-Lytham-Partners-Fall-2023-Virtual-Investor-Conference.html,Calendar of Events,10/5/2023 8:00,pre_market,6.320000172,6.349999905,424.6600037,424.3599854,0.004746793,-0.000706491,0.005453284,long,long,
724,845,ECOR,TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project,https://www.globenewswire.com/news-release/2023/06/27/2695227/0/en/TAC-STIM-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Inclusion-in-the-Air-Force-Research-Laboratories-Real-Time-Assessing-and-Augmenting-Cognitive-Performance-in-Extreme-Envi.html,Product / Services Announcement,6/27/2023 8:00,pre_market,3.869999886,3.828999996,431.4400024,432.3500061,-0.010594287,0.002109224,-0.012703511,short,short,
725,846,ECOR,electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference,https://www.globenewswire.com/news-release/2023/09/21/2747197/0/en/electroCore-to-Present-at-iAccess-Alpha-s-Top-10-Best-Ideas-from-the-Buyside-Virtual-Conference.html,Calendar of Events,9/21/2023 8:00,pre_market,5.440000057,5.260000229,438.6400146,435.7000122,-0.033088203,-0.006702541,-0.026385663,short,short,
726,847,ECOR,electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology,https://www.globenewswire.com/news-release/2023/10/11/2758277/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html,Product / Services Announcement,10/11/2023 8:00,pre_market,5.389999867,5.369999886,434.5400085,435.6400146,-0.003710572,0.002531427,-0.006241998,short,short,
727,848,ECOR,"electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum",https://www.globenewswire.com/news-release/2023/11/07/2775044/0/en/electroCore-to-Participate-in-Canaccord-Genuity-s-MedTech-Diagnostics-and-Digital-Health-Services-Forum.html,Health,11/7/2023 8:00,pre_market,6.130000114,6.119999886,435.6900024,435.6900024,-0.001631359,0,-0.001631359,short,short,
728,849,ECOR,electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/07/2739252/0/en/electroCore-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/7/2023 8:00,pre_market,5.974999905,5.96999979,446.2200012,443.1099854,-0.000836839,-0.006969692,0.006132853,long,long,
729,850,ECOR,electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering,https://www.globenewswire.com/news-release/2023/08/23/2730348/0/en/electroCore-Announces-Dismissal-of-All-Litigation-Related-to-Its-2018-Initial-Public-Offering.html,Initial Public Offerings,8/23/2023 8:00,pre_market,4.789999962,4.690000057,438.1499939,439.25,-0.020876807,0.00251057,-0.023387377,short,short,
730,851,ECOR,electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology,https://www.globenewswire.com/news-release/2023/09/26/2749414/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html,Patents,9/26/2023 8:00,pre_market,5.324999809,5.349999905,432.230011,429.0899963,0.004694854,-0.007264685,0.011959538,long,short,
731,903,ELTX,Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/06/2738299/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/6/2023 8:00,pre_market,8.409999847,8.989999771,449.2399902,448.3999939,0.068965509,-0.001869817,0.070835326,long,long,
732,835,DYAI,Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa,https://www.globenewswire.com/news-release/2023/11/20/2783242/0/en/Dyadic-s-C1-Platform-to-be-Used-to-Produce-Vaccines-for-Humans-and-Animals-in-Africa.html,Product / Services Announcement,11/20/2023 8:30,pre_market,1.710000038,1.74000001,450.7900085,450.5299988,0.017543843,-0.000576787,0.018120629,long,long,
733,836,DYAI,Dyadic to Attend BIO CEO & Investor Conference and European Industry Events,https://www.globenewswire.com/news-release/2024/02/01/2821988/0/en/Dyadic-to-Attend-BIO-CEO-Investor-Conference-and-European-Industry-Events.html,Calendar of Events,2/1/2024 8:30,pre_market,1.299999952,1.279999971,482.8800049,484.6300049,-0.015384601,0.003624089,-0.01900869,short,short,
734,837,DYAI,Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company,https://www.globenewswire.com/news-release/2024/02/06/2824325/0/en/Dyadic-Announces-Research-and-Development-Collaboration-Agreement-with-Global-Biopharmaceutical-Company.html,Partnerships,2/6/2024 8:30,pre_market,1.429999948,1.49000001,492.5499878,493.519989,0.041958087,0.001969346,0.039988741,long,long,
735,838,DYAI,Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing,https://www.globenewswire.com/news-release/2024/02/13/2828243/0/en/Dyadic-and-Cygnus-Technologies-Announce-Partnership-To-Provide-C1-HCP-ELISA-Assay-to-Enhance-Quality-Assurance-in-Biomanufacturing.html,Partnerships,2/13/2024 8:30,pre_market,1.340000033,1.340000033,500.980011,494.5299988,0,-0.01287479,0.01287479,long,long,
736,865,EDIT,Editas Medicine Announces Third Quarter 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2023/11/03/2773078/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-and-Business-Updates.html,Earnings Releases and Operating Results,11/3/2023 7:00,pre_market,7.03000021,7.25,430.7600098,433.1400146,0.031294422,0.00552513,0.025769292,long,long,
737,866,EDIT,Editas Medicine Reports Inducement Grant to New Chief Scientific Officer,https://www.globenewswire.com/news-release/2023/07/25/2710379/0/en/Editas-Medicine-Reports-Inducement-Grant-to-New-Chief-Scientific-Officer.html,Contests/Awards,7/25/2023 8:00,pre_market,8.659999847,8.720000267,454.2000122,453.9200134,0.006928455,-0.000616466,0.007544921,long,long,
738,868,EDIT,Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia,https://www.globenewswire.com/news-release/2023/06/06/2682746/0/en/Editas-Medicine-to-Host-Virtual-Event-to-Discuss-EDIT-301-Clinical-Data-from-the-RUBY-Trial-for-Severe-Sickle-Cell-Disease-and-the-EDITHAL-Trial-for-Transfusion-dependent-Beta-Thal.html,Clinical Study,6/6/2023 8:00,pre_market,9.43999958,9.449999809,427.1000061,426.6700134,0.001059346,-0.001006773,0.002066119,long,long,
739,869,EDIT,Editas Medicine Announces Upcoming Investor Events,https://www.globenewswire.com/news-release/2023/08/30/2734405/0/en/Editas-Medicine-Announces-Upcoming-Investor-Events.html,Conference Calls/ Webcasts,8/30/2023 9:00,pre_market,9.06000042,9.109999657,449.1600037,449.5100098,0.005518679,0.000779246,0.004739433,long,long,
740,852,ECOR,Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting,https://www.globenewswire.com/news-release/2023/10/24/2765530/0/en/Data-Highlighting-Non-invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Symptoms-of-Gastroparesis-Presented-at-2023-American-College-of-Gastroenterology-Annual-Meeting.html,Research Analysis and Reports,10/24/2023 8:00,pre_market,5.480000019,5.340000153,420.4599915,422.6499939,-0.025547421,0.005208587,-0.030756008,short,short,
741,853,ECOR,"electroCore to Announce Third Quarter Financial Results on Wednesday, November 8",https://www.globenewswire.com/news-release/2023/10/09/2756628/0/en/electroCore-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-November-8.html,Conference Calls/ Webcasts,10/9/2023 8:00,pre_market,5.590000153,5.5,429.5400085,427.5799866,-0.016100206,-0.004563072,-0.011537134,short,short,
742,854,ECOR,gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD),https://www.globenewswire.com/news-release/2023/09/27/2750322/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Working-Memory-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html,Product / Services Announcement,9/27/2023 8:00,pre_market,5.590000153,5.650000095,425.8800049,427.0899963,0.010733442,0.002841156,0.007892286,long,long,
743,855,ECOR,"Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023",https://www.globenewswire.com/news-release/2023/11/15/2781017/0/en/Dr-Peter-Staats-to-Host-Analyst-Day-on-the-Science-Behind-gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-on-Tuesday-November-21-2023.html,Calendar of Events,11/15/2023 8:15,pre_market,5.781000137,5.650000095,448.730011,450.1099854,-0.022660446,0.003075289,-0.025735735,short,short,
744,856,ECOR,electroCore to Participate in the LD Micro Main Event XVI Conference,https://www.globenewswire.com/news-release/2023/09/25/2748582/0/en/electroCore-to-Participate-in-the-LD-Micro-Main-Event-XVI-Conference.html,Conference Calls/ Webcasts,9/25/2023 8:00,pre_market,5.320000172,5.230000019,430.4200134,429.1700134,-0.016917321,-0.00290414,-0.014013181,short,long,
745,857,ECOR,Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress,https://www.globenewswire.com/news-release/2023/10/10/2757401/0/en/Data-Highlighting-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Acute-Neurological-Injury-Presented-at-2023-World-Stroke-Congress.html,Clinical Study,10/10/2023 8:00,pre_market,5.679999828,5.579999924,432.2900085,432.9400024,-0.017605618,0.001503606,-0.019109224,short,short,
746,858,ECOR,electroCore Provides Select Second Quarter 2023 Financial Guidance,https://www.globenewswire.com/news-release/2023/07/11/2702564/0/en/electroCore-Provides-Select-Second-Quarter-2023-Financial-Guidance.html,Pre-Release Comments,7/11/2023 8:00,pre_market,4.860000134,4.900000095,439.6600037,440.4500122,0.008230445,0.001796862,0.006433582,long,short,
747,859,ECOR,gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms,https://www.globenewswire.com/news-release/2023/07/06/2700272/0/en/gammaCore-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Study-Funded-by-the-National-Football-League-NFL-and-National-Football-League-Players-Association-NFLPA-on-Alleviating-C.html,Product / Services Announcement,7/6/2023 8:00,pre_market,4.644999981,4.630000114,443.1300049,439.4200134,-0.00322925,-0.008372242,0.005142992,long,long,
748,860,ECOR,electroCore Expands Intellectual Patent Portfolio for nVNS Technology,https://www.globenewswire.com/news-release/2023/07/18/2706335/0/en/electroCore-Expands-Intellectual-Patent-Portfolio-for-nVNS-Technology.html,Patents,7/18/2023 8:00,pre_market,4.565000057,4.559999943,450.8399963,450.5,-0.001095315,-0.00075414,-0.000341176,short,short,
749,861,ECOR,electroCore Expands Intellectual Property Portfolio,https://www.globenewswire.com/news-release/2024/02/06/2824242/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html,Patents,2/6/2024 8:00,pre_market,7.199999809,7.125,492.5499878,493.519989,-0.010416641,0.001969346,-0.012385986,short,short,
750,862,ECOR,electroCore Expands Intellectual Property Portfolio,https://www.globenewswire.com/news-release/2024/01/09/2806206/0/en/electroCore-Expands-Intellectual-Property-Portfolio.html,Patents,1/9/2024 8:00,pre_market,5.829999924,5.900000095,474.6000061,471.8699951,0.012006891,-0.005752236,0.017759126,long,short,
751,863,ECOR,electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology,https://www.globenewswire.com/news-release/2023/12/12/2794664/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Nerve-Stimulation-Technology.html,Patents,12/12/2023 8:00,pre_market,5.400000095,5.320000172,461.9899902,461.6300049,-0.0148148,-0.000779206,-0.014035595,short,short,
752,885,ELOX,Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,8/14/2023 8:30,pre_market,4.75,4.989999771,445.6499939,444.7000122,0.050526268,-0.002131677,0.052657944,long,long,
753,886,ELOX,Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome,https://www.globenewswire.com/news-release/2023/06/21/2692434/0/en/Eloxx-Pharmaceuticals-to-Host-Investor-and-Analyst-Call-on-Alport-Syndrome.html,Health,6/21/2023 13:30,market_open,5.03000021,4.429999828,436.1600037,434.9400024,-0.119284365,-0.002797141,-0.116487224,short,long,
754,871,EDIT,Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update,https://www.globenewswire.com/news-release/2023/07/26/2711149/0/en/Editas-Medicine-Announces-Second-Quarter-2023-Results-Conference-Call-and-Corporate-Update.html,Conference Calls/ Webcasts,7/26/2023 7:00,pre_market,8.659999847,8.630000114,455.4400024,454.4700012,-0.003464173,-0.002129811,-0.001334361,short,short,
755,872,EDIT,Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events,https://www.globenewswire.com/news-release/2023/10/27/2768274/0/en/Editas-Medicine-Announces-Third-Quarter-2023-Results-Conference-Call-and-Upcoming-Investor-Events.html,Conference Calls/ Webcasts,10/27/2023 7:00,pre_market,6.510000229,6.630000114,412.5499878,414.1900024,0.018433162,0.003975311,0.01445785,long,long,
756,873,EDIT,"Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer",https://www.globenewswire.com/news-release/2023/07/24/2709396/0/en/Editas-Medicine-Strengthens-Executive-Leadership-Team-with-Appointment-of-Linda-C-Burkly-Ph-D-as-Chief-Scientific-Officer.html,Directors and Officers,7/24/2023 7:00,pre_market,8.93999958,8.779999733,452.1799927,453.3699951,-0.017897076,0.002631701,-0.020528776,short,short,
757,874,EDIT,Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease,https://www.globenewswire.com/news-release/2023/04/27/2656430/0/en/Editas-Medicine-Receives-FDA-Orphan-Drug-Designation-for-EDIT-301-for-the-Treatment-of-Sickle-Cell-Disease.html,Clinical Study,4/27/2023 9:00,pre_market,7.900000095,7.96999979,404.3599854,407,0.008860721,0.006528872,0.002331849,long,long,
758,875,EDIT,Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar,https://www.globenewswire.com/news-release/2023/11/02/2772452/0/en/Editas-Medicine-to-Present-Clinical-Data-from-the-RUBY-and-EdiTHAL-Trials-of-EDIT-301-at-the-ASH-2023-Annual-Meeting-and-in-a-Company-sponsored-Webinar.html,Product / Services Announcement,11/2/2023 9:12,pre_market,6.900000095,6.980000019,422.6600037,426.5799866,0.011594192,0.009274554,0.002319638,long,long,
759,876,EDIT,Editas Medicine Announces Second Quarter 2023 Results and Business Updates,https://www.globenewswire.com/news-release/2023/08/02/2716708/0/en/Editas-Medicine-Announces-Second-Quarter-2023-Results-and-Business-Updates.html,Earnings Releases and Operating Results,8/2/2023 7:00,pre_market,8.649999619,8.5,456.480011,453.25,-0.017340997,-0.007075909,-0.010265088,short,short,
760,877,EDIT,Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease,https://www.globenewswire.com/news-release/2023/10/16/2760573/0/en/Editas-Medicine-Granted-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EDIT-301-for-the-Treatment-of-Severe-Sickle-Cell-Disease.html,Health,10/16/2023 8:00,pre_market,7.050000191,7.03000021,431.5,433.8200073,-0.002836877,0.00537661,-0.008213487,short,short,
761,878,EDIT,Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization,https://www.globenewswire.com/news-release/2023/07/27/2712247/0/en/Editas-Medicine-and-Azzur-Group-Expand-Partnership-to-Accelerate-Editas-Manufacturing-Capabilities-for-Advancing-the-EDIT-301-Program-Through-Approval-to-Commercialization.html,Partnerships,7/27/2023 9:00,pre_market,8.779999733,8.899999619,455.5100098,459.019989,0.013667413,0.007705603,0.005961811,long,long,
762,879,EDIT,Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803160/0/en/Editas-Medicine-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,1/3/2024 7:00,pre_market,9.979999542,9.779999733,472.6499939,470.4299927,-0.020040062,-0.004696924,-0.015343138,short,short,
763,880,EDIT,Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/08/2805430/0/en/Editas-Medicine-Highlights-2024-Anticipated-Milestones-and-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,1/8/2024 8:15,pre_market,9.090000153,9.029999733,467.9200134,468.4299927,-0.006600706,0.001089886,-0.007690592,short,short,
764,881,EDIT,Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9,https://www.globenewswire.com/news-release/2023/12/13/2795602/0/en/Editas-Medicine-and-Vertex-Pharmaceuticals-Enter-into-Non-exclusive-License-Agreement-for-Cas9.html,Licensing Agreements,12/13/2023 9:00,pre_market,9.840000153,10.38000011,464.1000061,464.4899902,0.054878044,0.000840302,0.054037742,long,long,
765,882,EDIT,Editas Medicine to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/01/31/2821218/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html,Conference Calls/ Webcasts,1/31/2024 9:00,pre_market,7.210000038,7.230000019,490.8900146,488.6199951,0.002773922,-0.004624294,0.007398216,long,long,
766,883,EDIT,"Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar",https://www.globenewswire.com/news-release/2023/12/11/2794110/0/en/Editas-Medicine-Announces-New-EDIT-301-Safety-and-Efficacy-Data-in-17-Patients-Presented-Today-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-and-in-a-Company-sponsored-W.html,Clinical Study,12/11/2023 12:00,market_open,10.44999981,9.909999847,459.6900024,461.9899902,-0.051674638,0.005003345,-0.056677984,short,short,
767,887,ELOX,Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study,https://www.globenewswire.com/news-release/2023/05/24/2675190/0/en/Eloxx-Pharmaceuticals-Intends-to-Advance-ELX-02-into-Pivotal-Trial-for-the-Treatment-of-Alport-Syndrome-with-Nonsense-Mutations-Following-Achievement-of-Remission-in-Patient-in-Pha.html,Clinical Study,5/24/2023 8:00,pre_market,8.590000153,8.289999962,414.0899963,412.4200134,-0.034924352,-0.004032899,-0.030891454,short,short,
768,899,ELTX,Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics,https://www.globenewswire.com/news-release/2023/08/28/2732545/0/en/Elicio-Therapeutics-Announces-Appointment-of-Megan-Filoon-as-General-Counsel-and-Dr-Thian-Kheoh-as-Senior-Vice-President-of-Biometrics.html,Directors and Officers,8/28/2023 8:00,pre_market,9.649999619,9.590000153,439.9700012,442.2399902,-0.006217562,0.005159418,-0.011376979,short,long,
769,888,ELOX,Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress,https://www.globenewswire.com/news-release/2023/06/21/2692112/0/en/Eloxx-Pharmaceuticals-Highlights-Recent-Alport-Syndrome-Natural-History-Data-Presented-at-60th-ERA-Congress.html,Clinical Study,6/21/2023 9:00,pre_market,4.960000038,5.03000021,437.1799927,436.1600037,0.014112938,-0.00233311,0.016446048,long,long,
770,889,ELOX,Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,Prospectus/Announcement of Prospectus,9/19/2023 8:00,pre_market,5.460000038,5.449999809,443.6300049,442.6799927,-0.001831544,-0.002141452,0.000309908,long,long,
771,890,ELOX,Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,https://www.globenewswire.com/news-release/2023/09/18/2744637/0/en/Eloxx-Pharmaceuticals-Reports-Independent-Confirmation-of-Positive-Biopsy-Results-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html,Clinical Study,9/18/2023 7:00,pre_market,5.880000114,5.989999771,443.3699951,443.0499878,0.018707424,-0.000721761,0.019429186,long,long,
772,891,ELOX,Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013,https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html,Clinical Study,9/7/2023 9:00,pre_market,5.260000229,5.639999867,446.2200012,443.1099854,0.072243274,-0.006969692,0.079212966,long,short,
773,892,ELOX,Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html,Clinical Study,8/14/2023 8:00,pre_market,4.75,4.989999771,445.6499939,444.7000122,0.050526268,-0.002131677,0.052657944,long,long,
774,893,ELOX,Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,https://www.globenewswire.com/news-release/2023/06/06/2682826/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html,Exchange Members,6/6/2023 8:30,pre_market,6.699999809,6.860000134,427.1000061,426.6700134,0.023880646,-0.001006773,0.024887419,long,long,
775,894,ELOX,Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit,https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html,Product / Services Announcement,7/10/2023 9:00,pre_market,3.619999886,3.660000086,438.5499878,438.1799927,0.011049779,-0.000843678,0.011893458,long,long,
776,895,ELOX,Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria,https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html,Health,10/9/2023 8:00,pre_market,4.320000172,4.300000191,429.5400085,427.5799866,-0.004629625,-0.004563072,-6.66E-05,short,short,
777,896,ELOX,Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02,https://www.globenewswire.com/news-release/2023/06/28/2696256/0/en/Eloxx-Pharmaceuticals-Key-Opinion-Leader-Event-Highlights-Significant-Unmet-Need-in-Treatment-of-Alport-Syndrome-Patients-with-Nonsense-Mutations-and-Additional-Positive-Results-fr.html,Clinical Study,6/28/2023 9:00,pre_market,4.059999943,4.019999981,436.1700134,435.0499878,-0.009852208,-0.002567865,-0.007284343,short,short,
778,897,ELOX,Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/04/03/2639530/0/en/Eloxx-Pharmaceuticals-Reports-Fourth-Quarter-2022-Financial-and-Operating-Results-and-Provides-Business-Update.html,Earnings Releases and Operating Results,4/3/2023 8:00,pre_market,2.509999991,2.509999991,409.3900146,408.8500061,0,-0.001319057,0.001319057,long,long,
779,914,ENTX,Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform,https://www.globenewswire.com/news-release/2023/11/29/2787754/0/en/Interim-Results-from-Ongoing-Clinical-Study-Confirm-EB613-Optimized-Profile-for-Osteoporosis-Treatment-and-Potential-for-Entera-s-Next-Generation-Oral-Peptide-Platform.html,Health,11/29/2023 8:30,pre_market,0.702000022,0.720000029,454.9299927,457.1499939,0.025641034,0.004879874,0.02076116,long,long,
780,915,ENTX,Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting,https://www.globenewswire.com/news-release/2023/10/16/2760611/0/en/Entera-Bio-Reports-Rapid-Pharmacodynamic-PD-Response-and-Consistent-Pharmacokinetic-PK-Data-for-its-First-in-Class-Oral-PTH-1-34-Mini-Tablets-at-the-ASBMR-2023-Annual-Meeting.html,Health,10/16/2023 8:00,pre_market,0.730000019,0.749000013,431.5,433.8200073,0.026027388,0.00537661,0.020650778,long,long,
781,916,ENTX,Entera Bio to Participate in the SVB Securities Global Biopharma Conference,https://www.globenewswire.com/news-release/2023/02/13/2606702/0/en/Entera-Bio-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html,Calendar of Events,2/13/2023 9:00,pre_market,0.910000026,0.889999986,408.0400085,408.7200012,-0.021978066,0.001666485,-0.023644551,short,short,
782,917,ENTX,"Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET",https://www.globenewswire.com/news-release/2022/09/21/2520186/0/en/Entera-Bio-Hosting-Key-Opinion-Leader-Webinar-on-the-Treatment-Landscape-for-Osteoporosis-and-EB613-s-Potential-Impact-on-Wednesday-September-28th-10am-ET.html,Calendar of Events,9/21/2022 8:30,pre_market,1.210000038,1.210000038,384.0899963,386.1099854,0,0.005259156,-0.005259156,short,long,
783,918,ENTX,"Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development",https://www.globenewswire.com/news-release/2023/11/14/2779971/0/en/Entera-Bio-Reports-Q3-2023-Financial-Results-Highlights-Transformational-Steps-and-Unveils-Vision-as-Premier-Oral-Peptide-Company-with-Five-Potential-Programs-in-Development.html,Earnings Releases and Operating Results,11/14/2023 7:30,pre_market,0.699999988,0.699999988,440.1900024,446.3200073,0,0.013925816,-0.013925816,short,long,
784,919,ENTX,"Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors",https://www.globenewswire.com/news-release/2023/06/07/2683653/0/en/Entera-Bio-Adds-Sanofi-Commercial-Leader-Haya-Taitel-to-its-Board-of-Directors.html,Directors and Officers,6/7/2023 7:30,pre_market,0.809000015,0.829999983,428.0299988,428.4400024,0.025957933,0.000957885,0.025000048,long,long,
785,904,ELTX,Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines,https://www.globenewswire.com/news-release/2023/09/07/2739266/0/en/Elicio-Therapeutics-Receives-2-6-Million-Grant-from-the-Gastro-Intestinal-GI-Research-Foundation-to-Fund-Research-for-Two-Therapeutic-Cancer-Vaccines.html,Product / Services Announcement,9/7/2023 8:00,pre_market,8.479999542,8.729999542,446.2200012,443.1099854,0.029481134,-0.006969692,0.036450825,long,long,
786,905,ELTX,Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference,https://www.globenewswire.com/news-release/2023/12/04/2789966/0/en/Elicio-Therapeutics-to-Present-at-the-H-C-Wainwright-4th-Annual-Precision-Oncology-Virtual-Conference.html,Conference Calls/ Webcasts,12/4/2023 8:00,pre_market,5.889999867,6.110000134,459.1000061,455.6000061,0.037351489,-0.007623611,0.044975101,long,long,
787,906,ELTX,Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002,https://www.globenewswire.com/news-release/2024/01/09/2806073/0/en/Nature-Medicine-Publishes-Updated-Preliminary-Phase-1-Data-From-Elicio-Therapeutic-s-AMPLIFY-201-Phase-1-Solid-Tumor-Study-of-ELI-002.html,Health,1/9/2024 6:00,pre_market,7.820000172,8.119999886,474.6000061,471.8699951,0.038363134,-0.005752236,0.044115369,long,long,
788,907,ELTX,Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/02/05/2823522/0/en/Elicio-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,Calendar of Events,2/5/2024 8:30,pre_market,4.400000095,4.5,494.3500061,493.7000122,0.022727251,-0.001314846,0.024042096,long,long,
789,908,ELTX,Elicio Therapeutics Announces $7.0 Million Private Placement Financing,https://www.globenewswire.com/news-release/2023/12/22/2800613/0/en/Elicio-Therapeutics-Announces-7-0-Million-Private-Placement-Financing.html,Financing Agreements,12/22/2023 9:00,pre_market,5.800000191,5.75,472.7000122,473.8599854,-0.008620722,0.002453931,-0.011074653,short,short,
790,909,ELTX,Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study,https://www.globenewswire.com/news-release/2024/01/11/2807912/0/en/Elicio-Therapeutics-Announces-First-Patient-Dosed-in-Randomized-Phase-2-Pancreatic-Cancer-Study.html,Health,1/11/2024 8:30,pre_market,5.539999962,5.449999809,476.5599976,477.5899963,-0.016245515,0.00216132,-0.018406835,short,short,
791,910,ELTX,Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium,https://www.globenewswire.com/news-release/2024/01/17/2810706/0/en/Elicio-Therapeutics-to-Present-ELI-002-7P-AMPLIFY-7P-Trial-in-Progress-Poster-on-Phase-1-2-Study-of-Lymph-Node-Targeted-Vaccine-at-ASCO-GI-Symposium.html,Calendar of Events,1/17/2024 8:30,pre_market,5.28000021,5.380000114,474.9299927,471.8200073,0.018939375,-0.006548303,0.025487678,long,long,
792,929,ETNB,89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH),https://www.globenewswire.com/news-release/2023/09/21/2747202/0/en/89bio-Announces-U-S-FDA-has-Granted-Breakthrough-Therapy-Designation-for-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH.html,Company Announcement,9/21/2023 8:00,pre_market,15.06499958,15.15999985,438.6400146,435.7000122,0.006306025,-0.006702541,0.013008566,long,long,
793,930,ETNB,89bio to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/05/02/2659103/0/en/89bio-to-Participate-in-Upcoming-Investor-Conferences.html,Trade Show,5/2/2023 8:00,pre_market,16.62999916,16.63999939,415.5100098,414.769989,0.000601337,-0.001780994,0.002382331,long,long,
794,931,ETNB,89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG),https://www.globenewswire.com/news-release/2023/05/23/2674259/0/en/89bio-Initiates-Phase-3-ENTRUST-Trial-of-Pegozafermin-in-Patients-with-Severe-Hypertriglyceridemia-SHTG.html,Clinical Study,5/23/2023 8:00,pre_market,17.31999969,17.45000076,418.7900085,417.0799866,0.007505836,-0.004083244,0.01158908,long,long,
795,932,ETNB,89bio to Participate in the 2023 Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/20/2746391/0/en/89bio-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html,Conference Calls/ Webcasts,9/20/2023 8:00,pre_market,16.70999908,16.73999977,442.7099915,444.0100098,0.001795373,0.002936501,-0.001141128,short,short,
796,933,ETNB,89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/10/2624905/0/en/89bio-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,3/10/2023 8:00,pre_market,12.76000023,12.93000031,391.5599976,390.9899902,0.01332289,-0.001455734,0.014778624,long,long,
797,920,ENTX,Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis,https://www.globenewswire.com/news-release/2022/10/06/2529359/0/en/Entera-Bio-Announces-FDA-Agreement-for-a-Single-Phase-3-Clinical-Trial-to-Support-an-NDA-for-EB613-for-the-Treatment-of-Osteoporosis.html,Clinical Study,10/6/2022 7:00,pre_market,1.049999952,1.129999995,377.0899963,375.6199951,0.076190521,-0.003898277,0.080088797,long,long,
798,934,ETNB,89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks,https://www.globenewswire.com/news-release/2023/03/22/2632062/0/en/89bio-s-Phase-2b-ENLIVEN-Trial-of-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH-Achieved-High-Statistical-Significance-on-Both-Primary-Histology-Endpoints-with-Weekly-QW-and-Ev.html,Health,3/22/2023 7:00,pre_market,10.93000031,14.69999981,398.9100037,398.730011,0.344922177,-0.000451211,0.345373389,long,long,
799,921,ENTX,Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program,https://www.globenewswire.com/news-release/2023/04/03/2639415/0/en/Entera-Bio-Provides-Guidance-from-FDA-Type-D-Meeting-Related-to-EB613-Pivotal-Program.html,Health,4/3/2023 7:00,pre_market,1.159999967,1.200000048,409.3900146,408.8500061,0.03448283,-0.001319057,0.035801886,long,long,
800,935,ETNB,89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH),https://www.globenewswire.com/news-release/2023/11/27/2786131/0/en/89bio-Announces-New-Positive-Long-Term-Data-from-the-ENLIVEN-Phase-2b-Trial-of-Pegozafermin-in-Patients-with-Nonalcoholic-Steatohepatitis-NASH.html,Clinical Study,11/27/2023 8:00,pre_market,7.920000076,7.78000021,455.2999878,454.6499939,-0.017676751,-0.001427617,-0.016249134,short,long,
801,922,ENTX,Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis,https://www.globenewswire.com/news-release/2023/11/09/2777730/0/en/Entera-Bio-Reports-Key-Milestone-Relating-to-Oral-PTH-1-34-Peptide-EB613-Phase-3-Program-ASBMR-SABRE-Has-Submitted-to-FDA-the-Full-Qualification-Plan-to-Approve-BMD-as-a-Surrogate-.html,Clinical Study,11/9/2023 14:30,market_open,0.660000026,0.730000019,438.4299927,433.8399963,0.106060591,-0.010469166,0.116529757,long,long,
802,923,ENTX,Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes,https://www.globenewswire.com/news-release/2023/09/12/2741673/0/en/Entera-Bio-Announces-Collaboration-with-OPKO-Biologics-to-Develop-Oral-Peptide-Tablet-Formulations-for-Obesity-and-Intestinal-Malabsorption-Syndromes.html,Partnerships,9/12/2023 8:30,pre_market,0.66900003,0.699999988,448.4500122,446.9500122,0.046337754,-0.003344854,0.049682608,long,long,
803,925,ENTX,"Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics",https://www.globenewswire.com/news-release/2023/05/03/2660482/0/en/Entera-s-Oral-Delivery-of-GLP-2-Pre-Clinical-Data-to-be-Published-in-Peer-Reviewed-International-Journal-of-Peptide-Research-and-Therapeutics.html,Clinical Study,5/3/2023 9:34,market_open,0.850000024,0.879999995,411.3599854,408.019989,0.035294083,-0.0081194,0.043413483,long,long,
804,926,ENTX,Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,https://www.globenewswire.com/news-release/2024/01/30/2820007/0/en/Entera-Bio-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html,Calendar of Events,1/30/2024 8:30,pre_market,0.887000024,0.879999995,491.269989,490.5599976,-0.007891803,-0.001445216,-0.006446586,short,short,
805,927,ENTX,Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule,https://www.globenewswire.com/news-release/2024/01/03/2803257/0/en/Entera-Bio-Receives-Extension-from-Nasdaq-to-Regain-Compliance-with-Minimum-Bid-Price-Rule.html,Management statements,1/3/2024 8:00,pre_market,0.654999971,0.660000026,472.6499939,470.4299927,0.007633672,-0.004696924,0.012330596,long,long,
806,943,EVAX,Evaxion präsentiert neueste klinische Daten der Phase II von EVX-01 in einem Webinar mit dem Key Opinion Leader Adnan Khattak,https://www.globenewswire.com/news-release/2023/11/07/2775301/0/de/Evaxion-pr%C3%A4sentiert-neueste-klinische-Daten-der-Phase-II-von-EVX-01-in-einem-Webinar-mit-dem-Key-Opinion-Leader-Adnan-Khattak.html,Calendar of Events,11/7/2023 10:15,market_open,12,11.69999981,435.6900024,436.9299927,-0.025000016,0.002846038,-0.027846054,short,short,
807,944,EVAX,Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01,https://www.globenewswire.com/news-release/2023/10/31/2770437/0/en/Evaxion-Announces-Encouraging-Initial-Phase-2-Clinical-Data-on-Its-Personalized-Cancer-Vaccine-EVX-01.html,Clinical Study,10/31/2023 11:15,market_open,9.800000191,11.19999981,416.1799927,418.2000122,0.142857101,0.004853716,0.138003385,long,short,
808,945,EVAX,Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company,https://www.globenewswire.com/news-release/2023/09/18/2744760/0/en/Evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company.html,Partnerships,9/18/2023 8:23,pre_market,7.519999981,7.300000191,443.3699951,443.0499878,-0.029255291,-0.000721761,-0.02853353,short,short,
809,946,EVAX,"Révolutionner la découverte de vaccins : De nouvelles données valident la plateforme d'intelligence artificielle d'Evaxion, promettant de réduire les risques et les coûts dans le développement de vaccins contre les maladies infectieuses",https://www.globenewswire.com/news-release/2023/09/12/2741564/0/fr/R%C3%A9volutionner-la-d%C3%A9couverte-de-vaccins-De-nouvelles-donn%C3%A9es-valident-la-plateforme-d-intelligence-artificielle-d-Evaxion-promettant-de-r%C3%A9duire-les-risques-et-les-co%C3%BBts-dans-le-d%C3%A9ve.html,Research Analysis and Reports,9/12/2023 7:59,pre_market,7.809999943,8,448.4500122,446.9500122,0.024327792,-0.003344854,0.027672647,long,long,
810,947,EVAX,Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,https://www.globenewswire.com/news-release/2023/10/05/2755383/0/en/Evaxion-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html,Major shareholder announcements,10/5/2023 8:30,pre_market,8.800000191,8.5,424.6600037,424.3599854,-0.03409093,-0.000706491,-0.033384439,short,short,
811,948,EVAX,Evaxion präsentiert Proof-of-Principle für sein einzigartiges KI-Modell zur Vorhersage des Ansprechens auf Krebsimmuntherapie,https://www.globenewswire.com/news-release/2023/11/16/2781872/0/de/Evaxion-pr%C3%A4sentiert-Proof-of-Principle-f%C3%BCr-sein-einzigartiges-KI-Modell-zur-Vorhersage-des-Ansprechens-auf-Krebsimmuntherapie.html,Health,11/16/2023 8:52,pre_market,7.449999809,7.230000019,449.6799927,449.2200012,-0.029530174,-0.001022931,-0.028507243,short,short,
812,949,EVAX,Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy,https://www.globenewswire.com/news-release/2023/11/15/2780971/0/en/Evaxion-Presents-Proof-of-Principle-for-Its-Unique-AI-Model-Predicting-Responses-to-Cancer-Immunotherapy.html,Health,11/15/2023 8:00,pre_market,7.139999867,7.5,448.730011,450.1099854,0.050420188,0.003075289,0.047344899,long,long,
813,950,EVAX,"Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development",https://www.globenewswire.com/news-release/2023/09/11/2740790/0/en/Revolutionizing-Vaccine-Discovery-New-Data-Validates-Evaxion-AI-Platform-Offering-Promise-to-Reduce-Risk-and-Cost-in-Infectious-Disease-Vaccine-Development.html,Research Analysis and Reports,9/11/2023 8:17,pre_market,6.820000172,7,445.519989,448.2399902,0.026392936,0.006105228,0.020287708,long,long,
814,1820,ORPHA.CO,Storaktionærmeddelelse,https://www.globenewswire.com/news-release/2023/12/08/2793179/0/da/Storaktion%C3%A6rmeddelelse.html,European Regulatory News,12/8/2023 8:12,pre_market,676.7999878,676,458.230011,457.4599915,-0.001182015,-0.001680421,0.000498406,long,long,
815,936,ETNB,"89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock",https://www.globenewswire.com/news-release/2023/03/24/2633885/0/en/89bio-Inc-Announces-Upsized-Pricing-of-275-Million-Public-Offering-of-Common-Stock.html,Stock Market News,3/24/2023 7:00,pre_market,16.94000053,17.29999924,393.1700134,391.8399963,0.021251399,-0.003382804,0.024634203,long,long,
816,937,ETNB,89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024,https://www.globenewswire.com/news-release/2023/12/04/2789876/0/en/89bio-Reaches-Alignment-with-the-FDA-and-EMA-on-Phase-3-Program-for-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH-Program-Initiation-Planned-in-the-First-Half-of-2024.html,Clinical Study,12/4/2023 7:00,pre_market,8.399999619,8.930000305,459.1000061,455.6000061,0.063095323,-0.007623611,0.070718934,long,long,
817,938,ETNB,89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference,https://www.globenewswire.com/news-release/2023/10/17/2761468/0/en/89bio-to-Participate-in-the-H-C-Wainwright-7%E1%B5%97%CA%B0-Annual-NASH-Investor-Conference.html,Conference Calls/ Webcasts,10/17/2023 8:00,pre_market,7.239999771,7.159999847,436.0400085,432.8099976,-0.011049714,-0.007407602,-0.003642111,short,short,
818,939,ETNB,89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares,https://www.globenewswire.com/news-release/2023/12/12/2794645/0/en/89bio-Announces-Closing-of-its-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,Major shareholder announcements,12/12/2023 7:30,pre_market,9.609999657,9.460000038,461.9899902,461.6300049,-0.015608702,-0.000779206,-0.014829496,short,short,
819,940,ETNB,"89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants",https://www.globenewswire.com/news-release/2023/12/07/2792370/0/en/89bio-Inc-Announces-Upsized-Pricing-of-150-0-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html,Warrants and Certificates,12/7/2023 7:00,pre_market,9.93999958,9.630000114,454.7600098,456.9100037,-0.03118707,0.004727755,-0.035914825,short,short,
820,952,EVAX,Evaxion announces Executive Management Changes to strengthen the AI-strategy,https://www.globenewswire.com/news-release/2023/08/29/2733405/0/en/Evaxion-announces-Executive-Management-Changes-to-strengthen-the-AI-strategy.html,Management Changes,8/29/2023 8:30,pre_market,8.800000191,9,442.7600098,442.6499939,0.022727251,-0.000248477,0.022975728,long,short,
821,953,EVAX,Evaxion présente les dernières données cliniques de la phase II d’EVX-01 à l’occasion d’un webinaire organisé en présence du leader d’opinion Adnan Khattak,https://www.globenewswire.com/news-release/2023/11/07/2775301/0/fr/Evaxion-pr%C3%A9sente-les-derni%C3%A8res-donn%C3%A9es-cliniques-de-la-phase-II-d-EVX-01-%C3%A0-l-occasion-d-un-webinaire-organis%C3%A9-en-pr%C3%A9sence-du-leader-d-opinion-Adnan-Khattak.html,Calendar of Events,11/7/2023 10:15,market_open,12,11.69999981,435.6900024,436.9299927,-0.025000016,0.002846038,-0.027846054,short,short,
822,955,EVAX,De nouvelles données cliniques passionnantes sur les vaccins anticancéreux individualisés d'Evaxion et basés sur l'AI-Immunology™ seront bientôt présentées,https://www.globenewswire.com/news-release/2023/10/27/2768411/0/fr/De-nouvelles-donn%C3%A9es-cliniques-passionnantes-sur-les-vaccins-anticanc%C3%A9reux-individualis%C3%A9s-d-Evaxion-et-bas%C3%A9s-sur-l-AI-Immunology-seront-bient%C3%B4t-pr%C3%A9sent%C3%A9es.html,Calendar of Events,10/27/2023 8:48,pre_market,8.199999809,8.300000191,412.5499878,414.1900024,0.012195169,0.003975311,0.008219857,long,long,
823,956,EVAX,Evaxion va lever le voile sur un concept potentiellement révolutionnaire de vaccin précis contre le cancer alimenté par sa plateforme IA-Immunology™,https://www.globenewswire.com/news-release/2023/11/29/2787781/0/fr/Evaxion-va-lever-le-voile-sur-un-concept-potentiellement-r%C3%A9volutionnaire-de-vaccin-pr%C3%A9cis-contre-le-cancer-aliment%C3%A9-par-sa-plateforme-IA-Immunology.html,Product / Services Announcement,11/29/2023 8:55,pre_market,7.920000076,7.679999828,454.9299927,457.1499939,-0.030303061,0.004879874,-0.035182936,short,short,
824,957,EVAX,Evaxion stellt potenziell bahnbrechendes Konzept für AI-Immunology™-gestützen Präzisions-Krebsimpfstoff vor,https://www.globenewswire.com/news-release/2023/11/29/2787781/0/de/Evaxion-stellt-potenziell-bahnbrechendes-Konzept-f%C3%BCr-AI-Immunology-gest%C3%BCtzen-Pr%C3%A4zisions-Krebsimpfstoff-vor.html,Product / Services Announcement,11/29/2023 8:55,pre_market,7.920000076,7.679999828,454.9299927,457.1499939,-0.030303061,0.004879874,-0.035182936,short,short,
825,958,EVAX,Evaxion geht Partnerschaft mit dem Pharmaunternehmen Afrigen Biologics zur Entwicklung eines neuartigen mRNA-Impfstoffs gegen Gonorrhoe ein,https://www.globenewswire.com/news-release/2023/09/20/2755536/0/de/Evaxion-geht-Partnerschaft-mit-dem-Pharmaunternehmen-Afrigen-Biologics-zur-Entwicklung-eines-neuartigen-mRNA-Impfstoffs-gegen-Gonorrhoe-ein.html,Partnerships,9/20/2023 8:26,pre_market,4.800000191,5.53000021,442.7099915,444.0100098,0.152083331,0.002936501,0.14914683,long,long,
826,960,EVAX,Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak,https://www.globenewswire.com/news-release/2023/11/06/2774255/0/en/Evaxion-Shares-Latest-EVX-01-Phase-2-Clinical-Data-in-Webinar-with-Key-Opinion-Leader-Adnan-Khattak.html,Calendar of Events,11/6/2023 10:12,market_open,12,11.10000038,435.4700012,435.6900024,-0.074999968,0.000505204,-0.075505172,short,short,
827,961,EVAX,Revolution in der Entdeckung von Impfstoffen: Neue Daten validieren die KI-Plattform von Evaxion und versprechen Senkung der Risiken und Kosten bei der Entwicklung von Impfstoffen gegen Infektionskrankheiten,https://www.globenewswire.com/news-release/2023/09/12/2741564/0/de/Revolution-in-der-Entdeckung-von-Impfstoffen-Neue-Daten-validieren-die-KI-Plattform-von-Evaxion-und-versprechen-Senkung-der-Risiken-und-Kosten-bei-der-Entwicklung-von-Impfstoffen-g.html,Research Analysis and Reports,9/12/2023 7:59,pre_market,7.809999943,8,448.4500122,446.9500122,0.024327792,-0.003344854,0.027672647,long,long,
828,962,EVAX,Evaxion gibt ermutigende erste klinische Daten der Phase II zu seinem personalisierten Krebsimpfstoff EVX-01 bekannt,https://www.globenewswire.com/news-release/2023/11/01/2771615/0/de/Evaxion-gibt-ermutigende-erste-klinische-Daten-der-Phase-II-zu-seinem-personalisierten-Krebsimpfstoff-EVX-01-bekannt.html,Clinical Study,11/1/2023 13:45,market_open,11.89999962,10.80000019,419.2000122,422.6600037,-0.09243693,0.008253796,-0.100690726,short,short,
829,963,EVAX,"Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus",https://www.globenewswire.com/news-release/2023/07/31/2714741/0/en/Evaxion-presents-promising-results-on-EVX-B1-an-AI-designed-vaccine-against-Staphylococcus-aureus.html,Clinical Study,7/31/2023 7:00,pre_market,12.69999981,12.39999962,456.9200134,457.4100037,-0.023622063,0.001072376,-0.024694439,short,short,
830,964,EVAX,Evaxion s'associe à la société pharmaceutique Afrigen Biologics pour développer un nouveau vaccin à ARN messager contre la gonorrhée,https://www.globenewswire.com/news-release/2023/09/20/2755536/0/fr/Evaxion-s-associe-%C3%A0-la-soci%C3%A9t%C3%A9-pharmaceutique-Afrigen-Biologics-pour-d%C3%A9velopper-un-nouveau-vaccin-%C3%A0-ARN-messager-contre-la-gonorrh%C3%A9e.html,Partnerships,9/20/2023 8:26,pre_market,4.800000191,5.53000021,442.7099915,444.0100098,0.152083331,0.002936501,0.14914683,long,long,
831,965,EVAX,Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea,https://www.globenewswire.com/news-release/2023/09/20/2746452/0/en/Evaxion-Partners-With-Pharmaceutical-Company-Afrigen-Biologics-to-Develop-Novel-mRNA-Vaccine-Against-Gonorrhea.html,Partnerships,9/20/2023 8:26,pre_market,4.800000191,5.53000021,442.7099915,444.0100098,0.152083331,0.002936501,0.14914683,long,long,
832,966,EVAX,Neue und aufregende klinische Daten zu AI-Immunology™-basierten personalisierten Krebsimpfstoffen von Evaxion werden präsentiert,https://www.globenewswire.com/news-release/2023/10/27/2768411/0/de/Neue-und-aufregende-klinische-Daten-zu-AI-Immunology-basierten-personalisierten-Krebsimpfstoffen-von-Evaxion-werden-pr%C3%A4sentiert.html,Calendar of Events,10/27/2023 8:48,pre_market,8.199999809,8.300000191,412.5499878,414.1900024,0.012195169,0.003975311,0.008219857,long,long,
833,968,EVAX,Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets,https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html,Product / Services Announcement,1/24/2024 8:30,pre_market,4.989999771,9.329999924,484.8599854,487.8099976,0.869739549,0.006084256,0.863655294,long,short,
834,969,EVAX,Evaxion répond de nouveau aux exigences du Nasdaq en matière de prix minimum de l'offre,https://www.globenewswire.com/news-release/2024/02/08/2825836/0/fr/Evaxion-r%C3%A9pond-de-nouveau-aux-exigences-du-Nasdaq-en-mati%C3%A8re-de-prix-minimum-de-l-offre.html,Financing Agreements,2/8/2024 6:20,pre_market,4.28000021,4.289999962,498.1000061,498.1000061,0.002336391,0,0.002336391,long,short,
835,970,EVAX,Evaxion Biotech gibt Preisfestsetzung für Emission in Höhe von 15 Mio. USD bekannt,https://www.globenewswire.com/news-release/2024/02/02/2822861/0/de/Evaxion-Biotech-gibt-Preisfestsetzung-f%C3%BCr-Emission-in-H%C3%B6he-von-15-Mio-USD-bekannt.html,Initial Public Offerings,2/2/2024 8:57,pre_market,4.599999905,4.599999905,489.2000122,489.6499939,0,0.000919832,-0.000919832,short,short,
836,971,EVAX,Evaxion kündigt Plan zur Änderung des ADS-Verhältnisses an,https://www.globenewswire.com/news-release/2024/01/09/2806034/0/de/Evaxion-k%C3%BCndigt-Plan-zur-%C3%84nderung-des-ADS-Verh%C3%A4ltnisses-an.html,Changes in company's own shares,1/9/2024 4:43,pre_market,7.670000076,6.840000153,474.6000061,471.8699951,-0.108213809,-0.005752236,-0.102461574,short,short,
837,972,EVAX,Evaxion Announces Plan to Implement ADS Ratio Change,https://www.globenewswire.com/news-release/2024/01/08/2805439/0/en/Evaxion-Announces-Plan-to-Implement-ADS-Ratio-Change.html,Changes in company's own shares,1/8/2024 8:30,pre_market,7.590000153,8,467.9200134,468.4299927,0.054018424,0.001089886,0.052928539,long,long,
838,973,EVAX,Evaxion présente la preuve de concept de son modèle unique d’IA prédisant les réponses à l’immunothérapie du cancer,https://www.globenewswire.com/news-release/2023/11/16/2781872/0/fr/Evaxion-pr%C3%A9sente-la-preuve-de-concept-de-son-mod%C3%A8le-unique-d-IA-pr%C3%A9disant-les-r%C3%A9ponses-%C3%A0-l-immunoth%C3%A9rapie-du-cancer.html,Health,11/16/2023 8:52,pre_market,7.449999809,7.230000019,449.6799927,449.2200012,-0.029530174,-0.001022931,-0.028507243,short,short,
839,974,EVAX,Evaxion Biotech gibt Abschluss einer Privatplatzierung bekannt,https://www.globenewswire.com/news-release/2023/12/22/2800800/0/de/Evaxion-Biotech-gibt-Abschluss-einer-Privatplatzierung-bekannt.html,Health,12/22/2023 15:13,market_open,6.869999886,7.099999905,473.8599854,473.6499939,0.033478897,-0.000443151,0.033922048,long,long,
840,975,EVAX,Evaxion gibt den Abschluss seiner Emission in Höhe von 15 Mio. USD bekannt,https://www.globenewswire.com/news-release/2024/02/07/2825018/0/de/Evaxion-gibt-den-Abschluss-seiner-Emission-in-H%C3%B6he-von-15-Mio-USD-bekannt.html,Initial Public Offerings,2/7/2024 6:13,pre_market,4.5,4.5,493.980011,496.2900085,0,0.004676298,-0.004676298,short,short,
841,976,EVAX,"Evaxion entwickelt maßgeschneiderte neuartige Krebsimpfstoffe auf der Grundlage einer neuen, bisher ungenutzten Quelle von durch KI entdeckten Targets",https://www.globenewswire.com/news-release/2024/01/25/2816750/0/de/Evaxion-entwickelt-ma%C3%9Fgeschneiderte-neuartige-Krebsimpfstoffe-auf-der-Grundlage-einer-neuen-bisher-ungenutzten-Quelle-von-durch-KI-entdeckten-Targets.html,Product / Services Announcement,1/25/2024 8:22,pre_market,10.64999962,10.64999962,485.3900146,487.5799866,0,0.004511778,-0.004511778,short,long,
842,977,EVAX,Evaxion erfüllt wieder die Anforderungen der Nasdaq an den Mindestangebotspreis,https://www.globenewswire.com/news-release/2024/02/08/2825836/0/de/Evaxion-erf%C3%BCllt-wieder-die-Anforderungen-der-Nasdaq-an-den-Mindestangebotspreis.html,Financing Agreements,2/8/2024 6:20,pre_market,4.28000021,4.289999962,498.1000061,498.1000061,0.002336391,0,0.002336391,long,short,
843,978,EVAX,Clôture du financement par placement privé pour Evaxion Biotech,https://www.globenewswire.com/news-release/2023/12/22/2800800/0/fr/Cl%C3%B4ture-du-financement-par-placement-priv%C3%A9-pour-Evaxion-Biotech.html,Health,12/22/2023 15:13,market_open,6.869999886,7.099999905,473.8599854,473.6499939,0.033478897,-0.000443151,0.033922048,long,long,
844,979,EVAX,Evaxion Biotech Announces Pricing of $15 Million Public Offering,https://www.globenewswire.com/news-release/2024/02/01/2822093/0/en/Evaxion-Biotech-Announces-Pricing-of-15-Million-Public-Offering.html,Initial Public Offerings,2/1/2024 9:20,pre_market,3.930000067,4.010000229,482.8800049,484.6300049,0.020356275,0.003624089,0.016732186,long,long,
845,980,EVAX,Evaxion annonce la clôture de son offre publique à 15 millions de dollars,https://www.globenewswire.com/news-release/2024/02/07/2825018/0/fr/Evaxion-annonce-la-cl%C3%B4ture-de-son-offre-publique-%C3%A0-15-millions-de-dollars.html,Initial Public Offerings,2/7/2024 6:13,pre_market,4.5,4.5,493.980011,496.2900085,0,0.004676298,-0.004676298,short,short,
846,981,EVAX,Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement,https://www.globenewswire.com/news-release/2024/02/07/2825208/0/en/Evaxion-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html,Financing Agreements,2/7/2024 8:30,pre_market,4.5,4.5,493.980011,496.2900085,0,0.004676298,-0.004676298,short,short,
847,982,EVAX,Evaxion Announces Closing of $15 Million Public Offering,https://www.globenewswire.com/news-release/2024/02/06/2824339/0/en/Evaxion-Announces-Closing-of-15-Million-Public-Offering.html,Initial Public Offerings,2/6/2024 8:30,pre_market,4.25,4.429999828,492.5499878,493.519989,0.042352901,0.001969346,0.040383555,long,long,
848,983,EVAX,Evaxion annonce un plan visant à mettre en œuvre la modification du ratio de ses ADS,https://www.globenewswire.com/news-release/2024/01/09/2806034/0/fr/Evaxion-annonce-un-plan-visant-%C3%A0-mettre-en-%C5%93uvre-la-modification-du-ratio-de-ses-ADS.html,Changes in company's own shares,1/9/2024 4:43,pre_market,7.670000076,6.840000153,474.6000061,471.8699951,-0.108213809,-0.005752236,-0.102461574,short,short,
849,984,EVAX,Evaxion announces financing commitments totaling up to USD 20 million with Negma Group,https://www.globenewswire.com/news-release/2023/08/01/2715621/0/en/Evaxion-announces-financing-commitments-totaling-up-to-USD-20-million-with-Negma-Group.html,Financing Agreements,8/1/2023 7:00,pre_market,12.39999962,12.30000019,457.7900085,456.269989,-0.00806447,-0.003320342,-0.004744128,short,short,
850,985,EVAX,Evaxion Biotech fixe le prix de son offre publique à 15 millions de dollars,https://www.globenewswire.com/news-release/2024/02/02/2822861/0/fr/Evaxion-Biotech-fixe-le-prix-de-son-offre-publique-%C3%A0-15-millions-de-dollars.html,Initial Public Offerings,2/2/2024 8:57,pre_market,4.599999905,4.599999905,489.2000122,489.6499939,0,0.000919832,-0.000919832,short,short,
851,1003,EYEN,"Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10",https://www.globenewswire.com/news-release/2023/08/07/2719644/0/en/Eyenovia-to-Report-Second-Quarter-2023-Results-on-Thursday-August-10.html,Calendar of Events,8/7/2023 8:00,pre_market,2.150000095,2.180000067,446.8099976,448.7099915,0.013953474,0.004252353,0.009701121,long,long,0
852,987,EVLO,Evelo Biosciences Provides Clinical and Business Updates,https://www.globenewswire.com/news-release/2023/02/01/2599332/0/en/Evelo-Biosciences-Provides-Clinical-and-Business-Updates.html,Annual report,2/1/2023 7:30,pre_market,20.79999924,15.92000008,406.480011,405.2099915,-0.234615353,-0.003124433,-0.23149092,short,long,
853,988,EVLO,Evelo Biosciences Announces Reverse Stock Split Effective,https://www.globenewswire.com/news-release/2023/06/29/2697068/0/en/Evelo-Biosciences-Announces-Reverse-Stock-Split-Effective.html,Changes in company's own shares,6/29/2023 9:00,pre_market,5.099999905,3.819999933,436.3900146,435.9599915,-0.250980391,-0.00098541,-0.249994981,short,long,
854,989,EVLO,Evelo Biosciences Provides Clinical Updates,https://www.globenewswire.com/news-release/2023/04/26/2654930/0/en/Evelo-Biosciences-Provides-Clinical-Updates.html,Health,4/26/2023 7:30,pre_market,2.980000019,2.700000048,406.0799866,406.7200012,-0.093959721,0.00157608,-0.095535802,short,long,
855,1004,EYEN,Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®,https://www.globenewswire.com/news-release/2023/10/09/2756566/0/en/Eyenovia-to-Present-Data-on-Preservative-Free-Microbial-Integrity-of-the-Optejet.html,Clinical Study,10/9/2023 7:00,pre_market,1.559999943,1.559999943,429.5400085,427.5799866,0,-0.004563072,0.004563072,long,long,
856,990,EVLO,Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/08/14/2724292/0/en/Evelo-Biosciences-Announces-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html,Earnings Releases and Operating Results,8/14/2023 7:30,pre_market,10.06000042,9.899999619,445.6499939,444.7000122,-0.015904652,-0.002131677,-0.013772975,short,short,
857,1005,EYEN,"Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals",https://www.globenewswire.com/news-release/2023/08/16/2726141/0/en/Eyenovia-Acquires-U-S-Commercial-Rights-to-APP13007-Clobetasol-Propionate-Ophthalmic-Nanosuspension-0-05-from-Formosa-Pharmaceuticals.html,Mergers and Acquisitions,8/16/2023 6:00,pre_market,2.019999981,2.099999905,442.8900146,442.4599915,0.039603923,-0.000970948,0.040574871,long,long,
858,1006,EYEN,Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals,https://www.globenewswire.com/news-release/2023/02/15/2608912/0/en/Eyenovia-Announces-Development-Collaboration-Agreement-with-Formosa-Pharmaceuticals.html,Health,2/15/2023 9:51,market_open,2.700000048,2.974999905,410.3500061,413.980011,0.101851797,0.008846119,0.093005678,long,long,
859,1001,EVLO,"Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial",https://www.globenewswire.com/news-release/2023/02/27/2615820/0/en/Evelo-Biosciences-Reports-that-EDP2939-its-First-Oral-Extracellular-Vesicle-Product-Candidate-Commenced-Dosing-in-a-Phase-2-Psoriasis-Trial.html,Clinical Study,2/27/2023 6:00,pre_market,12.72000027,13.35999966,396.3800049,399.8699951,0.050314416,0.008804658,0.041509759,long,long,
860,993,EVLO,Evelo Biosciences Announces Succession Plan,https://www.globenewswire.com/news-release/2022/08/11/2496459/0/en/Evelo-Biosciences-Announces-Succession-Plan.html,Directors and Officers,8/11/2022 6:01,pre_market,59,59,419.9899902,422.9899902,0,0.007143027,-0.007143027,short,short,
861,992,EVLO,Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference,https://www.globenewswire.com/news-release/2022/09/01/2508294/0/en/Evelo-Biosciences-to-Participate-in-Morgan-Stanley-20th-Annual-Global-Health-Care-Conference.html,Calendar of Events,9/1/2022 6:00,pre_market,43.79999924,42.79999924,395.1799927,392.8900146,-0.022831051,-0.005794772,-0.017036278,short,long,
862,994,EVLO,Evelo Biosciences Announces $25.5 Million Private Placement,https://www.globenewswire.com/news-release/2023/07/10/2701677/0/en/Evelo-Biosciences-Announces-25-5-Million-Private-Placement.html,Stock Market News,7/10/2023 7:30,pre_market,2.309999943,2.5,438.5499878,438.1799927,0.082251109,-0.000843678,0.083094787,long,long,
863,991,EVLO,Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference,https://www.globenewswire.com/news-release/2022/11/08/2550584/0/en/Evelo-Biosciences-to-Present-at-the-2022-Jefferies-London-Healthcare-Conference.html,Calendar of Events,11/8/2022 6:00,pre_market,39,39.20000076,379.9500122,381.1099854,0.005128225,0.003052963,0.002075262,long,short,
864,996,EVLO,Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis,https://www.globenewswire.com/news-release/2023/10/17/2761342/0/en/Evelo-Biosciences-Announces-Top-Line-Results-From-its-Phase-2-Clinical-Study-with-EDP2939-in-Moderate-Psoriasis.html,Clinical Study,10/17/2023 7:00,pre_market,2.910000086,1.139999986,436.0400085,432.8099976,-0.608247439,-0.007407602,-0.600839837,short,short,
865,997,EVLO,Evelo Biosciences Closes $25.5 Million Private Placement,https://www.globenewswire.com/news-release/2023/07/12/2703423/0/en/Evelo-Biosciences-Closes-25-5-Million-Private-Placement.html,Financing Agreements,7/12/2023 7:30,pre_market,3.380000114,3.400000095,442.4599915,446.3900146,0.005917154,0.008882211,-0.002965058,short,short,
866,998,EVLO,Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights,https://www.globenewswire.com/news-release/2022/08/11/2496455/0/en/Evelo-Biosciences-Announces-Second-Quarter-2022-Financial-Results-and-Business-Highlights.html,Health,8/11/2022 6:00,pre_market,59,59,419.9899902,422.9899902,0,0.007143027,-0.007143027,short,long,
867,1000,EVLO,Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference,https://www.globenewswire.com/news-release/2023/03/01/2617946/0/en/Evelo-Biosciences-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html,Conference Calls/ Webcasts,3/1/2023 6:00,pre_market,12.39999962,12.30000019,396.2600098,395.4100037,-0.00806447,-0.002145072,-0.005919399,short,short,
868,1022,FARON.HE,Faron Pharmaceuticals Announces Board Changes,https://www.globenewswire.com/news-release/2023/09/22/2748072/0/en/Faron-Pharmaceuticals-Announces-Board-Changes.html,Directors and Officers,9/22/2023 11:00,market_open,3.859999895,3.815000057,432.4500122,430.4200134,-0.011657989,-0.004694181,-0.006963808,short,short,
869,1008,EYEN,Eyenovia Announces First Commercial Sale of Mydcombi™,https://www.globenewswire.com/news-release/2023/08/03/2717937/0/en/Eyenovia-Announces-First-Commercial-Sale-of-Mydcombi.html,Product / Services Announcement,8/3/2023 8:00,pre_market,2.109999895,2.109999895,450.1300049,448.0400085,0,-0.004643095,0.004643095,long,long,
870,1007,EYEN,Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes,https://www.globenewswire.com/news-release/2023/06/26/2694372/0/en/Eyenovia-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html,Trading information,6/26/2023 8:00,pre_market,2.369999886,2.380000114,433.2099915,432.6199951,0.004219506,-0.001361918,0.005581424,long,short,
871,1023,FARON.HE,Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS,https://www.globenewswire.com/news-release/2023/07/19/2707037/0/en/Faron-to-Hold-Conference-Call-to-Discuss-New-Positive-Clinical-Data-from-Phase-I-II-BEXMAB-Study-of-Bexmarilimab-in-Relapsed-Refractory-AML-and-MDS.html,Calendar of Events,7/19/2023 4:54,pre_market,2.859999895,3.109999895,454.1900024,455.0100098,0.087412591,0.001805428,0.085607163,long,long,
872,1009,EYEN,Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/09/21/2747224/0/en/Eyenovia-to-Participate-in-Panel-Discussion-at-Cantor-Global-Healthcare-Conference.html,Calendar of Events,9/21/2023 8:00,pre_market,1.659999967,1.639999986,438.6400146,435.7000122,-0.012048182,-0.006702541,-0.005345641,short,long,
873,1010,EYEN,"Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30",https://www.globenewswire.com/news-release/2023/03/23/2633055/0/en/Eyenovia-to-Report-Fourth-Quarter-and-Full-Year-2022-Results-on-Thursday-March-30.html,Conference Calls/ Webcasts,3/23/2023 8:00,pre_market,2.730000019,2.789999962,392.1099854,395.0899963,0.021978001,0.007599937,0.014378064,long,short,
874,1011,EYEN,Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference,https://www.globenewswire.com/news-release/2023/08/09/2721562/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-3rd-Annual-Ophthalmology-Virtual-Conference.html,Conference Calls/ Webcasts,8/9/2023 8:00,pre_market,2.059999943,2.069999933,448.75,449.0299988,0.004854364,0.000623953,0.004230412,long,long,
875,1014,EYEN,Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops,https://www.globenewswire.com/news-release/2023/01/12/2587812/0/en/Eyenovia-Reveals-Positive-Evidence-That-Optejet-Delivery-Technology-Decreased-Inflammation-From-Preserved-Glaucoma-Solutions-Compared-to-Drops.html,Product / Services Announcement,1/12/2023 8:00,pre_market,1.879999995,1.950000048,395.519989,396.6700134,0.037234071,0.002907627,0.034326444,long,long,
876,1015,EYEN,Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/07/2739251/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/7/2023 8:00,pre_market,1.870000005,1.879999995,446.2200012,443.1099854,0.005347589,-0.006969692,0.01231728,long,long,
877,1016,EYEN,Eyenovia Announces Poster Presentation at ARVO 2023,https://www.globenewswire.com/news-release/2023/04/24/2652646/0/en/Eyenovia-Announces-Poster-Presentation-at-ARVO-2023.html,Product / Services Announcement,4/24/2023 8:00,pre_market,4.900000095,4.869999886,412.2000122,411.9899902,-0.006122492,-0.000509515,-0.005612977,short,short,
878,1017,EYEN,Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023,https://www.globenewswire.com/news-release/2023/06/01/2680264/0/en/Eyenovia-Announces-Presentation-at-the-OCTANE-Ophthalmology-Tech-Forum-2023.html,Calendar of Events,6/1/2023 8:00,pre_market,2.839999914,2.819999933,417.8500061,418.0899963,-0.007042247,0.000574345,-0.007616592,short,short,
879,1018,EYEN,Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility,https://www.globenewswire.com/news-release/2024/02/13/2828089/0/en/Eyenovia-Announces-FDA-Approval-of-Redwood-City-as-Commercial-Manufacturing-Facility.html,Product / Services Announcement,2/13/2024 7:00,pre_market,1.909999967,1.940000057,500.980011,494.5299988,0.015706854,-0.01287479,0.028581644,long,long,
880,1019,EYEN,Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production,https://www.globenewswire.com/news-release/2023/11/02/2772116/0/en/Eyenovia-Announces-FDA-Approval-of-Coastline-International-as-Contract-Manufacturer-to-Initiate-Mydcombi-Commercial-Production.html,Product / Services Announcement,11/2/2023 7:00,pre_market,1.409999967,1.460000038,422.6600037,426.5799866,0.035461045,0.009274554,0.026186491,long,long,
881,1020,EYEN,Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program,https://www.globenewswire.com/news-release/2023/10/30/2769019/0/en/Eyenovia-to-Sponsor-Course-on-Drug-Delivery-Innovation-at-IJCAHPO-s-51st-Annual-Continuing-Education-ACE-Program.html,Clinical Study,10/30/2023 7:00,pre_market,1.080000043,1.110000014,410.6799927,413.5599976,0.02777775,0.007012771,0.020764979,long,long,
882,1029,FBIO,Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program,https://www.globenewswire.com/news-release/2023/06/15/2688861/28889/en/Helocyte-Announces-3-22-Million-Grant-from-the-National-Cancer-Institute-for-Triplex-Phase-2-Clinical-Trial-Program.html,Clinical Study,6/15/2023 8:00,pre_market,9.300000191,9.449999809,437.1799927,436.3299866,0.016128991,-0.001944293,0.018073284,long,long,
883,1031,FBIO,Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States,https://www.globenewswire.com/news-release/2023/06/29/2696949/28889/en/Urica-Therapeutics-Announces-Topline-Data-from-the-Phase-1-Clinical-Trial-Evaluating-Dotinurad-in-Healthy-Volunteers-in-the-United-States.html,Clinical Study,6/29/2023 8:00,pre_market,7.949999809,7.949999809,436.3900146,435.9599915,0,-0.00098541,0.00098541,long,long,
884,1025,FARON.HE,Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference,https://www.globenewswire.com/news-release/2023/08/02/2716788/0/en/Faron-to-Participate-in-Fireside-Chat-at-the-Canaccord-Genuity-43rd-Annual-Growth-Conference.html,Calendar of Events,8/2/2023 8:00,pre_market,3.400000095,3.400000095,456.480011,453.25,0,-0.007075909,0.007075909,long,long,
885,1032,FBIO,"Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H",https://www.globenewswire.com/news-release/2023/04/24/2652668/28889/en/Aevitas-Therapeutics-a-Fortress-Biotech-Subsidiary-Announces-Asset-Purchase-Agreement-with-4D-Molecular-Therapeutics-for-World-Wide-Rights-to-Aevitas-Short-Form-Human-Complement-Fa.html,Health,4/24/2023 8:00,pre_market,10.64999962,10.5,412.2000122,411.9899902,-0.014084472,-0.000509515,-0.013574957,short,short,
886,1033,FBIO,"Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR",https://www.globenewswire.com/news-release/2023/02/16/2609775/28889/en/Helocyte-Inc-Announces-Positive-Data-from-Stem-Cell-Transplant-Donor-Vaccination-Trial-to-be-Presented-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-ASTC.html,Clinical Study,2/16/2023 8:30,pre_market,11.10000038,11.25,413.980011,408.7900085,0.013513479,-0.012536843,0.026050322,long,long,
887,1034,FBIO,Fortress Biotech Announces Pricing of $10.0 Million Public Offering,https://www.globenewswire.com/news-release/2023/11/10/2778298/28889/en/Fortress-Biotech-Announces-Pricing-of-10-0-Million-Public-Offering.html,Management statements,11/10/2023 8:15,pre_market,2.079999924,1.350000024,433.8399963,435.980011,-0.350961503,0.004932728,-0.355894231,short,short,
888,1035,FBIO,Fortress Biotech Announces Reverse Stock Split,https://www.globenewswire.com/news-release/2023/10/09/2756959/28889/en/Fortress-Biotech-Announces-Reverse-Stock-Split.html,Changes in share capital and votes,10/9/2023 12:50,market_open,4.949999809,4.349999905,427.5799866,432.2900085,-0.121212107,0.011015534,-0.132227641,short,long,
889,1036,FBIO,Fortress Biotech to Participate in Two March 2023 Investor Conferences,https://www.globenewswire.com/news-release/2023/03/07/2622003/28889/en/Fortress-Biotech-to-Participate-in-Two-March-2023-Investor-Conferences.html,Conference Calls/ Webcasts,3/7/2023 8:00,pre_market,12.14999962,12.14999962,404.4700012,404.4200134,0,-0.000123588,0.000123588,long,long,
890,1037,FBIO,"Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock",https://www.globenewswire.com/news-release/2022/10/05/2528702/28889/en/Fortress-Biotech-Announces-Timing-of-Regular-Monthly-Dividend-for-October-November-and-December-2022-for-its-9-375-Series-A-Cumulative-Redeemable-Perpetual-Preferred-Stock.html,Stock Market News,10/5/2022 8:30,pre_market,13.19999981,13.19999981,377.9700012,373.3900146,0,-0.012117328,0.012117328,long,long,
891,1038,FBIO,Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023,https://www.globenewswire.com/news-release/2023/08/03/2718058/28889/en/Fortress-Biotech-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2023.html,Calendar of Events,8/3/2023 8:30,pre_market,8.699999809,8.850000382,450.1300049,448.0400085,0.017241446,-0.004643095,0.02188454,long,short,
892,1039,FBIO,Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/02/10/2606152/28889/en/Fortress-Biotech-Announces-Closing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,Stock Market News,2/10/2023 12:50,market_open,11.10000038,11.39999962,405.8599854,408.0400085,0.027026957,0.005371368,0.02165559,long,short,
893,1040,FBIO,"Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.",https://www.globenewswire.com/news-release/2023/12/06/2791767/28889/en/Cyprium-Therapeutics-a-Fortress-Biotech-Subsidiary-Company-Completes-Asset-Transfer-of-CUTX-101-Copper-Histidinate-Product-Candidate-for-Treatment-of-Menkes-Disease-to-Sentynl-Ther.html,Health,12/6/2023 8:30,pre_market,2.670000076,2.690000057,456.6000061,458.8099976,0.007490629,0.004840104,0.002650526,long,long,
894,1026,FARON.HE,Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients,https://www.globenewswire.com/news-release/2023/10/11/2758195/0/en/Inside-information-Faron-Announces-Positive-BEXMAB-Study-Update-in-Relapsed-Refractory-AML-and-HMA-Refractory-MDS-Patients.html,Health,10/11/2023 7:00,pre_market,3.819999933,4.054999828,434.5400085,435.6400146,0.061518298,0.002531427,0.058986872,long,long,
895,1027,FARON.HE,Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting,https://www.globenewswire.com/news-release/2023/09/22/2747864/0/en/Faron-Pharmaceuticals-Ltd-Results-of-the-Extraordinary-General-Meeting.html,Annual Meetings & Shareholder Rights,9/22/2023 6:33,pre_market,3.825000048,3.859999895,431.3900146,432.4500122,0.009150287,0.002457168,0.006693119,long,long,
896,1041,FBIO,Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa,https://www.globenewswire.com/news-release/2022/12/14/2573643/28889/en/Urica-Therapeutics-Expands-Exclusive-License-Agreement-with-Fuji-Yakuhin-Co-Ltd-to-Develop-Dotinurad-in-Additional-Territories-Including-Turkey-and-the-Middle-East-and-North-Africa.html,Partnerships,12/14/2022 8:00,pre_market,9.899999619,9.899999619,401.9700012,401.6099854,0,-0.000895629,0.000895629,long,long,
897,1042,FBIO,Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1,https://www.globenewswire.com/news-release/2023/10/16/2760729/28889/en/Fortress-Biotech-Subsidiary-Helocyte-Announces-Option-Agreement-with-City-of-Hope-for-Exclusive-Worldwide-Rights-to-use-a-Novel-Bispecific-CMV-HIV-CAR-T-Cell-Therapy-optionally-in-.html,Product / Services Announcement,10/16/2023 9:00,pre_market,2.900000095,2.910000086,431.5,433.8200073,0.003448273,0.00537661,-0.001928338,short,short,
898,1043,FBIO,Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/07/2739367/28889/en/Fortress-Biotech-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Calendar of Events,9/7/2023 8:30,pre_market,5.849999905,5.699999809,446.2200012,443.1099854,-0.025641042,-0.006969692,-0.018671351,short,short,
899,1044,FBIO,"Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference",https://www.globenewswire.com/news-release/2022/12/06/2568308/28889/en/Fortress-Biotech-to-Participate-in-Cantor-Medical-Aesthetic-Dermatology-Ophthalmology-MedTech-Diagnostic-Conference.html,Trade Show,12/6/2022 8:30,pre_market,10.5,10.35000038,399.5899963,399.4200134,-0.014285678,-0.000425393,-0.013860285,short,short,
900,1045,FBIO,"Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors",https://www.globenewswire.com/news-release/2022/12/19/2576277/28889/en/Fortress-Biotech-Appoints-Lucy-Lu-M-D-to-its-Board-of-Directors.html,Directors and Officers,12/19/2022 8:00,pre_market,8.699999809,9,383.269989,383.4700012,0.034482781,0.000521857,0.033960924,long,long,
901,1049,FGEN,FibroGen to Report First Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/04/24/2652535/33525/en/FibroGen-to-Report-First-Quarter-2023-Financial-Results.html,Conference Calls/ Webcasts,4/24/2023 7:00,pre_market,20.39999962,20.28000069,412.2000122,411.9899902,-0.005882301,-0.000509515,-0.005372786,short,short,
902,1050,FGEN,FibroGen Announces Leadership Transition,https://www.globenewswire.com/news-release/2023/07/25/2710270/33525/en/FibroGen-Announces-Leadership-Transition.html,Directors and Officers,7/25/2023 7:00,pre_market,2.089999914,2.039999962,454.2000122,453.9200134,-0.023923423,-0.000616466,-0.023306957,short,short,
903,1051,FGEN,FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy,https://www.globenewswire.com/news-release/2023/06/07/2683598/33525/en/FibroGen-Announces-Topline-Results-from-LELANTOS-1-Phase-3-Clinical-Study-of-Pamrevlumab-in-Non-Ambulatory-Patients-with-Duchenne-Muscular-Dystrophy.html,Clinical Study,6/7/2023 6:55,pre_market,18.70999908,18.60000038,428.0299988,428.4400024,-0.00587914,0.000957885,-0.006837025,short,long,
904,1052,FGEN,"FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer",https://www.globenewswire.com/news-release/2024/01/25/2816553/33525/en/FibroGen-Announces-Completion-of-the-Pamrevlumab-Arm-in-Precision-Promise-Pancreatic-Cancer-Action-Network-s-Phase-2-3-Adaptive-Platform-Trial-for-Metastatic-Pancreatic-Cancer.html,Company Announcement,1/25/2024 7:00,pre_market,0.970000029,0.981000006,485.3900146,487.5799866,0.011340183,0.004511778,0.006828405,long,long,
905,1053,FGEN,FibroGen to Report Second Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/07/24/2709392/33525/en/FibroGen-to-Report-Second-Quarter-2023-Financial-Results.html,Conference Calls/ Webcasts,7/24/2023 7:00,pre_market,2.099999905,2.140000105,452.1799927,453.3699951,0.019047715,0.002631701,0.016416015,long,long,
906,1046,FBIO,Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/02/08/2603922/28889/en/Fortress-Biotech-Announces-Pricing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,Prospectus/Announcement of Prospectus,2/8/2023 8:00,pre_market,12.60000038,10.64999962,415.1900024,413.1300049,-0.154761961,-0.004961578,-0.149800383,short,short,
907,1054,FGEN,"FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis",https://www.globenewswire.com/news-release/2023/04/03/2639399/33525/en/FibroGen-Announces-Completion-of-Patient-Enrollment-in-ZEPHYRUS-2-a-Phase-3-Clinical-Study-of-Pamrevlumab-in-Idiopathic-Pulmonary-Fibrosis.html,Clinical Study,4/3/2023 7:00,pre_market,18.65999985,18.76000023,409.3900146,408.8500061,0.005359077,-0.001319057,0.006678134,long,long,
908,1055,FGEN,"FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024",https://www.globenewswire.com/news-release/2024/02/05/2823393/33525/en/FibroGen-To-Host-Part-I-of-Virtual-KOL-Investor-Event-Series-to-Review-Pamrevlumab-Clinical-Program-in-Pancreatic-Cancer-on-February-13-2024.html,Clinical Study,2/5/2024 7:00,pre_market,1.860000014,1.809999943,494.3500061,493.7000122,-0.026881759,-0.001314846,-0.025566913,short,short,
909,1056,FGEN,FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia,https://www.globenewswire.com/news-release/2023/05/18/2671783/33525/en/FibroGen-Announces-Positive-Topline-Results-from-China-Pivotal-Phase-3-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html,Clinical Study,5/18/2023 7:30,pre_market,17.81999969,17.97999954,415.230011,414.8999939,0.008978667,-0.000794781,0.009773449,long,long,
910,1047,FBIO,Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,https://www.globenewswire.com/news-release/2023/12/29/2802052/28889/en/Fortress-Biotech-Announces-Pricing-of-11-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,Financing Agreements,12/29/2023 8:20,pre_market,3.890000105,3.24000001,476.6900024,476.4899902,-0.167095136,-0.000419586,-0.16667555,short,short,
911,1064,GLUE,Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/03/16/2628536/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,3/16/2023 7:30,pre_market,6.53000021,6.369999886,389.2799988,386.8200073,-0.024502346,-0.006319337,-0.018183009,short,short,
912,1065,GLUE,Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors,https://www.globenewswire.com/news-release/2023/03/23/2633019/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Jan-Skvarka-to-Board-of-Directors.html,Directors and Officers,3/23/2023 7:30,pre_market,7,7.090000153,392.1099854,395.0899963,0.012857165,0.007599937,0.005257228,long,long,
913,1066,GLUE,Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/11/09/2777173/0/en/Monte-Rosa-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,11/9/2023 7:00,pre_market,3.690000057,3.670000076,437.25,438.4299927,-0.005420049,0.002698668,-0.008118717,short,short,
914,1067,GLUE,"Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases",https://www.globenewswire.com/news-release/2023/11/07/2775281/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-ACR-Convergence-2023-Demonstrating-Potential-of-MRT-6160-a-VAV1-targeted-Molecular-Glue-Degrader-to-Treat-Immunological-and-Inf.html,Clinical Study,11/7/2023 10:00,market_open,3.380000114,3.549999952,435.6900024,436.9299927,0.050295808,0.002846038,0.047449771,long,long,
915,1068,GLUE,Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors,https://www.globenewswire.com/news-release/2023/10/17/2761331/0/en/Monte-Rosa-Therapeutics-Announces-Interim-PK-PD-and-Clinical-Data-for-MRT-2359-in-Phase-1-2-Trial-for-MYC-Driven-Solid-Tumors.html,Conference Calls/ Webcasts,10/17/2023 7:00,pre_market,5,5.239999771,436.0400085,432.8099976,0.047999954,-0.007407602,0.055407557,long,long,
916,1069,GLUE,Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/08/10/2722527/0/en/Monte-Rosa-Therapeutics-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,8/10/2023 7:15,pre_market,6.789999962,6.869999886,445.75,448.1900024,0.011782021,0.005473926,0.006308095,long,long,
917,1070,GLUE,Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference,https://www.globenewswire.com/news-release/2023/11/21/2783927/0/en/Monte-Rosa-Therapeutics-to-Present-at-Piper-Sandler-Healthcare-Conference.html,Calendar of Events,11/21/2023 7:00,pre_market,3.25,3.200000048,454.2600098,453.1799927,-0.015384601,-0.002377531,-0.01300707,short,long,
918,1071,GLUE,Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates,https://www.globenewswire.com/news-release/2022/08/11/2496663/0/en/Monte-Rosa-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Business-Updates.html,Earnings Releases and Operating Results,8/11/2022 7:30,pre_market,8.710000038,9.43999958,419.9899902,422.9899902,0.083811658,0.007143027,0.07666863,long,long,
919,1072,GLUE,Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update,https://www.globenewswire.com/news-release/2023/05/11/2666597/0/en/Monte-Rosa-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,Earnings Releases and Operating Results,5/11/2023 7:30,pre_market,5.789999962,5.989999771,412.8500061,411.9500122,0.034542282,-0.002179954,0.036722235,long,short,
920,1073,GLUE,Monte Rosa Therapeutics to Present at Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2023/02/03/2601254/0/en/Monte-Rosa-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html,Calendar of Events,2/3/2023 7:30,pre_market,7.130000114,7.150000095,416.7799988,411.5899963,0.002805046,-0.012452619,0.015257665,long,long,
921,1074,GLUE,"Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases",https://www.globenewswire.com/news-release/2023/05/23/2674201/0/en/Monte-Rosa-Therapeutics-Advances-Second-Development-Candidate-MRT-6160-a-Novel-Highly-Selective-Molecular-Glue-Degrader-Targeting-VAV1-for-the-Treatment-of-Autoimmune-Diseases.html,Clinical Study,5/23/2023 7:30,pre_market,6.070000172,6.019999981,418.7900085,417.0799866,-0.008237264,-0.004083244,-0.004154019,short,short,
922,1057,FGEN,FibroGen to Present at Cowen’s 43rd Annual Health Care Conference,https://www.globenewswire.com/news-release/2023/02/27/2615910/33525/en/FibroGen-to-Present-at-Cowen-s-43rd-Annual-Health-Care-Conference.html,Calendar of Events,2/27/2023 7:00,pre_market,22.20999908,22.53000069,396.3800049,399.8699951,0.014407997,0.008804658,0.00560334,long,long,
923,1058,FGEN,FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results,https://www.globenewswire.com/news-release/2023/02/17/2610529/33525/en/FibroGen-to-Report-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,Conference Calls/ Webcasts,2/17/2023 7:00,pre_market,23.57999992,23.64999962,408.2799988,406.0599976,0.002968605,-0.005437448,0.008406052,long,long,
924,1059,FGEN,FibroGen to Report Third Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/10/23/2764572/33525/en/FibroGen-to-Report-Third-Quarter-2023-Financial-Results.html,Conference Calls/ Webcasts,10/23/2023 7:00,pre_market,0.550000012,0.532000005,421.1900024,419.6099854,-0.032727284,-0.003751317,-0.028975968,short,short,
925,1085,GMAB,Major Shareholder Announcement,https://www.globenewswire.com/news-release/2023/11/09/2777473/0/en/Major-Shareholder-Announcement.html,European Regulatory News,11/9/2023 9:14,pre_market,31,31.78000069,437.25,438.4299927,0.025161313,0.002698668,0.022462644,long,long,
926,1087,GMAB,Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL),https://www.globenewswire.com/news-release/2023/09/25/2748547/0/en/Genmab-Announces-European-Commission-Approval-of-TEPKINLY-epcoritamab-for-Adults-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html,European Regulatory News,9/25/2023 7:45,pre_market,36.08000183,36.02999878,430.4200134,429.1700134,-0.001385894,-0.00290414,0.001518246,long,long,
927,1088,GMAB,Grant of Restricted Stock Units and Warrants to Employees in Genmab,https://www.globenewswire.com/news-release/2023/09/28/2751599/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html,European Regulatory News,9/28/2023 14:38,market_open,35.75999832,35.33000183,425.480011,428.519989,-0.012024511,0.00714482,-0.019169331,short,short,
928,1089,GMAB,Genmab Announces Financial Results for the First Nine Months of 2023,https://www.globenewswire.com/news-release/2023/11/07/2775338/0/en/Genmab-Announces-Financial-Results-for-the-First-Nine-Months-of-2023.html,European Regulatory News,11/7/2023 11:01,market_open,28.92000008,29.52000046,435.6900024,436.9299927,0.020746901,0.002846038,0.017900863,long,long,
929,1091,GMAB,Capital Increase in Genmab as a Result of Employee Warrant Exercise,https://www.globenewswire.com/news-release/2023/09/12/2742015/0/en/Capital-Increase-in-Genmab-as-a-Result-of-Employee-Warrant-Exercise.html,European Regulatory News,9/12/2023 14:04,market_open,36.91999817,36.93999863,446.9500122,445.9899902,0.000541724,-0.00214794,0.002689665,long,long,
930,1090,GMAB,Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL),https://www.globenewswire.com/news-release/2023/07/21/2708724/0/en/Genmab-Announces-AbbVie-Receives-Positive-CHMP-Opinion-for-Epcoritamab-TEPKINLY-for-the-Treatment-of-Adults-with-Relapsed-Refractory-R-R-Diffuse-Large-B-cell-Lymphoma-DLBCL.html,European Regulatory News,7/21/2023 4:30,pre_market,41.45000076,41.36000061,452.1799927,453.9599915,-0.002171294,0.003936483,-0.006107777,short,long,
931,1092,GMAB,Major Shareholder Announcement,https://www.globenewswire.com/news-release/2023/11/08/2776465/0/en/Major-Shareholder-Announcement.html,European Regulatory News,11/8/2023 11:09,market_open,31.69000053,31,437.5499878,437.25,-0.021773447,-0.000685608,-0.021087839,short,long,
932,1075,GLUE,Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/01/04/2582790/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,1/4/2023 7:30,pre_market,7.78000021,7.860000134,380.8200073,383.1799927,0.010282766,0.006197115,0.004085651,long,long,
933,1076,GLUE,"Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors",https://www.globenewswire.com/news-release/2022/11/01/2545357/0/en/Monte-Rosa-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-MRT-2359-a-GSPT1-directed-Molecular-Glue-Degrader-for-Treatment-of-MYC-driven-Tumors.html,Product / Services Announcement,11/1/2022 7:30,pre_market,9.199999809,9.329999924,386.2099915,390.1400146,0.014130448,0.010175871,0.003954576,long,long,
934,1077,GLUE,Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates,https://www.globenewswire.com/news-release/2022/11/10/2553073/0/en/Monte-Rosa-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Business-Updates.html,Earnings Releases and Operating Results,11/10/2022 7:30,pre_market,7.599999905,7.869999886,374.1300049,388.0499878,0.035526314,0.037206273,-0.001679959,short,short,
935,1078,GLUE,Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases,https://www.globenewswire.com/news-release/2023/10/17/2761334/0/en/Monte-Rosa-Therapeutics-Announces-Strategic-Collaboration-with-Roche-to-Discover-Novel-Molecular-Glue-Degraders-Targeting-Cancer-and-Neurological-Diseases.html,Partnerships,10/17/2023 7:00,pre_market,5,5.239999771,436.0400085,432.8099976,0.047999954,-0.007407602,0.055407557,long,long,
936,1079,GLUE,Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors,https://www.globenewswire.com/news-release/2023/07/26/2711202/0/en/Monte-Rosa-Therapeutics-Appoints-Dr-Anthony-M-Manning-to-Board-of-Directors.html,Directors and Officers,7/26/2023 7:30,pre_market,6.699999809,6.690000057,455.4400024,454.4700012,-0.0014925,-0.002129811,0.000637311,long,long,
937,1080,GLUE,Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/03/2803173/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Calendar of Events,1/3/2024 7:00,pre_market,5.710000038,5.760000229,472.6499939,470.4299927,0.008756601,-0.004696924,0.013453525,long,long,
938,1081,GLUE,Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024,https://www.globenewswire.com/news-release/2024/01/08/2805310/0/en/Monte-Rosa-Therapeutics-Provides-Corporate-Update-and-Key-Anticipated-Milestones-for-2024.html,Calendar of Events,1/8/2024 7:15,pre_market,5.525000095,5.75,467.9200134,468.4299927,0.040723964,0.001089886,0.039634078,long,long,
939,1082,GLUE,Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences,https://www.globenewswire.com/news-release/2024/01/31/2820942/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html,Conference Calls/ Webcasts,1/31/2024 7:00,pre_market,5.320000172,5.260000229,490.8900146,488.6199951,-0.011278184,-0.004624294,-0.006653891,short,short,
940,1083,GLUE,Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023,https://www.globenewswire.com/news-release/2023/01/09/2585095/0/en/Monte-Rosa-Therapeutics-Outlines-Progress-Across-Portfolio-of-Molecular-Glue-Degraders-and-Key-Anticipated-Milestones-for-2023.html,Stock Market News,1/9/2023 7:30,pre_market,7.960000038,8.06000042,388.0799866,390.3699951,0.012562862,0.005900867,0.006661995,long,short,
941,1094,GMAB,Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH),https://www.globenewswire.com/news-release/2023/11/02/2772431/0/en/Genmab-Announces-Multiple-Abstracts-to-be-Presented-at-the-65th-Annual-Meeting-and-Exposition-of-the-American-Society-of-Hematology-ASH.html,European Regulatory News,11/2/2023 9:05,pre_market,28.95000076,28.98999977,422.6600037,426.5799866,0.001381658,0.009274554,-0.007892895,short,short,
942,1095,GMAB,Genmab Announces Financial Results for the First Half of 2023,https://www.globenewswire.com/news-release/2023/08/03/2718313/0/en/Genmab-Announces-Financial-Results-for-the-First-Half-of-2023.html,European Regulatory News,8/3/2023 11:01,market_open,38.68999863,39.27999878,448.0400085,448.8399963,0.015249423,0.001785528,0.013463895,long,long,
943,1096,GMAB,Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons,https://www.globenewswire.com/news-release/2023/06/01/2680792/0/en/Transactions-with-shares-and-linked-securities-in-Genmab-A-S-made-by-managerial-employees-and-their-closely-associated-persons.html,European Regulatory News,6/1/2023 15:40,market_open,39.33000183,39.33000183,418.0899963,421.8200073,0,0.00892155,-0.00892155,short,short,
944,1097,GMAB,Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons,https://www.globenewswire.com/news-release/2023/05/31/2679379/0/en/Transactions-with-Shares-and-Linked-Securities-in-Genmab-A-S-Made-By-Managerial-Employees-and-Their-Closely-Associated-Persons.html,European Regulatory News,5/31/2023 8:15,pre_market,39.27999878,39.09000015,420.1799927,418.2799988,-0.004837032,-0.004521857,-0.000315175,short,short,
945,1098,GMAB,Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference,https://www.globenewswire.com/news-release/2023/08/28/2732719/0/en/Genmab-to-Present-at-Morgan-Stanley-21st-Annual-Global-Healthcare-Conference.html,European Regulatory News,8/28/2023 10:06,market_open,38.18999863,38.27000046,442.2399902,442.7600098,0.002094837,0.001175876,0.000918961,long,long,
946,1100,GMAB,Capital Increase in Genmab as a Result of Employee Warrant Exercise,https://www.globenewswire.com/news-release/2023/06/20/2691549/0/en/Capital-Increase-in-Genmab-as-a-Result-of-Employee-Warrant-Exercise.html,European Regulatory News,6/20/2023 14:45,market_open,38.25,38.41999817,437.4500122,437.1799927,0.004444397,-0.000617258,0.005061655,long,long,
947,1101,GMAB,Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma,https://www.globenewswire.com/news-release/2023/11/27/2786009/0/en/Genmab-Announces-Positive-Regulatory-Updates-for-Epcoritamab-EPKINLY-TEPKINLY-for-the-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma.html,European Regulatory News,11/27/2023 7:00,pre_market,31.62000084,30.94000053,455.2999878,454.6499939,-0.021505385,-0.001427617,-0.020077769,short,long,
948,1102,GMAB,Genmab to Hold 2023 R&D Update and ASH Data Review Meeting,https://www.globenewswire.com/news-release/2023/12/12/2794601/0/en/Genmab-to-Hold-2023-R-D-Update-and-ASH-Data-Review-Meeting.html,European Regulatory News,12/12/2023 7:00,pre_market,31.92000008,30.21999931,461.9899902,461.6300049,-0.053258169,-0.000779206,-0.052478963,short,long,
949,1103,GMAB,Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023,https://www.globenewswire.com/news-release/2024/01/23/2813898/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-2023.html,European Regulatory News,1/23/2024 6:24,pre_market,28.68000031,28.04000092,483.4500122,484.0100098,-0.022315181,0.001158336,-0.023473517,short,short,
950,1104,GMAB,Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer,https://www.globenewswire.com/news-release/2024/02/02/2822739/0/en/Tisotumab-Vedotin-Marketing-Authorization-Application-Validated-by-European-Medicines-Agency-for-Treatment-of-Recurrent-or-Metastatic-Cervical-Cancer.html,European Regulatory News,2/2/2024 6:45,pre_market,28.17000008,27.82999992,489.2000122,489.6499939,-0.012069583,0.000919832,-0.012989415,short,short,
951,1105,GMAB,Notice to Convene the Annual General Meeting of Genmab A/S,https://www.globenewswire.com/news-release/2024/02/15/2829756/0/en/Notice-to-Convene-the-Annual-General-Meeting-of-Genmab-A-S.html,European Regulatory News,2/15/2024 6:00,pre_market,27.59000015,29.05999947,498.5700073,499.2900085,0.053280149,0.001444133,0.051836016,long,long,
952,1106,GMAB,TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer,https://www.globenewswire.com/news-release/2024/01/09/2806100/0/en/TIVDAK-tisotumab-vedotin-tftv-Supplemental-Biologics-License-Application-Accepted-for-Priority-Review-by-U-S-Food-and-Drug-Administration-for-Patients-with-Recurrent-or-Metastatic-.html,European Regulatory News,1/9/2024 6:45,pre_market,32.77000046,32.40999985,474.6000061,471.8699951,-0.010985676,-0.005752236,-0.005233441,short,long,
953,1107,GMAB,Genmab Files Annual Report with the U.S. Securities and Exchange Commission,https://www.globenewswire.com/news-release/2024/02/14/2829403/0/en/Genmab-Files-Annual-Report-with-the-U-S-Securities-and-Exchange-Commission.html,European Regulatory News,2/14/2024 14:09,market_open,26.78000069,27.59000015,496.7900085,498.5700073,0.030246432,0.003583,0.026663432,long,long,
954,1108,GMAB,Genmab Publishes 2023 Annual Report,https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html,European Regulatory News,2/14/2024 11:02,market_open,26.78000069,27.59000015,496.7900085,498.5700073,0.030246432,0.003583,0.026663432,long,long,
955,1109,GMAB,Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/02/2802745/0/en/Genmab-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,European Regulatory News,1/2/2024 9:52,market_open,31.35000038,32.11000061,472.1600037,472.6499939,0.024242431,0.001037763,0.023204668,long,long,
956,1110,GMAB,Grant of Restricted Stock Units and Warrants to Employees in Genmab,https://www.globenewswire.com/news-release/2024/01/25/2817339/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html,European Regulatory News,1/25/2024 14:22,market_open,27.93000031,28.14999962,487.5799866,488.0299988,0.00787681,0.000922951,0.00695386,long,short,
957,1114,GRFS,GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19,https://www.globenewswire.com/news-release/2021/08/11/2278973/0/en/GigaGen-Doses-First-Patient-in-Phase-1-Trial-of-Recombinant-Hyperimmune-Polyclonal-Antibody-GIGA-2050-for-COVID-19.html,Health,8/11/2021 10:26,market_open,14.67000008,14.59000015,443.8200073,443.7799988,-0.005453301,-9.01E-05,-0.005363155,short,short,
958,1115,GRFS,GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins,https://www.globenewswire.com/news-release/2023/10/19/2763125/0/en/GigaGen-Granted-Expansion-of-Contract-with-US-Department-of-Defense-to-Develop-Synthetic-Human-Antibody-Treatments-for-Botulinum-Neurotoxins.html,Business Contracts,10/19/2023 8:00,pre_market,8.550000191,8.31000042,430.2099915,430.9500122,-0.028070148,0.001720139,-0.029790287,short,long,
959,1116,GRFS,GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens,https://www.globenewswire.com/news-release/2022/09/15/2517071/0/en/GigaGen-Awarded-Contract-by-U-S-Department-of-Defense-to-Discover-Synthetic-Human-Antibody-Treatments-for-High-Priority-Toxins-and-Pathogens.html,Health,9/15/2022 10:29,market_open,8.260000229,8.369999886,392.9599915,390.1199951,0.013317149,-0.00722719,0.020544339,long,long,
960,1117,GRFS,GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19,https://www.globenewswire.com/news-release/2020/03/30/2008438/0/en/GigaGen-Initiates-Development-of-Recombinant-Polyclonal-Antibody-Therapy-for-COVID-19.html,Company Announcement,3/30/2020 10:17,market_open,20.44000053,20.60000038,255.6999969,261.6499939,0.007827781,0.023269445,-0.015441664,short,short,
961,1118,GRFS,GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting,https://www.globenewswire.com/news-release/2021/03/23/2197847/0/en/GigaGen-to-Present-Poster-at-the-2021-American-Association-for-Cancer-Research-AACR-Virtual-Annual-Meeting.html,Calendar of Events,3/23/2021 10:00,market_open,16.5,16.78000069,391.9100037,389.5,0.016969739,-0.00614938,0.023119119,long,long,
962,1119,GRFS,GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates,https://www.globenewswire.com/news-release/2021/09/30/2306358/0/en/GigaGen-Licenses-ProteoNic-s-2G-UNicTM-Technology-Platform-for-High-Yield-Production-of-GigaGen-s-Mono-and-Polyclonal-Antibody-Drug-Candidates.html,Product / Services Announcement,9/30/2021 10:17,market_open,14.90999985,14.60999966,436.019989,429.1400146,-0.020120737,-0.015779034,-0.004341703,short,short,
963,1120,GRFS,"GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies",https://www.globenewswire.com/news-release/2022/07/28/2487786/0/en/GigaGen-Publishes-Research-Showcasing-First-Ever-Clinical-GMP-Manufacturing-and-IND-Enabling-Studies-for-its-New-Class-of-Drugs-Recombinant-Polyclonal-Antibodies.html,Company Announcement,7/28/2022 8:00,pre_market,10.60000038,9.539999962,401.0400085,401.8900146,-0.100000036,0.002119505,-0.102119541,short,short,
964,1121,GRFS,GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium,https://www.globenewswire.com/news-release/2020/07/29/2069535/0/en/GigaGen-to-Present-at-the-Inaugural-LifeSci-Partners-Private-Company-Virtual-Summer-Symposium.html,Company Announcement,7/29/2020 9:30,market_open,19.27000046,19.29000092,322.1199951,325.1199951,0.001037906,0.0093133,-0.008275393,short,short,
965,1123,GRFS,GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development,https://www.globenewswire.com/news-release/2022/05/19/2447167/0/en/GigaGen-Publishes-Research-Demonstrating-the-Potential-of-its-Machine-Learning-Platform-to-Improve-Antibody-Drug-Discovery-and-Development.html,Research Analysis and Reports,5/19/2022 11:39,market_open,12.89999962,13.07999992,388.6199951,389.4599915,0.013953512,0.002161485,0.011792027,long,long,
966,1124,GRFS,GigaGen Announces Publication in the Peer-Reviewed Journal mAbs,https://www.globenewswire.com/news-release/2020/10/20/2111204/0/en/GigaGen-Announces-Publication-in-the-Peer-Reviewed-Journal-mAbs.html,Health,10/20/2020 10:17,market_open,19.43000031,19.53000069,343.4599915,343.3800049,0.0051467,-0.000232885,0.005379585,long,long,
967,1125,GRFS,GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies,https://www.globenewswire.com/news-release/2021/05/25/2235723/0/en/GigaGen-Publishes-Research-Describing-Potential-New-Avenues-to-Overcome-Resistance-to-anti-PD-L1-Therapies.html,Research Analysis and Reports,5/25/2021 10:15,market_open,18.37000084,18.64999962,420.3299866,418.2399902,0.015242176,-0.004972275,0.020214451,long,long,
968,1126,GRFS,GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology,https://www.globenewswire.com/news-release/2021/04/15/2211106/0/en/GigaGen-Publishes-Research-on-Company-s-Recombinant-Hyperimmunes-in-Nature-Biotechnology.html,Health,4/15/2021 11:59,market_open,17.85000038,18.27000046,413.7399902,415.8699951,0.023529416,0.005148173,0.018381243,long,long,
969,1127,GRFS,"GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023",https://www.globenewswire.com/news-release/2023/11/06/2774078/0/en/GigaGen-Presents-IND-Enabling-Data-and-Phase-1-Trial-Strategy-for-its-Novel-Anti-CTLA-4-Oncology-Drug-Candidate-GIGA-564-at-SITC-2023.html,Product / Services Announcement,11/6/2023 8:00,pre_market,9.31000042,9.260000229,434.6900024,435.4700012,-0.00537059,0.001794379,-0.007164969,short,short,
970,1111,GMAB,Genmab Announces Initiation of Share Buy-Back Program,https://www.globenewswire.com/news-release/2024/02/14/2829305/0/en/Genmab-Announces-Initiation-of-Share-Buy-Back-Program.html,European Regulatory News,2/14/2024 11:41,market_open,26.78000069,27.59000015,496.7900085,498.5700073,0.030246432,0.003583,0.026663432,long,long,
971,1132,GTHX,G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference,https://www.globenewswire.com/news-release/2023/02/28/2617561/0/en/G1-Therapeutics-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html,Conference Calls/ Webcasts,2/28/2023 14:10,market_open,3.450000048,3.619999886,397.230011,396.2600098,0.049275315,-0.002441913,0.051717228,long,long,
972,1133,GTHX,"G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023",https://www.globenewswire.com/news-release/2023/07/26/2711371/0/en/G1-Therapeutics-to-Release-Second-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-August-2-2023.html,Conference Calls/ Webcasts,7/26/2023 9:00,pre_market,2.359999895,2.359999895,455.4400024,454.4700012,0,-0.002129811,0.002129811,long,long,
973,1134,GTHX,"G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business  Update on May 3, 2023",https://www.globenewswire.com/news-release/2023/04/26/2655500/0/en/G1-Therapeutics-to-Release-First-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-May-3-2023.html,Conference Calls/ Webcasts,4/26/2023 12:45,market_open,2.470000029,2.460000038,406.7200012,404.3599854,-0.004048579,-0.005802557,0.001753978,long,long,
974,1144,GTHX,New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer,https://www.globenewswire.com/news-release/2023/05/16/2669845/0/en/New-Study-Confirms-Consistent-Risk-of-Myelosuppression-Across-All-Patients-Receiving-Chemotherapy-for-Small-Cell-Lung-Cancer.html,Health,5/16/2023 7:30,pre_market,2.920000076,2.880000114,413.0100098,411.8599854,-0.013698617,-0.002784495,-0.010914122,short,short,
975,1136,GTHX,G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,https://www.globenewswire.com/news-release/2023/09/05/2737611/0/en/G1-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,Conference Calls/ Webcasts,9/5/2023 11:00,market_open,1.710000038,1.700000048,450.730011,449.2399902,-0.005847948,-0.003305794,-0.002542153,short,short,
976,1137,GTHX,New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC),https://www.globenewswire.com/news-release/2023/05/10/2665451/0/en/New-Results-from-Phase-2-Trial-Confirm-Benefit-of-Trilaciclib-in-Reducing-Adverse-Events-Related-to-an-Antibody-Drug-Conjugate-ADC.html,Company Announcement,5/10/2023 7:31,pre_market,2.950000048,2.960000038,410.9299927,413.8800049,0.003389827,0.007178868,-0.003789041,short,short,
977,1138,GTHX,"G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business  Update on November 1, 2023",https://www.globenewswire.com/news-release/2023/10/18/2762229/0/en/G1-Therapeutics-to-Release-Third-Quarter-2023-Financial-Results-and-Provide-Business-Update-on-November-1-2023.html,Conference Calls/ Webcasts,10/18/2023 7:30,pre_market,1.230000019,1.259999991,436.019989,434.1900024,0.02439022,-0.004197025,0.028587245,long,long,
978,1139,GTHX,G1 Therapeutics to Participate in Two August Investor Conferences,https://www.globenewswire.com/news-release/2023/07/31/2715254/0/en/G1-Therapeutics-to-Participate-in-Two-August-Investor-Conferences.html,Calendar of Events,7/31/2023 14:30,market_open,2.380000114,2.400000095,457.4100037,457.7900085,0.008403353,0.000830775,0.007572578,long,long,
979,1135,GTHX,G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights,https://www.globenewswire.com/news-release/2023/11/01/2770927/0/en/G1-Therapeutics-Provides-Third-Quarter-2023-Financial-Results-and-Operational-Highlights.html,Earnings Releases and Operating Results,11/1/2023 6:30,pre_market,1.649999976,1.350000024,418.2000122,419.2000122,-0.181818156,0.0023912,-0.184209356,short,short,
980,1141,GTHX,G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium,https://www.globenewswire.com/news-release/2023/10/16/2760730/0/en/G1-Therapeutics-Announces-Upcoming-Presentations-at-the-2023-ASCO-Quality-Care-Symposium.html,Product / Services Announcement,10/16/2023 9:00,pre_market,1.139999986,1.149999976,431.5,433.8200073,0.008771922,0.00537661,0.003395311,long,long,
981,1142,GTHX,G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO),https://www.globenewswire.com/news-release/2023/10/18/2762334/0/en/G1-Therapeutics-COSELA-trilaciclib-Recommended-in-Updated-Small-Cell-Lung-Cancer-Guidelines-from-the-American-Society-of-Clinical-Oncology-ASCO.html,Health,10/18/2023 8:00,pre_market,1.230000019,1.259999991,436.019989,434.1900024,0.02439022,-0.004197025,0.028587245,long,long,
982,1143,GTHX,New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC),https://www.globenewswire.com/news-release/2023/07/31/2714895/0/en/New-Publication-Highlights-Real-World-Impact-of-Trilaciclib-on-Myelosuppressive-Events-in-Patients-with-Extensive-Stage-Small-Cell-Lung-Cancer-ES-SCLC.html,Clinical Study,7/31/2023 8:30,pre_market,2.349999905,2.380000114,456.9200134,457.4100037,0.012766047,0.001072376,0.011693671,long,long,
983,1140,GTHX,G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights,https://www.globenewswire.com/news-release/2023/08/02/2716638/0/en/G1-Therapeutics-Provides-Second-Quarter-2023-Financial-Results-and-Operational-Highlights.html,Earnings Releases and Operating Results,8/2/2023 6:30,pre_market,2.190000057,2.369999886,456.480011,453.25,0.0821917,-0.007075909,0.089267609,long,long,
984,1128,GRFS,GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564,https://www.globenewswire.com/news-release/2023/09/28/2751133/0/en/GigaGen-Partners-with-the-National-Cancer-Institute-to-Advance-Oncology-Drug-Candidate-GIGA-564.html,Health,9/28/2023 8:00,pre_market,9.090000153,9.149999619,426.0499878,425.480011,0.006600601,-0.001337817,0.007938418,long,long,
985,1129,GRFS,"GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors",https://www.globenewswire.com/news-release/2023/12/12/2794694/0/en/GigaGen-Receives-FDA-Clearance-of-IND-to-Begin-Phase-1-Trial-of-Oncology-Drug-Candidate-GIGA-564-in-Solid-Tumors.html,Clinical Study,12/12/2023 8:00,pre_market,10.18000031,10.27000046,461.9899902,461.6300049,0.008840879,-0.000779206,0.009620085,long,long,
986,1130,GRFS,"GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050",https://www.globenewswire.com/news-release/2020/09/09/2091073/0/en/GigaGen-Initiates-Large-Scale-Manufacturing-of-its-First-in-Class-Recombinant-Hyperimmune-Drug-for-COVID-19-GIGA-2050.html,Product / Services Announcement,9/9/2020 10:17,market_open,16.45000076,16.29999924,337.5499878,339.7900085,-0.009118633,0.006636116,-0.015754749,short,short,
987,1152,HARP,Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma,https://www.globenewswire.com/news-release/2023/06/27/2695191/0/en/Harpoon-Therapeutics-Announces-Completion-of-Planned-Patient-Enrollment-in-Phase-1-Study-of-HPN217-in-Relapsed-Refractory-Multiple-Myeloma.html,Clinical Study,6/27/2023 7:30,pre_market,6.300000191,6.300000191,431.4400024,432.3500061,0,0.002109224,-0.002109224,short,short,
988,1153,HARP,Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development,https://www.globenewswire.com/news-release/2023/08/01/2715708/0/en/Harpoon-Therapeutics-Appoints-Haibo-Wang-as-Senior-Vice-President-of-Business-Development.html,Management Changes,8/1/2023 7:30,pre_market,7.829999924,7.800000191,457.7900085,456.269989,-0.003831384,-0.003320342,-0.000511041,short,short,
989,1154,HARP,Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August,https://www.globenewswire.com/news-release/2023/08/03/2717893/0/en/Harpoon-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences-in-August.html,Conference Calls/ Webcasts,8/3/2023 7:30,pre_market,7.480000019,7.5,450.1300049,448.0400085,0.002673794,-0.004643095,0.007316889,long,long,
990,1155,HARP,Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting,https://www.globenewswire.com/news-release/2023/09/06/2738263/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Poster-Presentation-at-the-20th-International-Myeloma-Society-Annual-Meeting.html,Calendar of Events,9/6/2023 7:30,pre_market,8.5,8.760000229,449.2399902,448.3999939,0.030588262,-0.001869817,0.032458079,long,short,
991,1156,HARP,Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort,https://www.globenewswire.com/news-release/2023/09/15/2743899/0/en/Harpoon-Therapeutics-Announces-First-Patients-with-Small-Cell-Lung-Cancer-Dosed-in-HPN328-Combination-Cohort.html,Clinical Study,9/15/2023 7:15,pre_market,5.400000095,5.420000076,450.3599854,447.1400146,0.0037037,-0.007149771,0.010853471,long,long,
992,1157,HARP,Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023,https://www.globenewswire.com/news-release/2023/04/17/2648353/0/en/Harpoon-Therapeutics-Presents-Data-for-New-ProTriTAC-Development-Candidates-in-TROP2-and-ITGB6-expressing-Solid-Tumors-at-AACR-2023.html,Clinical Study,4/17/2023 13:30,market_open,7.03000021,6.920000076,412.3699951,413.9400024,-0.015647245,0.003807278,-0.019454523,short,short,
993,1158,HARP,Harpoon Therapeutics Announces Up to $150 Million Private Placement,https://www.globenewswire.com/news-release/2023/10/23/2764595/0/en/Harpoon-Therapeutics-Announces-Up-to-150-Million-Private-Placement.html,Financing Agreements,10/23/2023 7:17,pre_market,6.880000114,7.070000172,421.1900024,419.6099854,0.027616287,-0.003751317,0.031367604,long,long,
994,1159,HARP,Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference,https://www.globenewswire.com/news-release/2023/02/07/2602863/0/en/Harpoon-Therapeutics-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html,Calendar of Events,2/7/2023 7:30,pre_market,11.30000019,11.30000019,409.8299866,408.8699951,0,-0.002342414,0.002342414,long,long,
995,1146,GTHX,G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference,https://www.globenewswire.com/news-release/2023/04/11/2644770/0/en/G1-Therapeutics-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html,Conference Calls/ Webcasts,4/11/2023 12:30,market_open,2.509999991,2.569999933,410.2600098,409.7200012,0.02390436,-0.001316259,0.025220619,long,long,
996,1145,GTHX,G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights,https://www.globenewswire.com/news-release/2023/05/03/2660123/0/en/G1-Therapeutics-Provides-First-Quarter-2023-Financial-Results-and-Operational-Highlights.html,Earnings Releases and Operating Results,5/3/2023 6:30,pre_market,2.970000029,3.049999952,410.8399963,411.3599854,0.026936001,0.001265673,0.025670328,long,short,
997,1160,HARP,Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition,https://www.globenewswire.com/news-release/2023/11/02/2772457/0/en/Harpoon-Therapeutics-Abstract-for-HPN217-Accepted-for-Presentation-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html,Calendar of Events,11/2/2023 9:15,pre_market,5.050000191,5.050000191,422.6600037,426.5799866,0,0.009274554,-0.009274554,short,short,
998,1147,GTHX,G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2024/01/08/2805234/0/en/G1-Therapeutics-Provides-Corporate-Update-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,Health,1/8/2024 6:45,pre_market,2.910000086,2.950000048,467.9200134,468.4299927,0.013745691,0.001089886,0.012655805,long,long,
999,1161,HARP,Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium,https://www.globenewswire.com/news-release/2023/12/19/2798452/0/en/Harpoon-Therapeutics-Abstract-for-HPN328-Accepted-for-Rapid-Oral-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium.html,Calendar of Events,12/19/2023 7:30,pre_market,10.47999954,10.55000019,471.9700012,472.5299988,0.006679452,0.001186511,0.005492941,long,long,
